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Abstract 
Despite efforts to reduce cases of Human African trypanosomiasis (HAT), increased cases are 
reported. This is because of drug resistant Trypanosoma brucei (Tb), the organism linked to the 
disease. This has renewed the call for original approaches to anti-trypanosomal drugs. The 
recognition of biomedical targets and their role in a disease constitutes the start of the model for 
target-based therapies or probes. The blood stream form (BSF) of the parasite relies solely on the 
glycolytic pathway for energy production while in the human host. Disruption of this pathway 
effectively kills the parasite. Trypanosoma brucei hexokinase (TbHK) is the first enzyme in the 
pathway and any effectors or inhibitors of TbHK would have potential as anti-trypanosomal 
agents.  
 
TbHK and human glucokinase (hGCK) were over-expressed containing a 6 histidine-tag in E. 
coli BL21(DE3) cells containing the pRARE2 plasmid. TbHK exhibited thermal stability 
between 30°C and 55°C and pH stability between 7.5 and 8.5, while the hGCK was thermally 
stable between 30°C and 40°C and pH stable between pH 7.0 and 8.0. Kinetic studies revealed 
that TbHK had a Km of 39 µM, a of 0.066 µmol.min
-1
.ml
-1
, a Kcat of 2.05 min
-1
 and a Kcat/Km of 
0.0522 min
-1
.µmol
-1
. hGCK exhibited a Km of 4.5 mM, a Vmax of 0.032 µmol.min
-1
.ml
-1
, a Kcat of 
11.25, a Kcat/Km of 2.5 min
-1
.µmol
-1
 and a hill coefficient of 1.5. 
 
Interaction kinetic studies of 0.1 µM, chemically synthesized silver nanoparticles with an 
average size of 6 nm with TbHK and hGCK were conducted. The silver nanoparticles selectively 
inhibited TbHK over hGCK. TbHK showed a mixed type inhibition with a 38%, 50%, 28% 
reduction in Km, Vmax and Kcat/Km respectively. hGCK indicated an uncompetitive inhibition 
pattern with a 33% increase in Km, a 9% decrease in Vmax and a 50% increase in Kcat/Km. The 
highly selective inhibitory effects of AgNPs observed between TbHK and hGCK may be used in 
development of novel anti-trypanosomal drugs.  
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Chapter 1 
 
Literature review 
  
1.1. Introduction 
Human African trypanosomiasis (HAT), also called African sleeping sickness is a fatal and much 
neglected disease that plagues parts of Africa, it is a vector-borne parasitic disease. The parasites 
that are involved are protozoa belonging to the Trypanosoma genus. The tsetse fly (Glossina 
genus) is the insect vector for Trypanosoma that transmit the parasite to human hosts by bites. 
African sleeping sickness occurs in 36 sub-Saharan African countries where the tsetse flies are 
found, putting 70 million people at risk (Fèvre et al., 2008; Simarro et al., 2012; WHO, 2014). 
 
It is also reported that people living in rural populations in these regions where transmission 
occurs depend on their activities including fishing, animal husbandry and hunting. The ones that 
are most exposed to the tsetse fly have a greater possibility of being infected. The disease does 
develop in areas ranging from a single village to an entire region. Within an infected area it is 
said that the intensity of the disease can vary from one area to the next. There are about 20 000 – 
30 000 suspected cases world wide but 10 000 cases are reported (WHO, 2014). The World 
Health Organization reported that the disease was nearly eliminated in the 1960s, but it made a 
comeback of the disease in epidemic proportions mainly due to reasons including war, 
population movements as well as the collapse of health systems over the past two decades. 
 
1.2. Trypanosomiasis 
1.2.1. Human African Trypanosomiasis 
Depending on the parasite involved, the human African trypanosomiasis may take two forms: 
(i) Trypanosoma brucei gambiense (Tb gambiense) is found in west and central Africa, also 
termed as West African trypanosomiasis (CDC, 2012). This form is currently known to be 
responsible for over 95% of reported cases of sleeping sickness and causes a chronic infection. 
Most of the reported cases are in central Africa (Chad, Central African Republic, Angola, Sudan, 
Northern Uganda and Democratic Republic of Congo). 
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(ii) Trypanosoma brucei rhodesiense (Tb rhodesiense) found in eastern and southern Africa, also 
referred to as East African trypanosomiasis. Currently this form represents about 5% of reported 
cases and causes an acute infection. More than 95% of cases are reported from Malawi, Uganda, 
Zambia and Tanzania. Further distribution, disease, disease profile host preference and 
subspecies are presented in table 1.1 
Table 1.1: Tb subspecies characteristics. 
 
Subspecies 
 
Host 
 
Disease 
 
Disease profile Distribution 
      
in humans 
   Trypanosoma brucei  Wild and domestic Nagana 
 
None 
 
Tropical Africa 
brucei 
 
animals 
       Trypanosoma brucei  Humans, wild and Rhodesian  Acute 
 
East and south 
rhodesience animals 
 
sleeping sickness 
  
Africa 
 Trypanosoma brucei  Humans,wild and Gambian 
 
Chronic 
 
West and 
 ganbiense 
 
domestic animals sleeping sickness 
  
centra Africa 
 
 
 
1.2.2. Animal trypanosomiasis 
African animal trypanosomiasis also referred to as Nagana is caused by Tb spp, Tb congolense 
and Tb vivax. These parasites cause relatively mild infections in wild animals while in domestic 
animals they cause often a severe and fatal disease. Domesticated animals can be affected by 
Nagana. As the illness progresses, the infected animals becomes more weaken and eventually 
become unfit for work, hence the name of the disease "Nagana" which is a Zulu word meaning 
"powerless / useless / depressed" (Steverding, 2008). Infections caused by certain trypanosomes 
occur outside Africa. Tb evansi, the causative agent of “Surra” occurs not only in Africa but 
infections are reported in the Middle East, Asia and South and Central America. Camels, horses, 
cattle, dogs and buffaloes can be affected by Tb evansi. T. vivax was also reported in Latin 
America (Jones, T.W and Davila, A.M., 2001) 
 
1.2.3. Tb epidemiology and transmission  
1.2.3.1. Epidemiology 
All cases of HAT are exported from Africa to other parts of the world by travelers. On an 
international perspective, HAT is confined to tropical Africa (table 1.1). The prevalence of HAT 
varies by country and region (figure 1.1). In 2005, major outbreaks were observed in the 
Democratic Republic of Congo, Angola and Sudan (Truc et al., 2012). Simarro et al. (2008) 
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reported that sleeping sickness remains an important public health problem in countries like the 
Malawi, Central African Republic, Congo, Chad, Côte d'Ivoire, Uganda, Guinea and Tanzania in 
central Africa. However, Kohagne et al. (2011) reported that less than 50 new cases per year are 
reported in Cameroon, Burkina Faso, Equatorial Guinea, Kenya, Gabon, Mozambique, Rwanda, 
Nigeria, Zimbabwe and Zambia. Tb transmission seems to have stopped and no new cases of 
African trypanosomiasis have been reported for several decades in countries such as Botswana, 
Benin, Burundi, Gambia, Ghana, Guinea, Ethiopia, Bissau, Mali, Liberia, Namibia, Sierra Leone, 
Niger, Senegal, Togo and Swaziland. 
 
 
Figure 1.1: Map of sleeping sickness distribution (Adapted from Fevre et al., 2008). 
 
1.2.3.2. Transmission  
Infection occurs through the bite of infected tsetse flies. The main reservoir host, are humans for 
Tb gambiense. Wild animals including antelopes and domesticated cattle are the main animal 
reservoir of Tb rhodesiense (WHO, 2012). Khonde et al. (1997) also reported on the rising 
incidences of HAT in specific communities relative to others have been linked to more intense 
human-fly contact.  
 
Humans are exposed to the disease as far as it is in the vicinity of tsetse fly infested areas. 
Various human activities and not limited to farming, fishing, hunting, water-related activities and 
herding are known to be risk factors for acquiring sleeping sickness (Laveissière et al., 1986; 
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Gouteux et al., 1993; Kohagne, 2011) Despommier et al. (2005) reported that infection can be 
acquired by eating raw meat from an infected animal. Mother to child infection (Oba et al., 
2011); accidental infections in the laboratory, organ transplantation, blood transfusion and sexual 
activities, congenital African trypanosomiasis may also occur (Rocha et al., 2004). 
 
1.2.3.3. The vector 
Tsetse, sometimes spelt as tzetze and also referred to as tik-tik flies (figure 1.2), are large biting 
flies. Tsetse flies are from the genus Glossina, family Muscidae and from the order Diptera 
(WHO, 2013).  Tsetse flies are also the primary biological vectors of Wunchereria bancrofti that 
causes Elephantiasis. 
 
 
Figure 1.2: (Left and right) Tb ssp. in thin blood smears stained with Giemsa. (Center) A close 
up of a tsetse fly, insect vector of Tb (taken from CDC, 2012). 
                                                                                                                                                                                                             
 
1.3. Tb life cycle, clinical features and pathogenesis 
1.3.1. Life cycle 
Tb has a biphasic life cycle, which starts in the insect vector, tsetse fly, followed by human host.   
 
1.3.1.1. Life cycle in insect vector 
The tsetse fly becomes infected by ingesting a blood meal from an infected host (figure 1.3 step 
5). In the insect vector’s midgut (figure 1.3 step 6) the trypanosomes transforms into procyclic 
trypomastigotes then into epimastigotes in the salivary glands (Sharma et al., 2009; Chou et al., 
2010), these epimastigotes continue multiplication by binary fusion (figure 1.3 step 7). These 
forms, in turn divide and transform further into metacyclic trypanosomes (figure 1.3 step 8), the 
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infective stage (Hunt, 2010). During a blood meal the tsetse fly can inject over 40 000 metacyclic 
trypanosomes. The minimum infective dose for most hosts is 300-500 parasites, although 
experimental animals have been infected with a single trypanosome (Murakami, 2003). 
 
1.3.1.2. Life cycle in the human host 
 
 
 
Figure 1.3: Life cycle of Tb rhodesience and Tb gambience parasites (taken from CDC, 2012). 
 
During a blood meal of tsetse flies, the metacyclic trypomastigotes are injected into the skin of 
the humans (figure 1.3, step 1). The parasites enter the lymphatic system and pass into the blood 
stream. The metacyclic trypomastigotes undergo an asexual binary fission, transforming into 
long slender trypomastigotes (figure 1.3, step 2). They are transported to other sites throughout 
the body and they reach the lymph and spinal fluid whilst they continue the replication by binary 
fission (figure 1.3, step 3). Within the blood stream of the mammalian host, the long slender 
trypomastigotes develops into short stumpy forms (figure 1.3, step 4). The short stumpy forms 
are thought to be pre-adapted to tsetse flies (CDC, 2012). 
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1.3.2. Clinical features, pathogenesis and pathophysiology of HAT 
African trypanosomiasis has an extremely variable clinical picture. Asymptomatic carriers of 
both Tb gambiense and Tb rhodesiense have been reported (Wurapa et al., 1984). Southern 
Africa trypanosomiasis becomes symptomatic 1 to 3 weeks after infection which develops 
rapidly. It is more disabling and often causes death within 3 to 6 months in untreated patients 
(CDC, 2012; WHO, 2013). Western Africa trypanosomiasis however, is known to cause chronic 
infection characterized by a more prolonged course. Clinically both Western and Southern 
trypanosomiasis develops in 3 clinical stages: chancre, hemolymphatic invasion and 
meningoencephalitis (figure 1.4). Without treatment all African trypanosomiasis patients may 
progress to death. The hallmark of the disease is the disturbances in sleeping cycles (Odiit et al., 
1997). 
 
The injected trypomastigotes divide in the blood and lymphatic system and eventually, the 
parasite invades the central nervous system, causing behavioral and neurologic changes, death 
may also occur (Odiit, 1997). CNS manifestation include meningoencephalitis that is 
accompanied by edema, bleeding and granulomatous lesions. (Poltera et al., 1977; Poltera, 1985; 
Enanga et al., 2002; Checchi et al., 2008; Klassen et al., 2011). 
 
Figure 1.4: Possible outcomes of untreated HAT that progresses to stage one and two with a 
resultant death if remains untreated (taken from Checchi et al., 2008). 
 
1.4. Prevention/control  
1.4.1. Prevention 
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No vaccine against human African trypanosomiasis exists at present. Chemoprophylaxis is not 
recommended due to the toxicity of the available drugs. Prevention mainly relies on passive and 
active case detection, early treatment and vector control to reduce exposure to tsetse bites (CDC, 
2012). Vector control activities in highly endemic and epidemic areas include fly traps, 
sequential aerosol spraying, spraying animals and sterile insect techniques. Early techniques 
involved slaughtering all the wild animals which tsetse fed on. Another early technique involved 
complete removal of brush and woody vegetation from an area. The inorganic metal based 
pesticides such as Dichlorodiphenyltrichloroethane (DDT) has been applied as aerosol (Kuzoe 
and Schofield, 2004).  
Sterile Insect Technique (SIT) involves the separation of the males and then irradiating them 
with large doses of gamma rays to make them sterile and then releasing them, any mating with a 
sterile male prevents any reproduction. This technique has lead to possible local eradication of 
the flies from Zanzibar (Allosopp, 2001). 
 
1.4.2. Treatment  
The type of treatment of African sleeping sickness depends on the stage of the disease.  
 
1.4.2.1. First stage treatment 
Pentamidine was discovered in 1941, despite non-negligible undesirable effects, Pentamidine is 
well tolerated by patients. Side effects include hypotension in 10% of patients, skin rash, 
nephrotoxicity, leucopenia and liver enzyme abnormalities (Barrett et al., 2003). Suramin was 
discovered in 1921 and used for the treatment of the first stage of Tb rhodesiense. Barrett et al. 
(2003) indicated that Suramin incites some undesirable effects, in the urinary tract resulting in 
patients taking suramin experiencing cloudy urine, crawling or tingling of the skin, diarrhea, 
faintness, skin rash, hypocalceia, anaemia and loss of appetite.  
 
1.4.2.2. Second stage treatment 
Melarsoprol was discovered in 1949, is used in both forms of infection. The most striking side 
effect of Melarsporol is reactive encephalopathy (encephalopathic syndrome) which can be fatal 
(3% to 10%). Eflornithine was registered in 1990 and has been reported to be less toxic than 
Melarsoprol (Chappuis et al., 2005). It is only effective against Tb gambiense and the regimen is 
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strict and difficult to apply. Side effects of eflornithine may include sore throat, fever, unusual 
bleeding or bruising, and unusual fatigue or weakness (McAtee, 2010). Inorder to simplify the 
use of Eflornirthine in monotherapy, a combined treatment of Nifurtimox and Eflornithine has 
been recently introduced (Alirol et al., 2013). 
 
1.4.2.3. The phenomenon of treatment failures 
Robays et al. (2008) reported increasing cases of treatment failure in the Democratic republic of 
Congo in which a suggestion was made to switch to a safer Eflornithine regimen. In 1977, 
Ruppol and Burke (1977), reported up to 40% Melarsoprol relapses in Tb patients in Zaire; this 
was also observed by Perez et al., 1991; Brun et al., 2001). This present situation of increasing 
drug resistant cases of human African trypanosomiasis raises a number of questions as to its 
actual cause. Are they due to the intrinsic character of the parasite or they are associated with 
patient’s metabolism? Is the drug resistance due to an acquired feature of the parasite when 
exposed to inadequate doses or is it due to the genetic trait of parasitic strains and can that strain 
be transmitted (WHO, 1999) all these questions inspires scientists globally to put more efforts in 
research.  
Brun et al. (2001), Gehrig and Efferth (2008) reported that Trypanosome brucei drug resistance 
could be caused by different mechanisms including changes in the metabolic pathways in the 
parasite that prevents the drug from reaching its target, intracellular accumulation of the drug is 
reduced by the impacted drug intake and increased drug export by various transporters. Baker et 
al., 2013 reported that Melarsprol and Pentamidine drug resistance can possibly be caused by the 
mutation of AQP2, a receptor associated with the accumulation of the drugs in the parasites. 
 
1.5. Hexokinase 
Tb relies entirely on the glycolytic pathway for its energy production in the mammalian host 
(Dodson, 2010). This shift in the metabolic pattern presents a chance to exploit and kill the 
parasite. A number of approaches have been reported of the exploitation of the enzymes and 
other associated proteins involved in the pathway for the development of therapy. Disruption of 
the glycolytic pathway in the bloodstream form trypanosomes has proved to kill the parasite 
(Verlinde, 2001). Hexokinase catalyzes the first step of the pathway; its inhibition will result in 
disrupting the glycolytic pathway, concomitantly killing the parasite. 
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Evidence supporting the targeting of hexokinase as a drug target includes; (i) genetically, 
ribonucleic acid interference (RNAi) of 3UTR of TbHK in BSF trypanosomes results to cell 
death due to the resultant disruption of the glycolytic flux (Morris, 2002; Albert, 2005; Lyda, 
2009); (ii) biochemically, Tb was validated to be a promising therapeutic target by the 
employment of structurally and chemically based inhibitors that have proven to kill the parasite 
in high concentrations (Trinquir et al., 1995; Wilson et al., 2002; Chembers et al., 2008). Joice et 
al. (2013) reported the use of the high throughput approach in finding more compounds that 
successfully inhibit the activity of TbHK, with the evidence above it proves that TbHK is very 
different from the human hexokinase and this fact is also supported by the evidence that as 
compared to its counterpart in humans, TbHK has only 30-33% sequence identity (Sharlow et 
al., 2010). 
 
1.5.1. Human hexokinase 
Hexokinase (D-hexose 6-phospho-transferase, EC 2.7.1.1.) is a protein which is classified under 
the main grouping of transferase enzymes. HK structure was first determined from yeast by Tom 
Steitz at Yale University. It is the first enzyme in the glycolytic pathway converting glucose into 
glucose-6-phosphate (Wilson, 2003). It uses ATP to phosphorylate the 6-hydroxyl group of 
glucose. Although HK has the ability to phosphorylate different hexoses, phosphorylation of 
glucose is by far its most important function. Four different isozymes of HK have been identified 
in mammals, namely, type I, type II, type III, and type IV which vary in their tissue distribution 
and kinetic properties (Grifin et al., 1991; Wilson, 2003). As the latter isozyme has a strong 
specificity for D-Glucose is also known as glucokinase. It is different from the other isoenzymes 
by its low affinity for glucose, its lack of inhibition by glucose-6-phosphate and its molecular 
mass of 50 kDa as compared to the other isoforms with molecular mass of 100 kDa (Tanizawa et 
al., 1991). 
 
The structure of human hexokinase (figure 1.5) types I-III isozymes consists of two globular 
halves; the N-terminal and C-terminal regions which are held together by a connecting helix and 
a few hydrogen bonds. The structure of each half is similar to that of yeast HK, which consists of 
two regions, i.e. the large and the small lobe. The glucose binding site is located in the bottom of 
the cleft between the two lobes. These three types of mammalian hexokinases appear to have 
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evolved from an ancestral HK of 50 kDa, by means of gene duplication and fusion. They display 
extensive sequence repetition (Wilson, 2003) both between them and between their N-terminal 
and C-terminal regions.  
 
 
 
Figure 1.5: Human hexokinase structure (Adapted from Rabeth et al., 2006). 
 
A common feature of these isozymes, also present in the ancestral HK, is the regulatory role of 
glucose phosphorylation through inhibition by its product (glucose-6-phosphate). However, each 
isoenzyme displays particular properties and differs from the others in its tissue specificity and 
probable activity. For example, while type II isozyme possesses catalytic activity in both halves, 
type I and type III isozymes have lost the catalytic activity of the N-terminal region. HK type I 
show a very unique regulatory property which is that the physiological levels of inorganic 
phosphate (Pi) can reverse the inhibition of glucose phosphorylation affected by glucose-6-
phosphate. This characteristic defines HK type I as an enzyme with a catabolic role, while the 
other hexokinase isozymes are considered to have mainly an anabolic role. This supports the fact 
that hexokinase type I is particularly abundant in highly energy-demanding cells (Wilson, 2003). 
The intracellular reactions mediated by HK can be typified by equation 1.1, where hexose-
CH2OH represents any of several hexoses (like glucose) that contain an accessible -CH2OH 
moiety. The hexose in the presence of magnesium ions and ATP is phosphorylated to glucose-6-
phosphate (figure 1.6) that also results in releasing ADP and hydrogen ion as by products. 
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Equation 1.1:   
Hexose-CH2OH + MgATP2  Hexose-CH2O-PO2
-3
 + MgADP
-
 + H 
 
 
Figure 1.6: Phosphorylation, catalyzed by hexokinase, is the first step in common pathways of 
glucose metabolism (taken from Wilson, 2003). 
 
In brief, glycolysis is a sequence of 10 enzyme-catalyzed reactions by which glucose is 
converted to pyruvate. Most of the enzymes found in this pathway are present in all living 
species and they are found in the cytosol of the cells. The conversion of one molecule of glucose 
to two molecules of pyruvate is also accompanied by the net conversion of two molecules ADP 
to two molecules ATP (figure 1.6). In addition to the two molecules of ATP produced (figure 
1.7), two molecules of NAD
+
 are reduced to NADH. In multicellular organisms, this pathway is 
found in all differentiated cell types. The overall reaction of glycolysis may be represented by 
equation 1.2 where glucose is converted into 2 molecules of pyruvate, with a resultant production 
of adenosine triphosphate and reduced nicotinamide adenine dinucleotide and 2 hydrogen 
molecules. 
 
Equation 1.2: 
C6H12O6 + 2 NAD
+
 + 2 ADP + 2 P  2(CH3(C=O) COOH + 2 ATP + 2 NADH + 2 H
+ 
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1.5.2. Tb hexokinase 
Tb expresses two hexokinases named TbHK1 and TbHK2 which are expressed in blood stream 
form and procyclic forms of the parasite (Colasante et al., 2006). The genes are arranged in 
tandem on chromosome 10. Other medically important parasites have similarly arranged 
hexokinase genes.  Leishmania major has a pair of hexokinase gene located on chromosome 21 
which is 62% identical to TbHK (Morris et al., 2006). The two polypeptides are approximately 
98% identical, with 7 of 10 differences in the C-terminus region of the protein. These changes 
are very influential in ATP binding and hence its activity (Chambers et al., 2008). TbHK have 
previously been reported to be localized to the glycosome where Tb glycolysis occurs (Misset 
and Opperdoes, 1984; Colasante et al., 2006). Biochemical studies have revealed that authentic 
and recombinant TbHK multimerize to hexamers (Misset and Opperdoes, 1984; Morris et al., 
2006). Notably recombinant TbHK2 (rTbHK2) is not active by itself but in complex with TbHK1 
the enzyme is active (Chambers et al., 2008). 
 
1.5.2.1. Tb glycolytic pathway as a drug target  
Glycolysis has proved to be an exploitable pathway for anti-trypanosome therapeutic 
development. This change in metabolic pattern is the weakness that can be exploited to kill the 
parasite. 
 
The BSF of the parasite cannot survive disruption of glycolysis (Verlinde et al., 2001). When the 
parasites differentiate to the BSF they change not only their metabolic pathway to that of 
glycolysis but also lose most functionality of the singular mitochondrion through the repressed 
expression of mitochondrial targeted proteins (Williams, 2008). Therefore, without a completely 
functional mitochondrion, inhibition of the glycolytic pathway is toxic. Glycolysis in the African 
trypanosome occurs in the specialized organelles known as glycosomes (Opperdoes and Szikora, 
2006). This is distinct from most organisms in which glycolytic activities are cytosolic. 
Targeting of proteins to the glycosome is mediated by two peptide sequences known as 
peroxisomal targeting sequence 1 (PTS 1) (Gould, 1989) and peroxisomal targeting sequence 2 
(PTS 2). PTS1 sequences are found on the C-terminus of proteins while PTS2 sequences are 
found on the N-terminus of proteins. Both PTS sequences mediate the incorporation of 
glycosomal proteins (Blattner et al., 1995; Lyda, 2009). However, all glycolytic and metabolic 
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enzymes are not exclusive to the glycosome. Some of these metabolic enzymes such as adenylate 
kinase, enolase and phosphoglycerate mutase have been shown to be found in flagellum and 
cytosol of Tb (Pullen et al., 2004). 
 
1.5.2.2. TbHK as drug target 
Studies on genetic evidence support the targeting of TbHK1 in anti-trypanosome therapeutic 
development. RNA interference of TbHK1 and TbHK2 in the blood stream form parasites, led to 
cell death due to a disruption of glycolytic flux (Albert et al., 2005; Lyda, 2009), however gene 
silencing of TbHK1 and TbHK2 in the insect form parasite had not significant effect as the 
parasite can adapt to the inactivation of hexokinase and switch to the use of amino acid 
metabolism for its energy production (Chembers et al., 2008). Biochemical validation of TbHK 
as therapeutic targets has also been carried out. Inhibitors of TbHK1 can be tested easily in vitro 
by using a simple hexokinase assay to monitor the inhibition patterns. Chambers et al. (2008) 
demonstrated that TbHK have showed inhibition by fatty acids. 
 
Structurally based inhibitors of TbHK have been used in the past but are trypanocidal at high 
concentrations (Trinquier et al., 1995; Willson et al., 2002). Known hexokinase inhibitors were 
tested against TbHK1 and trypanosomes, and from these inhibitors of hexokinases, two were 
investigated, lonidamine (1-(2, 4-dichlorobenzyl)-1H-indazole-3-carboxylic acid) and quercetin 
(QCN) (Sharlow et al., 2010). Lonidamine has shown to inhibit hexokinases bound to the 
mitochondrion of mammals; hence lonidamine is described as an inhibitor of aerobic glycolysis. 
In the past, lonidamine mediated hexokinase inhibition has been used for cancer therapeutics and 
male contraception (Silvestrini et al., 1984 and 1991; Lyda. 2009). However, lonidamine has not 
yet been approved for use as a male contraceptive in humans. In recent years, lonidamine has 
been found to inhibit recombinant TbHK1 in vitro, hence, a promising drug for Tb infection 
(Chambers et al., 2008). Lonidamine has also been reported to have similar effects of inhibiting 
TbHK counterparts in Leishmania mexicana promastigotes (Turrens and Cuzzulo, 1987) and Tb 
cruzi epimastigotes (Turrens, 1986). In both L. Mexicana promastigotes and Tb cruzi 
epimastigotes this inhibition of hexokinase resulted in concomitant inhibition of glycolysis 
(Chembers et al., 2008). Turrens in 1986 reported the impact of lonidamine on the respiration of 
the parasitic forms of Tb where the blood forms of the parasite were sensitive, however; 
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Chembers et al. (2008) reported the inhibition if the recombinant TbHK1 and hence the activity 
of hexokinase from Tb trypomastigotes lysates. 
 
Quercertin (3,5,7,3’,4’-pentahydroxyflavone) is a bioflavonoid isolated from plants, has shown 
to exhibit antioxidant properties as well as play a role in the signaling between plants and 
microbes for nodulation.The key feature of QCN is that it inhibits enzymes such as tyrosine 
protein kinase, a phosphorylase kinase, a phosphatidyl 3-kinase and a DNA topoisomerase. QCN 
has been shown to inhibit the growth of cancer cell lines. QCN not only affects cancer cells it 
also appears to affect any rapidly dividing cell, even BSF parasites. QCN is toxic and induces 
apoptosis at a relatively low level with an LD50 of 10 µM QCN. While the connection between 
QCN and apoptosis is not resolved, apoptosis is linked in mammalian cells with mitochondrial 
associated hexokinase activity. In fact, an increase in hexokinase activity can prevent apoptosis 
induced by oxidative stress (Lyda, 2009; Dodson et al., 2011). QCN has toxic effects against 
Leishmania donovan (Mittra et al., 2000) and Tb gambience (Mamani-matsuda et al., 2004).  
 
1.6. Nanotechnology 
Nanotechnology refers to the manipulation of matter on an atomic or molecular level. In recent 
years nanotechnology is emerging as the most interesting and promising technology that is used 
in various disciplines, such as, physics, chemistry, biology, material science and medicine. A 
nanometer is 1 x 10
-9
 m or one millionth of a millimeter. The prefix “nano” is derived from the 
Greek word “nanos” which means “dwarf”.  
 
1.6.1. Nanoparticles (NPs) 
NPs are those particles that are in sizes ranging from 1-100 nm, classified as natural, incidental 
and engineered. NPs may be known by a number of alternative and trade-specific names, 
including particulate matter, aerosols, colloids, nanocomposites, nanopowders, and nanoceramics 
depending on the application of interest. During the 1970s when the first studies were conducted 
with NPs in the USA by Granqvist and Buhrman and in Japan by C.H. Hayashi within the 
ERATO project they were referred to as ultrafine particles. However in the 1990s the name NPs 
came to full use. The original concept of nanotechnology was spoken by Richard Feynman in his 
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lecture entitled “There’s plenty of room at the bottom” at the American Institute of Technology 
in 1959; the idea that was later published in his book in 1961. 
 
1.6.2. Properties of NPs 
Great scientific interest is put on NPs as they are said to be an effective bridge between bulk 
materials and atomic or molecular structures. At the nano-scale, size-dependent properties are 
often observed as compared to the bulk material that have constant physical properties regardless 
of its size, thus, the properties of materials change as their size approaches the nano-scale and as 
the percentage of atoms at the surface of a material becomes significant (Thakkar et al., 2010; 
Ahmed et al., 2013).  
 
1.6.2.1. Optical properties 
NPs often possess unexpected optical properties as they are small enough to confine their 
electrons and produce quantum effects. For example gold NPs (AuNPs) appear deep red to black 
in solution. Silver NPs (AgNPs) appear yellow to deep reddish-yellow in color and they exhibit a 
plasmon resonance of ± 400 nm (Das et al., 2009), as compared to gold NPs that has a plasmon 
resonance band of ± 500 nm (Huang et al., 2009; Khlebtsov and Dykman, 2009). 
 
1.6.2.2. Melting properties 
AuNPs are reported to have much lower melting temperatures (~300°C for 2.5 nm sizes) than the 
gold slabs (1064°C) (Buffat and Borel, 1976). Lower melting temperatures were also observed 
(Chang-dong Zou et al., 2009) for Tin NPs with diameters of 81, 40, 36 and 34 nm which were 
226.1, 221.8, 221.1 and 219.5°C, respectively. Tin/silver alloy nanoparticle of around 10 nm 
melted at 198°C, 13°C lower than the micrometer sized nanoparticle which was 222.6°C (Jiang 
et al., 2007). Yang et al (2013) as well as Li et al. (2013) reported on an increase in solar 
absorption observed in solar cells coated with silver NPs. 
 
1.6.2.3. Magnetic properties 
Oxides (ferrite), metallic and metallic with shell NPs (Fe, Co, Ni, Gd) are the current magnetic 
NPs. However these NPs have properties that largely depend on the synthesis and chemical 
structure. Ferrite NPs once they become smaller they display a phenomenon called 
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“superparamagnetism” which is a random flip of the direction of magnetism under the influence 
of temperature thermal energy (Conchero et al., 2010). Other size-dependent property changes of 
NPs include quantum confinement in semiconductor particles and surface plasmon resonance in 
some metal particles.  
 
1.6.3. Applications of NPs 
1.6.3.1. NPs in medicine 
Nanomedicine is a subdivision of nanotechnology that refers to the use of nanotechnology in the 
field of medicine (Sadanandan, 2011). Terms such as biomedical nanotechnology, 
nanobiotechnology and nanomedicine are used to refer to this new field.  
 
1.6.3.1.1. NPs in diagnostics  
NPs have been used in the detection of Influenza A DNA sequence (Bonanni et al. 2010; 
Driskell et al., 2011), quantification of HIV-1 (Block et al., 2012), direct detection of 
Mycobacterium tuberculosis in clinical samples (Baptista et al., 2006), identification of 
methicilline-resistant Staphylococcus aureas (Ramakrishnan et al., 2004).  
 
1.6.3.1.2. NPs in drug delivery systems 
NPs are widely researched and actively developing in the targeted delivery of drugs (Dykman et 
al., 2011). Prepositions were made on the conjugation of various antitumor agents to NPs, with a 
reported high efficacy when conjugated to NPs. Antibodies, antibiotics and NP conjugates have 
also been studied. Vancomycine and gold NPs have been used against E. coli, E. faecium and E. 
faecalis (Mitra et al., 2001; Zamboni, 2005; Dykman and Khlebtsov, 2011; Samra et al., 2013).    
 
1.6.3.1.3. NPs in therapy 
NPs have been reported to be used in a variety of ways for therapeutic purposes. Photothermal 
therapy (photothermal cell damage) is an emerging therapy for both tumor and infectious 
diseases (Dykman et al., 2011). Hirsch et al. (2003) as well as Zharov et al. (2003) described the 
application of gold NPs as an agent of Photothermal therapy; Pitsillides et al. (2003) reported a 
technique of selectively damaging targeted cells by the use of 20-30 nm. NPs could be delivered 
into the tumor cell by passive and active methods (Sinha et al., 2006), with active delivery 
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method reported to be the most efficient and reliable. Antibodies to the tumor markers like 
Epidermal Growth Factor Receptor (EGFR) and the Tumor Necrotic Factor (TNF) are employed 
(Dykman et al., 2011; Nguyen, 2012; Liu et al., 2013).  
 
Photodynamic therapy can be used in the treatment of cancer, dermal and infectious diseases. It 
is based on the use of light sensitive agents and visible light of a particular wavelength to destroy 
diseased cells and tissues by producing toxic oxygen after the photosensitizers have been exited 
(Dykman et al., 2011). Rodriguez et al. (2011) reported the use of photodynamic usage in vitro 
photodynamic inactivation of Cryptococcus neoformans cells.  
 
Magnetic NPs have been employed in tissue engineering strategies called Magnetic force-based 
tissue engineering (Mag-TE). Cells may be manipulated and organized by the use of a magnetic 
force while maintaining their functionality. This has been tested with various cell lines including 
human umbilical vein, endothelial cells, retinal pigment epithelial cells, keratinocytes, 
mesenchymal stem cells and cardiomyocytes (Corchero et al., 2010). The same NP magnetic 
properties have been utilized in gene therapy procedures. NPs complexes with viral vectors and 
nucleic acids as a new approach in gene therapy called magnetoinfection were made available 
(Herranz et al., 2011). The above approaches have reported results that are 40 fold higher in 
transfection efficiency over the standard conditions (Conchero et al., 2010). 
  
NPs have been reported to be used in water treatment studies (Doyle, 2006; Diallo, 2006 Shen et 
al., 2011), energy production storage and conservation (Li et al., 2013), aircraft and vehicle 
manufacturing (Meyer et al., 2009), in civil engineering and construction (Mann, 2006), in 
production, processing, safety and packaging of food stuffs, with a reported 1317 known or 
claimed nano-products.  In cosmetics, nanotechnology has been applied in production of 
sunscreens (Scown et al., 2009). In sports such as soccer, football and baseball, nanotechnology 
also plays a role (Thomas et al., 2006). 
 
1.6.4. Metallic nanoparticle 
It has been reported that metal NPs have shown and reported to have unusual properties that they 
normally will not have while in their bulk form. With their unlimited potential and benefits they 
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have been reported to be used in various nanotechnological studies and innovations such as in 
biochemistry as they are considered good catalysts, in information systems and in medicine, in 
heavy industry (Fauss, 2008; Sennuga, 2011). 
 
1.6.4.1. Synthesis of metallic NPs 
Metal NPs are an important tool for the advancement of nanotechnology in various areas. For the 
fact that they are not only abundant in nature since living organisms operate at a nano-scale 
(Doyle, 2006), and since NPs display unusual properties depending on their size and shape it is 
the imperative that NPs must be synthesized with limited variations in shapes and sizes 
(Sennuga, 2011). NPs are a product of various processes be it chemical, physical or biological, 
some of which have been available for long in conventional science and technology and some of 
these processes are fairly different (Aitken et al., 2004; Sennuga, 2011). 
 
Nanoparticle synthesis may occur in either top-down or bottom up processes. Top-down methods 
involves the production of NPs from its bulk material which involves the breakdown of the bulk 
materials into smaller pieces by the use of chemical and mechanical means via attrition or 
milling. This leads to NPs with a bread size distribution (10-1000 nm), varied particle shapes or 
geometry and impurities (Overney, 2010). The bottom-up approach involves the synthesis of 
NPs by the chemical reaction between atomic or molecular species; it allows the gradual growth 
of the precursor particles via Pyrolisis, Inert Gas Condensation, Solvothermal reaction, Sol-Gel 
Fabrication and Structured Media. Both top-down and bottom-up methods can be carried out in 
liquid, gas or supercritical fluids, solids or in a vacuum (Sennuga et al., 2012). 
 
1.6.4.1.1. Chemical synthesis of metallic NPs 
The major chemical methods for the synthesis of metal NPs in use are categorized into two main 
categories; sol-gel and gas phase synthesis. With these methods metal NPs of diameter ranges 
from 1-10 nm are realized with a very uniform crystal structure and also with a high level of 
monodispersity of about 20% variation in their sizes. However in order to achieve a much better 
quantum confinement, the monodispersity must be reduced to as low as 5% or even less (Murray 
et al., 1993). These chemical methods of synthesis of NPs greatly depend on the availability of 
the right metal/metal organic precursors (Theodore and Kunz, 2005). The main disadvantage 
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with this approach is that it needs high and harsh conditions, such as temperature, pressure, and 
the use of highly flammable organic solvents that are required in the production of the NPs. 
These processes have little control over the monodispersity (Mukherjee et al., 2001). 
 
Gas phase process employs the use of the following; a vacuum chamber with heating elements, 
the precursor metal, equipment to collect the powder as first reported in 1930 (Luther, 2004). 
The process utilizes an inert gas, at pressures high enough to enable the formation of NPs, but 
low enough to allow the production of spherical NPs. Metal precursor is then introduced onto a 
heated element and is rapidly melted. The metal is quickly taken to temperatures far above its 
melting point, but less than its boiling point in order to adequate vapor pressure. Gas is 
continuously introduced into the chamber and removed by the pumps, so the gas flow moves the 
evaporated metal away from the hot element. NPs start to be formed as the gas cools the metal 
vapor; the formed NPs are still in a liquid form due to the extreme high initial temperatures 
(Kruis et al., 1998). 
 
While the NPs are still in their liquid state they collide and fuse together in a fixed environment 
and the NPs grow to specification, remaining spherical and with smooth surfaces. As the liquid 
particles are further cooled under control, they become solid and grow no longer. At this point 
the NPs are very reactive, so they are coated with a material that prevents further interaction with 
other particles or with other materials. Other chemical techniques used in the chemical synthesis 
of NPs includes; sonochemical technique, cavitation technique, microemulsion technique and 
high-energy ball milling technique (Santra et al., 2001). 
 
1.6.4.1.2. Biological synthesis of metal NPs 
The biological method of synthesis of NPs has a number of advantages as compared to the 
previously described chemical methods. Chemical methods involve the use of toxic solvents and 
the generation of toxic by-products. High energy consumption, these threaten the well being of 
the environment and humans. In addition their high cost and the production of limited shapes of 
the synthesized NPs negatively affect their potential properties and usability (Thakkar et al., 
2010). Accordingly, there is an urgent need to develop other more environmentally friendly 
methods for the synthesis of NPs that will possibly eliminate all the above mentioned drawbacks 
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as well as produce the desired results. The biological approach looks to be the promising 
approach in achieving low-cost, energy-efficient, and non-toxic metallic NPs synthesis (Riddin 
et al., 2006; Thakkar et al., 2010). 
 
The use of microorganisms in bioremediation technologies have previously been reported 
(Riddin et al., 2006) and due to their ability to detoxify an environment by reduction of metal, 
they have been reported to be very environmentally friendly nanofactories. Riddin et al. (2006) 
reported that many single-celled organisms are capable of producing mineral structures from 
inorganic materials be it intra- or extracellular. Studies have shown that these particles are not 
monodispersed and the rates at which they are formed are rather slow despite reports that NPs 
synthesized by microorganisms are stable (Sennuga, 2011). In order to overcome the above 
challenge, the optimization of some of the factors involved in the synthesis process needs to be 
done, parameters includes the cultivation methods of the microorganisms and the technique of 
harvesting or the use of combination approach such as photo-biological method (Vaidyanathan et 
al., 2010; Narayanan and Sakthivel, 2010). 
 
A better understanding of the mechanisms involved in the synthesis of metallic NPs by these 
microorganisms at cellular, biochemical and molecular levels may provide vital information on 
how to improve the rate of synthesis, nanoparticle quality and their properties (Sennuga, 2011). 
Plant extracts or biomass has also been reported to be another biological tool in the synthesis of 
metallic NPs (Thakkar et al., 2010). Gold and silver and other noble metallic NPs have been 
reported to have been synthesized using plant leaf and fruit extracts. However these routes do not 
sufficiently address the problem of particle monodispersity and uniformity which is very 
important in the applications of these NPs (Thakkar et al., 2010). 
 
Recently biomeneralisation involving cage-like proteins as a growth limiting aspect in the NP 
synthesis has given more light as a potential method of obtaining NPs with a homogeneous size 
distribution. The protein is reported to serve as a guide to control nanoparticle growth and also 
prevents aggregation of the NPs since each nanoparticle is coated as it is produced (Xu, 2005). 
Figure 1.7 summarizes the protein shells being used to synthesize various types of NPs 
especially of metal origin, with ferritin and apoferritin being the most commonly used. Ferritin 
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and apoferritin have exactly the same structure except that ferritins have an iron core and 
apoferritin have no iron core (Sennuga, 2011).  
 
 
 
Figure 1.7: A schematic drawing of the cage of protein apoferritin without iron core and ferittin 
with iron core (Adapted from Iwahori and Yamashita, 2007). 
 
NPs encapsulated in protein cages have recently been proven to be efficient in carrying food and 
drugs to specific targets in biological system because of their useful properties of 
biodegradability, non-toxicity, non-antigenicity, high stability and long shelf life (Rahimnejad et 
al., 2009; Sennuga, 2011). 
 
1.6.5. Characterization of metal NPs 
NPs can be characterized in many various ways as nanotechnology is an interdisciplinary field. 
Some of the more common NPs characterization techniques used is summarized in table 1.2. 
 
There are over 700 methods for NPs characterization and about 100 of those have been 
documented. Nanoparticle characterization methods are mainly based on two physical processes; 
the first is primary (1
o
) analytical probes such as photons, neutrons, ions and electrons. The 
second process is the measurable second effects obtained e.g. the release or absorption of 
electrons, electromagnetic radiation, volume change, mechanical distortion. During the process 
of characterization, the primary probe upon interaction with the analyte causes a change in its 
equilibrium and responds so as to gain its equilibrium state in so doing it modifies the primary 
probe. This primary probe modification produces secondary effects which is now the measured 
signal (Sennuga, 2011). 
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Table 1.2: Examples of techniques used to characterize NPs (adapted from Sennuga, 2011). 
Characterization  
technique 
Properties analyzed Brief description 
 
UV-Visible 
spectroscopy 
 
Surface plasmon of metal NPs  
 
Based on the absorbance of photons in the 
visible, near UV and near infrared regions of 
the electromagnetic spectrum.  
 
 
ICP AES/OES 
 
Identification, quantification of 
chemical elements in NPs 
 
Utilizes the intensity of light emitted by exited 
atoms at their characteristic wavelength and 
quantifies it as the concentration of the 
elements within a sample. 
 
 
 
TEM, SEM and 
EDAX 
 
 
Size, shape, monodispersity and 
composition 
TEM utilizes transmitted electrons while SEM 
backscattered electrons to generate sample 
images. 
 
XPS 
 
Analysis of surface/depth atoms 
of NPs 
 
Very sensitive to chemical composition and 
environment of elements in a material, provides 
quantitative analysis of the surface 
composition. 
 
 
FTIR 
 
 
Functional groups of NPs 
 
Secondary symmetrical and asymmetrical 
vibrations are measured and quantified by 
Raman and infrared spectroscopes respectively.  
 
 
DLS 
 
Size distribution in solution 
 
Utilizes the NPs Brownian motion and relate it 
to an equivalent hydrodynamic diameter. 
 
AFM 
Topology/imaging/surface 
structure of NPs 
Utilizes probe-sample interaction. 
 
 
 
1.6.6. Safety of NPs 
The novel and unique physicochemical, magnetic, optical and biological properties of NPs 
though very vital in science and technology compared to their bulk materials may potentially 
lead to serious human and environmental risks (Oberdorster et al., 2005; Sennuga. 2011). 
However, the toxicity of the current and emerging nanomaterials is not fully understood by 
scientists hence its one of the growing area of investigation. In working towards dealing with 
toxicity associated with nanomaterials, a new field of Nanotoxicology has been developed with 
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the aim of investigating possible harmful effects due to exposure to nanomaterials, also 
encompassing proper nanomaterials characterization (Donaldson et al,. 2004; Oberdorster et al., 
2005). Lam et al. (2003) reported pulmonary toxicity of single celled carbon nanotubes in mice 7 
and 90 days following intratrachael instillation observed by induced lung lesions. Recently in 
vitro and in vivo studies have reported that inhalation and dermal absorption of some NPs may 
have very detrimental health effects (Dreher, 2004; Nowack and Bucheli, 2007; Kagan et al., 
2005; Inoue et al., 2006; Linkov et al., 2008; Mironava et al., 2010). While many uptakes and 
translocation routes have been demonstrated (figure 1.8), many others are still hypothetical that 
needs investigations. Largely what are mostly unknown are translocation rates, accumulation and 
retention in vital sites and their underlying mechanisms (Oberdorster, 2005). 
 
Figure 1.8: Biokinetics of NPs (taken from Oberdorster, 2005). 
 
1.6.7 NPs – protein interaction 
The study of the behavior of NPs once introduced to physiological conditions both in vitro and in 
vivo is receiving much interest in research circles. Its application in the medical field is also in 
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huge possibility. The surface of NPs, which have been introduced into a biosystem, would be 
covered by numerous biomolecules present; these are mainly proteins (Ashby et al., 2013). 
These interactions govern the functions and fate of the NPs once in the biosystem. There are over 
3000 proteins present in plasma, a range of equilibrium constants, each with affinities and 
exchange times that are different (Lynch and Dawson, 2008; Ashby et al., 2013). Nanoparticle-
protein corona, a concept of how NPs and proteins associate in a biosystem was introduced in 
2008 by Lynch and Dawson. In this phenomenon, proteins in high concentration rate and with 
high affinity constants would associate first with the nanoparticle surface. This association may 
also dissociate rapidly and be replaced by a lower concentration, slower exchange by higher 
affinity protein. However, little information is available on how particle size and surface 
characteristics would affect the association and dissociation rates and how it would 
simultaneously affect the interactions between NPs and all cellular surface receptors (Ashby et 
al., 2013). 
 
1.7. Research focus  
1.7.1. Hypothesis 
This research will be centered on the hypothesis as deduced below: 
The inhibitory effects of silver NPs on the activity of Trypanosoma brucei hexokinase and 
human hexokinase differ. 
 
1.7.2. Objectives 
 Cloning, expression, purification and characterization of TbHK and hGCK.  
 Chemical synthesis of silver NPs. 
 Evaluation of the effect of NPs on the activity of the biomedical target, human and 
TbHK. 
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Chapter 2 
Molecular cloning 
2.1 Introduction 
Molecular cloning refers to a set of experiments in the molecular biology discipline that are 
employed to assemble a recombinant DNA molecule and to direct its replication within a host 
organism. Cloning itself refers to the amplification of a single molecule of DNA to a large 
population of DNA molecules that are identical. Despite cloning being a set of fairly simple and 
straight forward procedures, it is of paramount importance because it allows the attainment of a 
pure sample of a specific gene (Brown, 2010). In order for the gene of interest to be successfully 
transferred into the host cell, the use of DNA transfer vehicles is employed. Plasmids and viral 
chromosomes are natural DNA molecules that are widely used as DNA transfer vehicles (Brown, 
2010). 
 
For a DNA molecule to act as a vehicle for gene transfer in molecular cloning, it should be 
capable of entering and replicating in a host cell (Brown, 2010). Plasmids are small circular 
DNA molecules that are found in almost all bacteria and other organisms including yeast and 
algae (Griffiths, 1995). The replication of these extra chromosomal DNA molecules depend on 
the encoded enzymes and proteins to enable the host bacterial cells to replicate them, they often 
contain genes that code for enzymes that are advantageous to the host bacteria (Brown, 2010; 
Sambrook and Russel, 2001). Virus chromosomes are essentially the chromosomes of 
bacteriophage; these are viruses that usually affect bacteria. 
 
Further characteristics of plasmids reveal that they carry origins of replication that are derived 
from a single stranded bacteriophage; such vectors are also termed phagemids. Plasmid vectors 
have promoters from bacteriophage; these promoters may be T3, T7 and/or SP6 that are placed 
next to the multiple cloning sites of the plasmids. Characteristically, several plasmid vectors also 
contain gene sequences that encode for a lethal gene that only gets suppressed when a foreign 
DNA segment is inserted into the plasmid vectors on the multiple cloning sites of the plasmid 
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vectors. This property helps in the positive selection of the transformed host cells (Sambrook and 
Russel, 2001). 
 
2.1.1. Steps in molecular cloning 
A set of molecular cloning experiments usually revolves around seven main steps: (i) Selection 
of plasmid vector and host organism required for a specific activity: specialized applications 
need specialized host-vector systems, (ii) Preparation of vector DNA, (iii) Preparation of DNA to 
be inserted, (iv) Creation of recombinant DNA, (v) Propagation of plasmid vectors carrying 
foreign DNA of interest, (vi) Transfection and (vii) Identification of clones with a DNA insert 
(Neumann et al., 1982; Wirth et al., 1989; Russel and Sambrook, 2001; Brown, 2010). 
Transformation is one of the major aspects in molecular cloning because it allows the 
introduction of modified DNA molecules into the host cells. Some bacteria such as Bacillus 
subtilis, Haemophillus influenza, Streptococcus pneumonia and Cyanobacteria are naturally 
transformable, while others such as Salmonella species, some Pseudomonas strains and E. coli 
can be made transformable by treatment with chemicals such as calcium. E. coli is the most 
widely used bacterial host in molecular cloning procedures and it effectively interacts with DNA 
molecules in the presence of calcium ions, lower temperatures and heat pulses (Mandel and 
Higa, 1970; Hanahan and Harbor, 1983). 
Plasmid vectors are important because they can be used in the generation of multiple proteins, 
they are very small in size making them simple to manipulate and purify, they have their own 
origin of replication and with this property they can duplicate independently, selectable agents 
such as antibiotics can be incorporated for screening and separation, and commercial plasmids 
have restriction endonuclease sites incorporated, this facilitates easy cutting and ligation of genes 
(Casadaban et al., 1980; Madigan and Martinko, 2006).  
 
2.1.2. Application of molecular cloning 
Molecular cloning provides an unlimited use in various disciplines including basic applied 
biological sciences. Molecular cloning provides a platform for the production of various 
recombinant proteins that may be applied in medicine. Clinically, recombinant proteins have 
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been approved for the treatment of patients with cystic fibrosis (Phung et al., 2010); various 
leukemias (Quesada et al., 1986), chronic hepatitis C infections (Yang et al., 1989), genital warts 
(Yang et al., 2009), multiple sclerosis (Sellebjerg et al., 2012), thrombosis (Eriksson et al., 
1996), anemia (Schreiber et al., 1996), correction of hemophilia (Oldenburg et al., 2009). 
 
Anti-trypanosome therapeutic development has taken advantage of the various ways by which Tb 
glycolytic pathway can be exploited. Studies conducted by Colosante et al. (2006) showed that 
Tb survival was affected when the glycolytic pathway was disrupted. When the parasite 
differentiates into the blood stream form it almost solely depends on glycolysis for its energy 
production, hence disruption of the pathway is toxic to the parasite. Hexokinase is the first 
enzyme in the pathway; its inhibition is of importance in the disruption of the pathway. The use 
of structural inhibitors (Trinquier et al., 1995), as well as gene silencing and RNA interference 
studies (Lyda, 2009; Albert et al., 2005) have shown that inhibition of TbHK activity disrupts the 
glycolytic pathway, leading to cell death. 
 
The aims of this chapter are: 
1. PCR amplification of the Tb (TREU 927) hexokinase and human glucokinase genes. 
2. Cloning of the PCR amplified genes into cloning vectors and confirming nucleotide 
sequences by Sanger sequencing. 
3. Sub-cloning of the sequence confirmed genes into the relative expression vectors. 
4. Transformation of chemically competent host cells with the recombinant DNA constructs. 
 
 
2.2. Materials and Methods 
In order to obtain TbHK and hGCK genes, both genes were PCR amplified (Saiki et al., 1988) 
using genomic DNA (gDNA) for TbHK and complemetary DNA (cDNA) for hGCK as 
templates 
 
Initial denaturation of the double strand deoxyribonucleic acid (dsDNA) with the subsequent 
formation of a single stranded deoxyribonucleic acid (ssDNA) is achieved by heating the dsDNA 
at temperatures of 95
°
C
 
or 98
°
C. The sample is then cooled to facilitate the annealing of the 
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primers to their specific target sites. This also initiates the replication of the DNA by polymerase 
downstream of the primer binding site over a period termed elongation time. After DNA 
amplification, the DNA was cloned into cloning plasmid vectors, i.e. Clonejet
®
 plasmid for 
TbHK utilizing blunt end cloning and pGEM-T
®
 easy plasmid for hGCK utilizing sticky end 
cloning. For further amplification, plasmids were transformed into E. coli JM109 cell lines for 
TbHK and E. coli TOP10 cell lines for hGCK. DNA plasmid extractions were performed 
accordingly. Screening for positive insertion of the genes was performed by double restriction 
digestion with subsequent DNA agarose gel electrophoresis for visualization. 
 
Sequencing of the cloning plasmid vectors harboring respective target genes was performed. 
Two main methods of DNA sequencing are available; the Maxan-Gilbert method, this method is 
based on the use of chemical modification of the DNA followed by cleavage at specific bases. 
This method allowed possible sequencing of purified dsDNA without further cloning. However 
this method was discouraged due to its extensive employment of radioactive labeles. The Sanger 
method also known as the chain-termination method is an automated method which takes 
advantage of the DNA polymerase from E. coli that is capable of synthesizing a compliment 
DNA strand from a ssDNA without employing primers. This technique utilizes 2',3'-
deoxynucleotide triphosphates (ddNTPs). ddNTPs are different from the normal 
deoxynucleotides because they lack a hydroxyl group that is replaced with a hydrogen atom at 
the 3' carbon. These modified molecules are responsible for causing the termination of DNA 
chain extension because they are incapable of forming a phosphodiester bond with the 
subsequent deoxynucleotide (Sanger and Coulson, 1975). Sequencing results were analyzed 
using FinchTV version 1.4.0 and BioEdit Version 7.2.3 and DNAssist version 3.0 softwares. 
 
2.2.1. Bacterial strains, plasmids and culture conditions 
Chemically competent E. coli strains JM109 (Promega), TOP10 (Invintrogen) and BL21(DE3) 
containing pRARE2 (Lucigen) were used as hosts for genetic manipulation and expression of 
proteins. Transformed E. coli cells were cultured in Luria-Bertani (LB) medium (agar and broth) 
(10 g.l
-1
 tryptone, 5 g.l
-1
, yeast extract, 5 g.l
-1
, sodium chloride, pH 7) at 37°C, aerobically (200 
rpm). Selective pressure was achieved by using the required antibiotic/s, either 100 µg.ml
-1 
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ampicillin (AMP) and 100 µg.ml
-1 
spectinomycin (SPSM), 34 µg.ml
-1 
chloramphenicol (CAM) 
or 30 µg.ml
-1 
kanamycine (KAN). 
 
The TbHK PCR product (obtained as described in section 2.3) was sub-cloned into the CloneJet
®
 
(Thermo Scientific) vector system (figure 2.1A). CloneJet
®
 can be used for either blunt-end or 
sticky end cloning. It contains a β-lactamase gene which confers resistance to AMP. It also 
contains a lethal gene (eco471R) which is disrupted by the ligation of the target gene into the 
vector. This facilitates screening as only cells with recombinant plasmids are able to grow on the 
ampicillin containing LB agar plates. 
 
Figure 2.1: (A) Vector map of CloneJet
®
 indicating ampicillin resistance gene, T7 promoter, and 
the multiple cloning site. (B) Vector map of pGEM-T
®
 easy vector indicating ampicillin 
resistance gene, F1 origin of plasmid replication, T-overhangs, T7 promoter and LacZ coding 
Sequence. 
 
The hGCK PCR product (obtained as described in section 2.3) was sub-cloned into the pGEM-
T
®
 Easy vector system (figure 2.1B). The vector contains T7 and SP6 polymerase promoters 
within the α-peptide coding region of the enzyme β-galactosidase. Ligation of a DNA insert into 
the cloning site inactivates the α-peptide and allows for the selection of recombinant DNA 
constructs based on blue/white screening (Chaffin, 1998). The vector has T-overhangs in the 
cloning site that allows for TA-cloning and it also prevents the vector from re-circularising. 
30 
 
 
The pET28b(+) plasmid vector are designed for generation of proteins fused with an N-terminal 
Histidine-tag / T7-tag. Proteins having their native N-terminus can be expressed by the use of the 
NdeI insertion site (figure 2.2A). The vector encodes for a protease recognition site that 
facilitates the removal of the N-terminal His-tag. The pET22b(+) plasmid vector (figure 2.2B) 
was designed for fusion of proteins to signal sequences that facilitate export into the periplasmic 
space. Unfused proteins can also be expressed by cloning into the NdeI site of the vector. 
pET22b(+) can be used for production of proteins fused with a C-terminal His-tag. The sequence 
verified TbHK gene (section 2.9) was sub-cloned in pET28b(+) , while the sequence verified 
hGCK (section 2.9) was sub-cloned into pET22b(+). 
 
 
Figure 2.2: (A) Vector map of pET22b(+) expression vector system indicating Lac1, ampicillin 
resistance gene, replication origin, C-terminal His-tag and the multiple cloning site. (B) Vector 
map of pET28b(+) expression vector system showing Lac1, ampicillin resistance gene, 
replication origin N- and C-terminal His-tag and the multiple cloning site. 
 
2.2.2. Primer design and virtual cloning 
The TbHK nucleotide sequence was obtained from the National Center for Biotechnology 
Information (NCBI) database, accession number XM_817363.1. hGCK nucleotide sequence was 
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obtained from Addgene Inc. using Addgene plasmid number 23750 (Jonannessen et al., 2010). 
Reverse and forward primers (table 2.1) were designed using the ORFs and restriction sites were 
incorporated to facilitate cloning of the genes into the desired plasmids (section 2.4). The 
designed forward and reverse primers were evaluated for their theoretical parameters using freely 
available oligoanalyzer tool on the IDT DNA website. The primer sequences were blasted 
against the NCBI database. Primer properties were obtained using the oligoanalyzer tool 
available on the IDTDNA website. PCR fragments were virtually generated using the 
corresponding primers sets. These PCR fragments were used for in silico cloning, to assess the 
validity of the cloning procedures and to identify possible experimental problems that may be 
encountered. In silico cloning was achieved using pDRAW32 (AcaClone software, 2012). The 
generated TbHK PCR fragment was cloned into the CloneJet
®
 vector (figure 2.1A) and the 
generated hGCK PCR fragment was cloned into the pGEM-T
®
 easy vector (figure 2.1B). The 
generated constructs were virtually digested using the restriction enzymes incorporated into the 
primer sequences to evaluate the digestion products. Evaluation of the recombinant proteins was 
also done using the pDRAW32 software. The generated TbHK PCR fragment was cloned into 
the pET28b(+) vector (figure 2.2A) and the generated ORF proteins blasted against the NCBI 
database using the NCBI BLAST search tool. This verified whether the recombinantly expressed 
protein would have a fused N-terminal His-tag. The generated hGCK PCR fragment was cloned 
into the pET22b(+) vector (figure 2.2B) and the generated ORF proteins blasted against the 
NCBI database. This verified whether the recombinantly expressed protein would have a fused 
C-terminal His-tag. 
 
Table 2.1: Oliginucleotide primers used for PCR amplification and sequence PCRs (underlined 
sequences indicated the introduced restriction sites for NdeI and XhoI). 
 
Primer Sequence 
Tm 
 (
o
C) 
TbHex- NdeI 5'- CAT ATG TCT AGA CGC CTA AAC AAT ATC CTC G -3' 58.0 
TbHex-XhoI 5'-CTC GAG TTA CTT GTC GTT CAC CAC C -3' 
59.2 
 
hGCK- NdeI 5'- CAT ATG CTG GAC GAC AGA GCC AGG -3' 
61.3 
 
hGCK-XhoI No 
stop codon (TGA) 
5'- CTC GAG TCA CTG GCC CAG CAT ACA GG -3' 61.5 
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2.3. Gene amplification 
2.3.1. Gradient PCRs 
Genomic Tb DNA, a gift from Professor Buddy Ullman (Oregon Health Sciences University, 
USA) was used as template for the PCR amplification of the hexokinase gene. PCR reactions 
were carried out using a T100 Thermal Cycler (BIO RAD). A 100 µl master mixture was 
prepared and contained 20 µl 5x HF buffer, 2 µl of 10 mM dNTP’s, 50 ng DNA template, 1 µl 
(0.02 U) Phusion Hot start polymerase, 1 µl of 10 µM of forward (TbHK-NdeI) and reverse 
(TbHK-XhoI) primers (table 2.1), filled to reaction volume with sterile distilled water. The 
master mixture was aliquoted (10 μl) into 8 separate PCR tubes, one for each of the selected 
annealing temperatures. Reaction conditions consisted of steps, durations and cycles as presented 
in table 2.2.  
 
Table 2.2: Phusion hot start PCR reaction protocol. 
    
Temperature Duration 
 
Cycles 
    
(°C) 
 
(min) 
  Initial denaturation 
  
98 
 
3 
  Denaturation 
  
98 
 
0.5 
  Annealing 
  
50 to 65 
 
30 
  Elongation 
  
72 
 
2.5 
 
35x 
Final elongation 
  
72 
 
10 
  Hold 
   
4 
 
infinity 
   
 
PCR amplification of hGCK gene, a 100 µl master mixture was also prepared containing 10 µl of 
10x buffer, 2 µl of 10 mM dNTP’s, 50 ng NDA template (pDORN223-GCK plasmid), 1 µl of 10 
µM forward and reverse primers (table 2.1), Expand high fidelity enzyme (2.6 U/reaction 
volume), filled to reaction volume with sterile distilled water. The master mixture was aliquoted 
(10 μl) into 8 separate PCR tubes, one for each of the selected annealing temperatures. A two 
step PCR protocol as stated in table 2.3, reactions were carried out using T100 Thermal Cycler 
(BIO RAD). The PCR products were analyzed by the use of agarose gel electrophoresis as 
described in section 2.3.3.  
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Table 2.3: Two step Expand polymerase PCR reaction protocol. 
     
Temperature Duration Cycles 
     
(°C) 
 
(min) 
 Step 1 A Initial denaturation 
 
94 
 
2 
 
 
B Denaturation 
 
94 
 
0.5 
 
 
C Annealing (gradients) 45-65 
 
0.5 
 
 
D Elongation 
 
72 
 
1.5 10x 
Step 2 E Initial denaturation 
 
94 
 
0.5 
 
 
F Annealing (gradients) 48-68 
 
0.5 
 
 
G Elongation 
 
72 
 
2.5 20x 
 
H Final elongation 
 
72 
 
10 
 
 
I Hold 
  
4 
 
infinity 
  
 
2.3.2. Optimized PCR reactions 
The optimized PCR conditions ascertained from the PCR reactions described in section 2.3.1 
were used to performed up-scaled PCR reactions (total reaction volume of 50 µl). The reaction 
mixture contained 10 µl 5X HF buffer, 1 µl 10 mM dNTP’s, Tb gDNA (50 ng), 0.5 µl (0.02 U) 
Phusion hot start polymerase, 0.2 µl of 10 µmol forward (TbHK-NdeI) and reverse (TbHK-XhoI) 
primers (table 2.1), filled to the reaction volume with sterile redistilled water. A negative control 
reaction mixture containing everything as in the optimized mixture, except with the DNA 
template excluded, the negative control was run simultaneously with the optimized PCR 
reaction. PCR reaction conditions were as presented in table 2.2. 
 
Up scale PCR amplification of the hGCK gene was done as follows: A 50 μl reaction mixture 
was prepared and consisted of 5 µl 10X buffer with MgCl2, 1 µl 10 mM dNTP’s, 50 ng DNA 
template, 1 µl (10 µM) forward (hGCK-NdeI) and 1 µl (10 µmol) reverse (hGCK-XhoI No stop 
codon) primers (table 2.1), Expand high fidelity enzyme (2.6 U / reaction volume) filled to the 
reaction volume with sterile redistilled water. The reaction conditions were as described in table 
2.3. The PCR products and the negative control were prepared and run on 0.8% agarose gel as 
described in 2.3.3. 
 
2.3.3. Agarose gel electrophoresis 
All agarose gels consisted of 0.8% agarose in TAE buffer (0.04 M Tris-HCl, 1 mM EDTA pH 
8.0 and 0.021 mM glacial acetic acid) with 0.6 μg.ml-1 ethidium bromide. Separation of the DNA 
within the gel was achieved by running the gel at 100 V for 60-90 min. DNA was visualized 
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under a high radiation UV source (ChemiDoc XRS Gel Documentation system; Bio-Rad, USA) 
and a low radiation UV source (Darkreader, BioLabo, Switzerland), DNA fragment sizes were 
estimated based on electrophoretic mobility relative to that of the MassRuler™ DNA Ladder 
standards (Thermo Scientific) during the same electrophoretic run. 
 
2.3.4. DNA gel extraction 
After the PCR reaction was completed and after digestion of DNA, the products were run on 
agarose gel that was prepared as described in section 2.3.3, the DNA product to be extracted was 
visualizes using low radiation UV source at 365 nm (Darkreader, BioLabo, Switzerland) to limit 
DNA damage. The applicable band was excised from the gel using the BioFlux BioSpin gel 
extraction kit (Bioer Technology Co., Ltd), according to the manufacturer’s recommendations. 
Briefly, the excised gel slice was added to extraction buffer and the samples incubated for 10 
min at 50°C with periodic vortexing until the gel had completely liquefied. 
 
The sample was transferred to a spin column and centrifuged at 6 000 xg for 1 min. The flow-
through discarded. This was repeated until the entire sample had been loaded onto the column 
and the flow through discarded after each repeat. This was followed by washing the column with 
500 µl of extraction buffer at 12 000 xg; 30 sec and the flow through again discarded. Seven 
hundred and fifty microliters of wash buffer was added and the column allowed standing for 5 
min at room temperature. This was followed by centrifugation (12 000 xg; 60 sec) and the 
column transferred to a clean 1.5 ml Eppendorf tube. Fifty microliters of elution buffer was 
added onto the column and incubated for 15 min at 37°C. The DNA was eluted by centrifugation 
(12 000 xg; 60 sec). Concentration, purity and integrity of the nucleic acids were determined 
using a NanoDrop-2000 spectrophotometer at 260 nm (Thermal scientific, USA). 
 
2.4. Ligations 
The purified 1.4 kb TbHK and hGCK PCR products were ligated into CloneJet
®
 (Thermal 
Scientific) and pGEM-T
®
 cloning vector system (Promega). Ligation reactions were set up using 
equations 2.1 and 2.2 to come up with the final concentrations and volumes of vector and insert 
DNA.  
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Equation 2.1: 
      
kb size of vector
ng of vector    x   kb size of insert 
ng of insert = x Insert : vector molar ratio
 
 
Equation 2.2: 
                                   
ng of linearized vector
50 ng of vector
μl of vector =
 
The ligation protocols were performed as per the manufacturer’s instructions. For TbHK ligation 
reaction was performed in a 20 µl reaction volume which consisted of 2 x ligation buffer, (10 
µl), CloneJet
®
 vector (50 ng), PCR product (8 µl) and T4 DNA ligase (0.3 Weiss units) with a 
3:1 insert: vector DNA molar ratio. The ligation mixture was incubated for overnight at 4
o
C. The 
purified 1.4 kb hGCK PCR product, it was ligated into pGEM-T
®
 cloning system (Promega). 
 
The ligation reaction was performed in a 20 µl total reaction volume consisting of 10x ligation 
buffer, (2 µl) pGEM-T
®
 vector (50 ng), 6 µl PCR product (equation 2.1) and T4 DNA ligase (0.3 
Weiss units) with a 1:1 insert : vector DNA molar ratio. The ligation mixture was incubated at 
4°C, overnight. The 1.4 kb extracted TbHK gene was ligated into pET28b(+) expression vector 
system (Thermal Scientific). A 10 µl reaction mixture consisted of 10x ligation buffer (1 μl), 
with a 1:1 insert: vector DNA molar ratio, pET28b(+) vector (50 ng), TbHK gene insert (0.5 μl) 
and T4 DNA ligase (0.75 Weiss units) filled up to reaction volume with milliQ water. For the 
cleaned 1.4 kb hGCK gene, ligation into the linear pET22b(+) expression vector system 
(Thermal Scientific) was performed using the protocol as per the manufacturer’s instructions. 
The ligation reaction was performed in a 10 µl final reaction volume which consisted of 10x 
ligation buffer (1 μl), with a 1:1 insert: vector DNA molar ratio, pET22b(+) vector (50 ng), 
hGCK gene insert (2.5 μl) and T4 DNA ligase (0.75 Weiss units) filled up to reaction volume 
with milliQ water. The ligation mixtures were then incubated at 4°C, overnight. 
 
2.5. Preparation of competent cells 
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E. coli TOP10 (Invitrogen), JM109 (Promega) and BL21(DE3) containing the pRARE2 
(Lucigen) plasmid, were made chemically competent using the protocol described by Hanahan 
(1983) with slight modifications. Briefly, flasks containing 100 ml Psi broth (5 g.l
-1
 yeast extract, 
20 g.l
-1
 trypton, 5 g.l
-1 
magnesium sulphate, pH 7.6 [adjusted with potassium hydroxide]) were 
inoculated with 1 ml of an overnight culture and incubated at 37°C until an optical density of 
0.48 at 550 nm was achieved. Cells were placed on ice for 15 minutes, followed by 
centrifugation (3 000 xg; 5 min; 4°C). The supernatant was discarded and the pellets re-
suspended in 40 ml TfbI buffer (30 mM potassium acetate, 100 mM rubidium chloride, 10 mM 
calcium chloride, 50 mM manganese chloride, 15% glycerol, pH 5.8 adjusted with acetic acid) 
and kept on ice for 15 minutes. This was followed by collection of the cells by centrifugation (3 
000 xg; 5 minutes; 4
o
C). The supernatant was discarded and pellets re-suspended in 4 ml TfbII 
buffer (10 mM 3- (N-morpholino) propanesulfonic acid (MOPS), 75 mM calcium chloride, 10 
mM rubidium chloride, 15% glycerol, pH 6.5 adjusted with diluted sodium hydroxide). Cells 
were kept on ice for 15 min. The cooled cell suspension was aliquoted (50 μl) and snaps frozen 
in liquid nitrogen prior to storage at -80
°
C. 
 
2.6. Transformations 
A stock (50 µl / 100 μl) of the chemically competent E. coli strain (section 2.5) was retrieved 
from the -80°C freezer and placed on ice to thaw (~5 min). The ligation mixture / plasmids was 
transferred to the competent cells and the transformation mixture kept on ice for 30 min after 
which it was heat shocked at 42°C for 40 seconds and placed back on ice for 2 min. Two 
hundred and fifty microliters pre-heated (37°C) SOC media (20 g.l
-1
 tryptone, 5 g.l
-1
 yeast 
extract, 0.01 M NaCl, 2.5 mM KCl, 0.01 M MgCl2, 0.01 M MgSO4 and 0.02 M glucose) was 
added to the transformation mixture and incubated at 37°C for 1 h with intermittent gentle 
shaking. After the 1 h incubation, various aliquots (200 µl and 100 µl) of the transformed 
cultures were spread plated onto LB agar plates containing the appropriate antibiotic/s to 
maintain selective pressure and incubated at 37°C for 14-16 h. Positive transformants were 
inoculated into 5 ml LB media containing the appropriate antibiotic and grown for 16 h at 37°C. 
DNA mini-preparations followed the 16 h growth of the positive transformants as described in 
section 2.7. E. coli cells transformed with pET22b(+) and CloneJet
®
 were spread plated onto 
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AMP/CAM plates (100 µg.ml
-1
). E. coli cells that were transformed with pET28b(+) pRARE2 
was spread plated onto KAN/CAM plate (30 µg.ml
-1 
and 34 µg.ml
-1
).  
 
When the pGEM
®
-T easy vector system was used, various aliquots of the transformed culture 
was plated onto LB plates containing ampicillin (100 µg.ml
-1
), isopropyl β-D-thiogalactoside 
(IPTG, 0.12 mg.ml
-1
) and 5-bromo-4-chloro-3-indolyl β-D-galactoside (X-Gal, 0.08 mg.ml-1) 
and incubated overnight at 37°C to verify DNA ligation using blue / white selection. Positive 
transformants were inoculated into 5 ml LB media containing 100 µg.ml
-1
 ampicillin to maintain 
selective pressure and grown for 16 h at 37°C. DNA mini-preparations followed the 16 h growth 
of the positive transformants as described in section 2.7.  
 
2.7. DNA plasmids extraction 
DNA mini-preparations followed the 16 h growth of the positive transformants (section 2.6). 
This was performed using the BioFlux BioSpin Plasmid Extraction Kit as per the manufacturer’s 
recommendations (Bioer Technologies Co, Ltd). Briefly; the cultured bacterial cells were 
centrifuged down at 10 000 xg for 30 sec and the supernatant discarded. Resuspension buffer 
(250 µl) was added followed by lysis buffer (250 µl), gently inverted (4-6 times). Neutralization 
buffer (350 µl) was added and gently inverted (4-6 times). Tubes were centrifuged at 13 000 xg 
(10 min), supernatants were transferred into spin columns, centrifuged at 6 000 xg (1 min), the 
flow through were discarded and wash buffer (650 µl) was added and centrifuged at 6 000 xg (1 
min), this was done twice followed by a third dry spin. The columns were transferred into 1.5 ml 
Epperndorf tubes, elution buffer (50 µl) was added and tubes were incubated at 37°C for 15 
minutes. This was followed by a final spin (12 000 xg) for 1.5 min. DNA concentrations were 
determined using a NanoDrop ND 2 000 spectrophotometer as described in section 2.3.4. 
 
2.8. Screening for inserts 
Plasmids obtained as described in section 2.7 were screened to confirm insertion of ThrHK and 
hGCK genes. The plasmids were subjected to a double digestion using NdeI and XhoI restriction 
enzymes. Reaction conditions for the selected restriction enzymes were obtained using the 
double digestion tool available on the Fermentas website. Table 2.4 lists the relationship between 
the selected restriction enzymes.  
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Table 2.4: Showing features of selected restriction enzymes. 
 
Enzyme Temperature Amount Buffer Percentage 
 
(°C) 
   
(%) 
 NdeI 37 
 
1x O 100 
 XhoI 37 
 
2x O 100 
    
Double digestion reaction mixtures (20 µl) were prepared and contained NdeI (1 μl), XhoI (2 μl), 
10x buffer O (2 µl), 50 ng of plasmid (using equation 2.1 and 2.2), filled to reaction volume with 
sterile redistilled water. The double digestion mixtures were incubated at 37°C, overnight and 
run on an agarose gel as described in section 2.3.3. 
 
2.9. Sequence verification 
Plasmids with a positive restriction enzyme digestion profile (sections 2.8) were sent to Inqaba 
Biotech, (Hatfield, Pretoria, Gauteng, South Africa) for sequencing. Sequencing PCR reactions 
were done using the BigDye terminator kit (ABI, Life Technologies, Carlsbad, USA) according 
to manufacturer’s instructions. The PCR reactions were cleaned using the Zymo research 
sequencing clean-up kit (Zymo Research). The clean products were subsequently analyzed using 
a 3500 XL Genetic Analyzer (ABI, Life Technologies, Carlsbad, California, USA). 
Electropherograms were analyzed and edited using Geospiza’s FinchTV (version 1.4.0). Reverse 
complementation was performed using BioEdit (Hall, 1999). Sequence alignments were 
performed using DNAssist version 3.0. 
 
2.10. Results and discussions 
The following sub-sections of the current chapter presents the outcomes of the experimental 
work done to obtain TbHK and hGCK expression ready constructs. 
 
2.10.1. TbHK and hGCK gene amplifications 
Virtual cloning processes (section 2.2.2) conducted on the expression vectors indicated that both 
proteins (TbHK and hGCK) would be expressed in frame with the N-terminal His-tag for TbHK 
and C-terminal His-tag for hGCK. C-terminal His-tagged proteins can be purified using the same 
purification techniques as the N-terminal His-tag without significant protein activity differences. 
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Studies have shown that in some cases the N-terminal His-tag may not be accessible for metal 
affinity purification strategy; therefore the use of the C-terminal His-tag may circumvent the 
problem (Eschenfeldt et al., 2011). His-tags have shown to provide good yields of recombinant 
proteins as compared to other tags in use i.e. Maltose-binding protein tag (MBP tag), Glutathione 
S-transferase-tag (GST-tag) (Lichty et al., 2005), however no sole affinity tag is most 
advantageous in regards of all the required properties of a tag (Arnau et al., 2005; Waugh, 2005). 
Gradient PCRs (section 2.3.1) performed using hGCK as template indicated an optimum Tm of 
59°C and this parameter was used during the upscale PCR reaction, evidenced by the 1.4 kb 
band that was obtained (figure 2.3.B) (Lynch et al., 2000; Desai et al., 2001; Willson et al., 
2002). 
  
 
Figure 2.3: (A) Agarose gel image of the gradient PCR amplified TbHK gene. B: Agarose gel 
image showing the amplified hGCK gene by gradient PCR.  
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Figure 2.4 (A) Agarose gel image of the amplified TbHK gene. (B) Agarose gel image showing 
the amplified hGCK gene. 
 
The TbHK (TREU 927) and human glucokinase genes were amplified by the optimized PCR 
reaction as described in section 2.3.2. The 1.4 kb bands were obtained (figure 2.4A for TbHK 
and figure 2.4B for hGCK), confirming amplification of the target genes. The bands 
corresponding to the 1.4 kb products were purified from the gels using the BioFlux, BioSpin Gel 
Extraction kit as described in section 2.3.4. The extracts were stored at -20°C for further 
downstream experiments.                                            
2.10.2. Cloning and sequencing  
2.10.2.1. Cloning of TbHK and hGCK 
The PCR amplified and gel purified TbHK and hGCK genes (sections 2.3.2 and 2.3.4) were 
ligated into CloneJet
®
 and pGEM
®
-T easy cloning vector systems respectively as described in 
section 2.4. The virtual cloning of the 2 genes into the respective cloning vectors confirmed the 
viability of the cloning procedures (figures 2.5A and B). The cloning experiments commenced 
with the ligation of gel extracted PCR products into the CloneJet
®
 cloning vector for TbHK and 
pGEM-T
®
 easy cloning vector for hGCK (Section 2.4). The TbHK ligation mixture was 
transformed into competent E. coli JM109 cells, while the hGCK ligation mixture was 
transformed into competent E. coli TOP10 cells as described in sections 2.6. 
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Figure 2.5: (A) Vector map of CloneJet
®
 indicating ampicillin resistance gene, T7 promoter and 
TbHK gene insert. (B) Vector map of pGEM-T
®
 easy vector indicating ampicillin resistance 
gene, F1 origin of plasmid replication, T7 promoter and LacZ coding sequence and hGCK gene 
insert. 
 
For TbHK, 5 single colonies were picked and aseptically sub-cultured in LB broth supplemented 
with 100 µg.ml
-1
 ampicillin. Plasmids were extracted using the BioFlux Biospin plasmid 
extraction kit (Section 2.7). Plasmids were subjected to double digestion reactions using NdeI 
and XhoI restriction enzymes as described in section 2.8. Double digestion reactions were 
separated on an agarose gel (section 2.3.3). Figure 2.6A shows that plasmids 1 (lane 4), plasmid 
2 (lane 5) and plasmid 4 (lane 7) had positive gene inserts (a 1.4 kb band corresponding to the 
TbHK gene insert and a 2.9 kb band corresponding the cloneJet
®
 backbone). Plasmid extract 1 
was sequenced by Inqaba Biotech (Hatfield, Pretoria, Gauteng, South Africa) for sequencing as 
described in section 2.9. 
 
For hGCK five single colonies were picked and aseptically sub-cultured in LB broth 
supplemented with 100 µg.ml
-1
 ampicillin. Plasmids were extracted using the BioFlux Biospin 
plasmid extraction kit (Section 2.7). Plasmids were subjected to double digestion reactions using 
NdeI and XhoI restriction enzymes as described in section 2.8. Double digestion reactions were 
separated on an agarose gel (section 2.3.3.).  
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Figure 2.6: (A) CloneJet
®
 plasmid containing TbHK gene digested with NdeI and XhoI. Lane 1 
represents MassRuler™ DNA Ladder standards (Thermo Scientific) and lanes 4 to 8 represents 
cloned plasmids screened for gene inserts. (B) pGEM-T
®
 easy plasmid containing hGCK gene 
digested with NdeI and XhoI. Lane 1 represents the marker and lanes 2 to 6 represents cloned 
plasmids screened for gene inserts. 
 
Figure 2.6B shows that plasmid number 3 (lane 4) had a positive gene insert (1.4 kb band 
corresponding to the hGCK gene insert and a 5.4 kb band corresponding the pGEM-T
®
 easy 
backbone). Plasmid number 3 was sequenced by Inqaba Biotech (Hatfield, Pretoria, Gauteng, 
South Africa) for sequencing as described in section 2.9. 
 
2.10.2.2 Sequence analysis 
Sequencing results for both TbHK and hGCK were analyzed using Finch TV version 1.4.0, 
BioEdit version 7.2.3 and DNAssist version 3.0 software as described in section 2.9. After 
aligning TbHK sequencing results with the reference TbHK gene using DNAssist (figure 2.7), it 
showed a 99% identity to the reference gene (NCBI accession number XM_817363.1) and the 
translated protein sequence of the cloned TbHK gene with the protein sequence from NCBI 
accession number XM_817363.1 100% identical (figure 2.8).  
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Ref gene       ATGTCTAGACGCCTAAACAATATCCTCGAACACATCTCGATCCAGGGAAATGATGGTGAG  
TbHK gene      ATGTCTAGACGCCTAAACAATATCCTCGAACACATCTCGATCCAGGGAAATGATGGTGAG  
  
Ref gene       ACTGTGCGTGCCGTTAAGCGTGATGTTGCAATGGCAGCGCTGACCAACCAATTCACAATG  
TbHK gene      ACTGTGCGTGCCGTTAAGCGTGATGTTGCAATGGCAGCGCTGACCAACCAATTCACAATG  
 
Ref gene       AGTGTCGAGTCTATGCGACAGATCATGACATACCTCCTGTACGAGATGGTGGAGGGTCTT  
TbHK gene      AGTGTGGAGTCTATGCGACAGATCATGACATACCTCCTGTACGAGATGGTGGAGGGTCTT  
 
Ref gene       GAGGGTCGTGAAAGCACCGTCCGCATGTTACCATCTTATGTATACAAGGCGGACCCTAAG  
TbHK gene      GAGGGTCGTGAAAGCACCGTCCGCATGTTACCATCTTATGTGTACAAGGCGGACCCTAAG  
 
Ref gene       CGTGCTACTGGCGTCTTCTACGCACTTGACCTCGGTGGTACCAACTTCCGTGTGCTGCGC  
TbHK gene      CGTGCTACTGGCGTCTTCTACGCACTTGACCTCGGTGGTACCAACTTCCGTGTGCTGCGC  
 
Ref gene       GTTGCATGCAAGGAGGGTGCCGTGGTGGATTCCTCTACTTCTGCATTCAAGATTCCCAAA  
TbHK gene      GTTGCATGCAAGGAGGGTGCCGTGGTGGATTCCTCTACTTCTGCATTCAAGATTCCCAAA  
 
Ref gene       TATGCCCTTGAGGGTAACGCCACCGATCTGTTTGGCTTCATTGCATCCAATGTGAAGAAA  
TbHK gene      TATGCCCTTGAGGGTAACGCCACCGATCTGTTTGGCTTCATTGCATCCAATGTGAAGAAA  
  
Ref gene       ACCATGGAAACTCGTGCACCTGAGGACCTCAATCGCACAGTTCCTCTTGGGTTTACCTTC  
TbHK gene      ACCATGGAAACTCGTGCACCTGAGGACCTCAATCGCACAGTTCCTCTTGGGTTTACCTTC  
 
Ref gene       AGTTTCCCCGTGGAGCAGACGAAGGTTAACCGTGGTGTGCTTATCCGGTGGACGAAGGGC  
TbHK gene      AGTTTCCCCGTGGAGCAGACGAAGGTTAACCGTGGTGTGCTTATCCGGTGGACGAAGGGC  
 
Ref gene       TTCAGCACGAAAGGCGTTCAAGGAAATGATGTGATTGCCCTTCTTCAGGCTGCTTTTGGG  
TbHK gene      TTCAGCACGAAAGGTGTTCAAGGAAATGATGTGATTGCCCTTCTTCAGGCTGCTTTTGGG  
   
Ref gene       CGAGTGAGCTTGAAGGTGAATGTTGTGGCGTTGTGCAACGACACTGTTGGAACATTAATT  
TbHK gene      CGAGTGAGCTTGAAGGTGAATGTTGTGGCGTTGTGCAACGACACTGTTGGAACATTAATT  
 
Ref gene       TCGCATTACTTTAAGGACCCTGAGGTACAGGTTGGTGTGATTATCGGCACTGGTTCCAAT  
TbHK gene      TCGCATTACTTTAAGGACCCTGAGGTACAGGTTGGTGTGATTATCGGCACTGGTTCCAAT  
 
Ref gene       GCGTGCTACTTTGAGACGGCGTCTGCTGTGACGAAGGACCCTGCCGTTGCTGCTCGTGGG  
TbHK gene      GCGTGCTACTTTGAGACGGCGTCTGCTGTGACGAAGGACCCTGCCGTTGCTGCTCGTGGG  
 
Ref gene       TCAGCACTTACTCCCATCAATATGGAAAGCGGCAACTTTGACTCCAAGTACCGGTTTGTC  
TbHK gene      TCAGCACTTACTCCCATCAATATGGAAAGCGGCAACTTTGACTCCAAGTACCGGTTTGTC  
 
Ref gene       CTCCCTACGACGAAGTTCGACTTGGATATTGACGATGCGTCGTTGAACAAAGGTCAACAG  
TbHK gene      CTCCCTACGACGAAGTTCGACTTGGATATTGACGATGCGTCGTTGAACAAAGGTCAACAG  
   
Ref gene       GCGCTGGAGAAGATGATATCCGGCATGTACCTCGGCGAAATCGCCCGCCGCGTTATTGTG  
TbHK gene      GCGCTGGAGAAGATGATATCCGGCATGTACCTCGGTGAAATCGCCCGCCGCGTTATTGTG  
 
Ref gene       CACCTGTCGTCTATTAACTGCCTTCCTGCGGCACTGCAGACTGCTTTGGGCAACCGGGGG  
TbHK gene      CACCTGTCGTCTATTAACTGCCTTCCTGCGGCACTGCAGACTGCTTTGGGCAACCGGGGG  
 
Ref gene       TCGTTTGAGTCCCGATTTGCCGGGATGATCAGTGCTGACCGTATGCCCGGACTTCAGTTC  
TbHK gene      TCGTTTGAGTCCCGATTTGCCGGGATGATCAGTGCTGACCGTATGCCCGGACTTCAGTTC  
 
Ref gene       ACTCGCAGCACGATCCAGAAGGTGTGTGGTGTTGACGTGCAGTCAATTGAAGACCTTCGC  
TbHK gene      ACTCGCAGCACGATCCAGAAGGTGTGTGGTGTTGACGTGCAGTCAATTGAAGACCTTCGC  
 
Ref gene       ATCATTCGCGATGTGTGCCGCCTTGTCCGTGGGAGGGCTGCGCAACTCTCTGCTTCCTTC  
TbHK gene      ATCATTCGCGATGTGTGCCGCCTTGTCCGTGGGAGGGCTGCGCAACTCTCTGCTTCCTTC  
 
Ref gene       TGCTGCGCTCCACTGGTTAAGACTCAAACACAGGGCCGTGCAACTATTGCAATTGACGGC  
TbHK gene      TGCTGCGCTCCACTGGTTAAGACTCAAACACAGGGCCGTGCAACTATTGCAATTGACGGC  
 
Ref gene       TCCGTGTTTGAGAAGATTCCGTCATTCCGCCGCGTCTTGCAGGACAACATCAACCGTATC  
TbHK gene      TCCGTGTTTGAGAAGATTCCGTCATTCCGCCGCGTCTTGCAGGACAACATCAACCGTATC  
 
Ref gene       CTTGGCCCTGAGTGCGATGTCAGGGCCGTTCTCGCAAAGGATGGCAGTGGAATTGGTGCT  
TbHK gene      CTTGGCCCTGAGTGCGATGTCAGGGCCGTTCTCGCAAAGGATGGCAGTGGAATTGGTGCT  
 
Ref gene       GCATTTATTTCCGCAATGGTGGTGAACGACAAGTAA  
TbHK gene      GCATTTATTTCCGCAATGGTGGTGAACGACAAGTAA  
 
 
         
 
Figure 2.7: Alignments of the reference hexokinase gene sequence of Tb TREU 927and the 
cloned TbHK gene.  
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Figure 2.8: Alignments of reference protein sequence of TbHK TREU 927 and the translated 
protein sequence of the sequenced TbHK gene. 
 
Alignments of the sequencing results for the hGCK gene (figure 2.9) showed a 100% identity to 
the Addgene author sequence, and the translated protein sequence of the cloned hGCK gene with 
the translated protein sequence were 100% identical (figure 2.10). 
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Reference gene     ATGCTGGATGATCGTGCGCGTATGGAAGCGGCGAAAAAAGAAAAAGTGGAACAGAT  
hGCK gene          ATGCTGGATGATCGTGCGCGTATGGAAGCGGCGAAAAAAGAAAAAGTGGAACAGAT  
 
Reference gene     TCTGGCGGAATTTCAGCTGCAGGAAGAAGATCTGAAAAAAGTGATGCGTCGTATGC  
hGCK gene          TCTGGCGGAATTTCAGCTGCAGGAAGAAGATCTGAAAAAAGTGATGCGTCGTATGC  
 
Reference gene     AGAAAGAAATGGATCGTGGCCTGCGTCTGGAAACCCATGAAGAAGCGAGCGTGAAA  
hGCK gene          AGAAAGAAATGGATCGTGGCCTGCGTCTGGAAACCCATGAAGAAGCGAGCGTGAAA  
 
Reference gene     ATGCTGCCGACCTATGTGCGTAGCACCCCGGAAGGCAGCGAAGTGGGCGATTTTCT  
hGCK gene          ATGCTGCCGACCTATGTGCGTAGCACCCCGGAAGGCAGCGAAGTGGGCGATTTTCT  
 
Reference gene     GAGCCTGGATCTGGGCGGCACCAACTTTCGTGTGATGCTGGTGAAAGTGGGCGAAG  
hGCK gene          GAGCCTGGATCTGGGCGGCACCAACTTTCGTGTGATGCTGGTGAAAGTGGGCGAAG  
 
Reference gene     GCGAAGAAGGCCAGTGGAGCGTGAAAACCAAACATCAGATGTATAGCATTCCGGAA  
hGCK gene          GCGAAGAAGGCCAGTGGAGCGTGAAAACCAAACATCAGATGTATAGCATTCCGGAA  
    
Reference gene     GATGCGATGACCGGCACCGCGGAAATGCTGTTTGATTATATTAGCGAATGCATTAG  
hGCK gene          GATGCGATGACCGGCACCGCGGAAATGCTGTTTGATTATATTAGCGAATGCATTAG  
 
Reference gene     CGATTTTCTGGATAAACATCAGATGAAACATAAAAAACTGCCGCTGGGCTTTACCT  
hGCK gene          CGATTTTCTGGATAAACATCAGATGAAACATAAAAAACTGCCGCTGGGCTTTACCT  
 
Reference gene     TTAGCTTTCCGGTGCGTCATGAAGATATTGATAAAGGCATTCTGCTGAACTGGACC  
hGCK gene          TTAGCTTTCCGGTGCGTCATGAAGATATTGATAAAGGCATTCTGCTGAACTGGACC  
 
Reference gene     AAAGGCTTTAAAGCGAGCGGCGCGGAAGGCAACAACGTGGTGGGCCTGCTGCGTGA  
hGCK gene          AAAGGCTTTAAAGCGAGCGGCGCGGAAGGCAACAACGTGGTGGGCCTGCTGCGTGA  
 
Reference gene     TGCGATTAAACGTCGTGGCGATTTTGAAATGGATGTGGTGGCGATGGTGAACGATA  
hGCK gene          TGCGATTAAACGTCGTGGCGATTTTGAAATGGATGTGGTGGCGATGGTGAACGATA  
 
Reference gene     CCGTGGCGACCATGATTAGCTGCTATTATGAAGATCATCAGTGCGAAGTGGGCATG  
hGCK gene          CCGTGGCGACCATGATTAGCTGCTATTATGAAGATCATCAGTGCGAAGTGGGCATG  
 
Reference gene     ATTGTGGGCACCGGCTGCAACGCGTGCTATATGGAAGAAATGCAGAACGTGGAACT  
hGCK gene          ATTGTGGGCACCGGCTGCAACGCGTGCTATATGGAAGAAATGCAGAACGTGGAACT  
 
Reference gene     GGTGGAAGGCGATGAAGGCCGTATGTGCGTGAACACCGAATGGGGCGCGTTTGGCG  
hGCK gene          GGTGGAAGGCGATGAAGGCCGTATGTGCGTGAACACCGAATGGGGCGCGTTTGGCG  
 
Reference gene     ATAGCGGCGAACTGGATGAATTTCTGCTGGAATATGATCGTCTGGTGGATGAAAGC  
hGCK gene          ATAGCGGCGAACTGGATGAATTTCTGCTGGAATATGATCGTCTGGTGGATGAAAGC  
 
Reference gene     AGCGCGAACCCGGGCCAGCAGCTGTATGAAAAACTGATTGGCGGCAAATATATGGG  
hGCK gene          AGCGCGAACCCGGGCCAGCAGCTGTATGAAAAACTGATTGGCGGCAAATATATGGG  
 
Reference gene     CGAACTGGTGCGTCTGGTGCTGCTGCGTCTGGTGGATGAAAACCTGCTGTTTCATG  
hGCK gene          CGAACTGGTGCGTCTGGTGCTGCTGCGTCTGGTGGATGAAAACCTGCTGTTTCATG  
 
Reference gene     GCGAAGCGAGCGAACAGCTGCGTACCCGTGGCGCGTTTGAAACCCGTTTTGTGAGC  
hGCK gene          GCGAAGCGAGCGAACAGCTGCGTACCCGTGGCGCGTTTGAAACCCGTTTTGTGAGC  
 
Reference gene     CAGGTGGAAAGCGATACCGGCGATCGTAAACAGATTTATAACATTCTGAGCACCCT  
hGCK gene          CAGGTGGAAAGCGATACCGGCGATCGTAAACAGATTTATAACATTCTGAGCACCCT  
 
Reference gene     GGGCCTGCGTCCGAGCACCACCGATTGCGATATTGTGCGTCGTGCGTGCGAAAGCG  
hGCK gene          GGGCCTGCGTCCGAGCACCACCGATTGCGATATTGTGCGTCGTGCGTGCGAAAGCG  
 
Reference gene     TGAGCACCCGTGCGGCGCATATGTGCAGCGCGGGCCTGGCGGGCGTGATTAACCGT  
hGCK gene          TGAGCACCCGTGCGGCGCATATGTGCAGCGCGGGCCTGGCGGGCGTGATTAACCGT  
 
Reference gene     ATGCGTGAAAGCCGTAGCGAAGATGTGATGCGTATTACCGTGGGCGTGGATGGCAG  
hGCK gene          ATGCGTGAAAGCCGTAGCGAAGATGTGATGCGTATTACCGTGGGCGTGGATGGCAG  
  
Reference gene     CGTGTATAAACTGCATCCGAGCTTTAAAGAACGTTTTCATGCGAGCGTGCGTCGTC  
hGCK gene          CGTGTATAAACTGCATCCGAGCTTTAAAGAACGTTTTCATGCGAGCGTGCGTCGTC  
 
Reference gene     TGACCCCGAGCTGCGAAATTACCTTTATTGAAAGCGAAGAAGGCAGCGGCCGTGGC  
hGCK gene          TGACCCCGAGCTGCGAAATTACCTTTATTGAAAGCGAAGAAGGCAGCGGCCGTGGC  
 
Reference gene     GCGGCGCTGGTGAGCGCGGTGGCGTGCAAAAAAGCGTGCATGCTGGGCCAGTAA  
hGCK gene          GCGGCGCTGGTGAGCGCGGTGGCGTGCAAAAAAGCGTGCATGCTGGGCCAGTAA  
 
 
 
Figure 2.9: Alignments of the reference gene sequence of hGCK cDNA and the cloned hGCK 
gene.  
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Figure 2.10: Alignments of reference protein sequence of hGCK and the translated protein 
sequence of the sequenced hGCK gene. 
 
2.11. Construction of expression vectors 
Figure 2.11A and B show the results obtained for the virtual cloning of both the sequence 
verified. 
 
Figure 2.11 A: Vector map of pET28b(+) expression vector indicating ampicillin resistance gene, 
N-terminal His-tag, ori, LacI and TbHK gene insert. B: Vector map of pET22b(+) expression 
vector indicating ampicillin resistance gene, origin of plasmid replication, C-terminal His-tag, 
LacI and hGCK gene insert. 
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TbHK and hGCK genes were ligated into the respective expression vectors as described in 
section 2.4. Analysis of the open reading frames indicated that both the proteins will be 
expressed in frame with the desired 6 Histidine tag. An N-terminal tag for TbHK (figure 2.12) 
and a C-terminal tag for hGCK (figure 2.13). 
 
MGSSHHHHHHSSGLVPRGSHMSRRLNNILEHISIQGNDGETVRAVKRDVAMAALTNQF
TMSVESMRQIMTYLLYEMVEGLEGRESTVRMLPSYVYKADPKRATGVFYALDLGGTN
FRVLRVACKEGAVVDSSTSAFKIPKYALEGNATDLFGFIASNVKKTMETRAPEDLNRTV
PLGFTFSFPVEQTKVNRGVLIRWTKGFSTKGVQGNDVIALLQAAFGRVSLKVNVVALCN
DTVGTLISHYFKDPEVQVGVIIGTGSNACYFETASAVTKDPAVAARGSALTPINMESGNF
DSKYRFVLPTTKFDLDIDDASLNKGQQALEKMISGMYLGEIARRVIVHLSSINCLPAALQ
TALGNRGSFESRFAGMISADRMPGLQFTRSTIQKVCGVDVQSIEDLRIIRDVCRLVRGRA
AQLSASFCCAPLVKTQTQGRATIAIDGSVFEKIPSFRRVLQDNINRILGPECDVRAVLAKD
GSGIGAAFISAMVVNDK 
 
Figure 2.12: Sequence analysis of the ORF for the inserted Tb gene showing in frame expression 
with the N-terminal His-tag (bold and underlined). 
MLDDRARMEAAKKEKVEQILAEFQLQEEDLKKVMRRMQKEMDRGLRLETHEEASVM
LPTYVRSTPEGSEVGDFLSLDLGGTNFRVMLVKVGEGEEGQWSVKTKHQMYSIPEDAM
TGTAEMLFDYISECISDFLDKHQMKHKKLPLGFTFSFPVRHEDIDKGILLNWTKGFKASG
AEGNNVVGLLRDAIKRRGDFEMDVVAMVNDTVATMISCYYEDHQCEVGMIVGTGCNA
CYMEEMQNVELVEGDEGRMCVNTEWGAFGDSGELDEFLLEYDRLVDESSANPGQQLY
EKLIGGKYMGELVRLVLLRLVDENLLFHGEASEQLRTRGAFETRFVSQVESDTGDRKQI
YNILSTLGLRPSTTDCDIVRRACESVSTRAAHMCSAGLAGVINRMRESRSEDVMRITVG
VDGSVYKLHPSFKERFHASVRRLTPSCEITFIESEEGSGRGAALVSAVACKKACMLGQLE
HHHHHH 
 
Figure 2.13: Sequence analysis of the ORF for the inserted human glucokinase gene showing in 
frame expression with the C-terminal His-tag (bold and underlined) 
 
Experimental assembly of the individual expression constructs started with the removal of the 
inserts from the CloneJet
®
 and pGEM-T
®
 easy constructs through double digestion reactions 
using NdeI and XhoI as described in section 2.8. The inserts were separated from the backbone 
fragments on a 0.8% agarose gel (section 2.3.3) and purified from the gel (section 2.3.4). The 
purified inserts were ligated into NdeI and XhoI linearised and gel purified pET vectors. TbHK 
was sub-cloned into pET28b(+) and hGCK into pET22b(+) as described in section 2.4. For the 
TbHK pET28b(+) constructs, 4 single colonies were picked and aseptically sub-cultured in LB 
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broth supplemented with 30 µg.ml
-1
 kanamycin. Plasmids were extracted using the BioFlux 
Biospin plasmid extraction kit (Section 2.7). Plasmids were subjected to double digestion 
reactions using NdeI and XhoI restriction enzymes as described in section 2.8. Double digestion 
reactions were separated on an agarose gel (section 2.3.3). Figure 2.14 showed four clones were 
positive for gene insertion. Clone 1 (lane 3) was selected for expression experiments and stored 
at -20°C.  
 
                                                                                            
Figure 2.14: pET28b(+) plasmid containing TbHK gene, double digested with XhoI and NdeI 
restriction enzymes. Lane 1 represents the DNA ladder, lanes 3 to 6 represents the clones 
screened for positive gene inserts. 
 
For the hGCK pET22b(+) construct 6 single colonies were picked and aseptically sub-cultured in 
LB broth supplemented with 100 µg.ml
-1
 ampicillin. Plasmids were extracted using the BioFlux 
Biospin plasmid extraction kit (Section 2.7). 
 
Plasmids were subjected to double digestion reactions using NdeI and XhoI restriction enzymes 
as described in section 2.8. Double digestion reactions were separated on an agarose gel (section 
2.3.3). Figure 2.15 shows that 4 clones had insertion of the desired gene and clone 2 (lane 3) was 
selected for expression experiments and stored at -20°C. 
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Figure 2.15: pET22b(+) plasmid containing human glucokinase gene, double digested with XhoI 
and NdeI restriction enzymes. Lane 1 represents the DNA ladder, lanes 2 to 7 represents the 
clones screened for positive gene inserts. 
 
2.12 Conclusions 
Both the hGCK and TbHK genes were successfully PCR amplified and cloned into the respective 
cloning vectors (CloneJet
®
 and pGEM-T
®
 easy). Sequencing results showed that no mutations 
were incorporated during the amplification. The translated TbHK and hGCK protein sequences 
with their translated reference sequences, revealed a 100% sequence identity. The sequence 
verified genes were sub-cloned into their respective expression vectors. pET28b(+) for TbHK 
and pET22b(+) for hGCK that will facilitate N-terminal and C-terminal His-tagged TbHK and 
hGCK expressions respectively (Chapter 3). Screening of the ligated pET28b(+) harboring 
TbHK gene and pET22b(+)  harboring hGCK gene showed positive insertion of the genes of 
interest. 
 
The results obtained in this chapter allow the continuation of the research project. Since both 
TbHK and hGCK genes were PCR amplified without mutations and successfully cloned into the 
expression vectors. This will be followed by transforming the gene constructs into the expression 
cell lines and continue with expression, purification and characterization of the respective 
recombinant proteins. 
50 
 
                                                   Chapter 3 
Recombinant hexokinase expression and purification 
3.1. Introduction 
Recombinant proteins can be expressed and purified in high quantities in vector systems which 
can easily be handled in the laboratory. Bacteria, yeast, insect and mammalian cell systems have 
been reported and employed in the production of recombinant proteins (Rai and Padh, 2001). 
The expression and purification of the two enzymes (TbHK and hGCK) will allow the 
comparison of the effects of silver NPs on their activities (chapter 4).  
 
3.1.1. Recombinant protein expression systems 
The choice of an expression system depends on several factors including; levels of expression, 
cell growth characteristics, intracellular and extracellular expression capabilities, post-
translational modifications and biological activity of the protein of interest (Makrides, 1996). 
 
3.1.1.1. Bacterial system 
E. coli is one of the most widely used host organism for recombinant protein expression (Baneyx 
and Mujacic, 2004; Berrow et al., 2006). E. coli have various advantages as an expression host, 
these include; easy and rapid growth in large numbers on cheap media and the strain used for this 
purpose is non-invasive to humans and the environment (Rai and Pagh, 1996; Baneyx, 1999; 
Chart et al., 2000; Sørensen and Mortensen, 2004). For the optimization of recombinant protein 
expression in these prokaryotic expression systems, strategies have been developed to maximize 
the yields of the expressed proteins. These strategies include the configuration of the genetic 
elements that affect the transcriptional and translational stages of the proteins (Hannig and 
Makrides, 1998). 
 
Expression of recombinant proteins in E.coli can be induced either by isopropyl β-D-1-
thiogalactopyranoside (IPTG) or auto-induction methods. Of these, IPTG is more often used as 
the recombinant protein expression inducer. Protein expression induced by IPTG is based on the 
lac-type promoter; the lac-promoter is situated next to the lacI gene that suppresses the 
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transcription of the promoter. The removal of this repression by IPTG initiates transcription of 
the lac-promoter, thus protein expression. A small amount of IPTG is enough to induce 
recombinant protein expression. However, high concentrations of IPTG may negatively affect 
cell growth (Hansen et al., 1998). 
 
Several papers have been published on the use of the auto-induction method for the expression of 
recombinant proteins (Sreenath et al., 2005; Studier et al., 2005; Tyler et al., 2005). In this 
method, the production of recombinant protein is based on the function of lac-operon regulatory 
elements in a mixture of glucose, glycerol and lactose (Jacob and Monod, 1961). During the 
initial phase of growth, glucose is the first metabolite used as a carbon source and protein 
expression is low due to catabolite repression of alternative carbon utilization pathways and 
binding interactions between lacI and lac-operators (lacO). As glucose levels decrease, the 
catabolite repression is relieved; leading to a shift in cellular metabolism toward consumption of 
lactose and glycerol. The use of lactose results in the production of allolactose. Allolactose then 
acts as the physiological inducer of the lac-operon (Holms, 1996; Wong et al., 1997). 
 
Auto-induction is advantageous over conventional recombinant protein expression protocols 
because it requires no monitoring of cell growth, it minimizes the required handling of cultures 
from inoculation until harvesting, produces high cell mass for harvesting, it is useful for the 
simultaneously induction of numerous expression clones and it can easily be performed for both 
small-scale screening and large-scale production (Studier et al., 2005; Sreenath et al., 2005; 
Tyler et al., 2005). 
 
3.1.1.2. Yeast systems 
Yeast systems are alternative expression systems to bacterial systems; they are mostly used in the 
production of pharmaceutical recombinant proteins. S. cerevisiae, H. polymorphia (Gellisen and 
Hollenberg, 1996), P. pastoris (Cereghino and Cregg, 2000) have been used in the production of 
recombinant proteins.  
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3.1.1.3. Insect cell systems 
Bacculovirus vectors have been used in the production of recombinant proteins in insect cells. 
Insect cells have presented several advantages over other systems including; their easiness to 
culture, their higher tolerance to osmotic pressure and higher levels of expression (Rai and Padh, 
2001; Ikonomou et al., 2003). 
 
3.1.1.4. Mammalian cell systems 
Some proteins that need post translational modification are expressed in mammalian cell line 
(Rai and Padh, 2001). Host cell types include; human embryonic kidney (HEK), baby hamster 
kidney (BHK) and Chinese hamster ovary (CHO) have been used to synthesize various 
recombinant proteins (Wurm and Benard, 1999; Matasci et al., 2003; Rosser et al., 2005; Hasebe 
et al., 2012).  
 
The current chapter describes the expression and purification of 50 kDa proteins encoded by a 1 
417 bp and 1 398 bp region of the genes that code for TbHK and hGCK proteins, respectively. 
Previously, TbHK and hGCK genes have been sub-cloned into E. coli pGE30 expression vectors 
for their expression in M15 (pREP) and E. coli M15 bacterial expression systems (Tiedge et al., 
1997 and 2000; Morris et al., 2006). In the current study, TbHK and hGCK genes were sub-
cloned into pET28b(+) and pET22b(+) , respectively for over-expression in an E. coli 
BL21(DE3) bacterial expression system harbouring the pRARE2 plasmid. The expressed 
proteins will be purified using experimental procedures such as; (i) ultra-centrifugation. The rate 
at which these molecules sediment is dependent on the centrifugal force, shape, size and as well 
as the density of the particles, the density and viscosity of the suspended medium; (ii) 
immobilized metal ion affinity chromatography (IMAC) using a fast protein liquid 
chromatography system (FPLC); (iii) size exclusion chromatography, that employs the 
separation of proteins, polysaccharides, nucleic acids, and other biological macromolecules 
according to their differences in size and (iv) dialysis, which is based on the diffusion 
phenomenon of the smaller sized molecules through a semi permeable membrane (snake skin) 
until equilibrium is reached. This process allows for exchange of buffers and removal of low 
molecular weight contaminants without significant loss of the molecules of interest. Purified 
proteins will be characterized in terms of pH and temperature stability and kinetic properties. 
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The aims of this chapter are: 
1. Expression of recombinant TbHK and hGCK proteins.  
2. Purification of the recombinant proteins (TbHK and hGCK proteins).  
3. Characterization of the purified TbHK and hGCK proteins to obtain optimum conditions 
and thermal stability. 
4. Determination of kinetic parameters of the purified proteins. 
 
3.2. Methods and materials 
The current section will outline procedures, equipment and consumables that were utilized in the 
expression, enzyme purification, optimization and characterization experiments. 
 
3.2.1. Recombinant protein expression by auto-induction 
An adaptation of the protocol that was first described by Studier et al. (1995) was employed in 
the current study for the expression of the TbHK and hGCK proteins. 
 
3.2.1.1. Preparation of glycerol stocks 
After confirmation of the positive insertion of the TbHK and hGCK genes into pET28b(+) or 
pET22b(+) expression vectors respectively, (Chapter 2, section 2.11), 2 µl of each construct was 
transformed into competent E. coli BL21(DE3) cells containing the pRARE2 plasmid using the 
transformation protocol described in section 2.6. Cells transformed with the pET28b(+) 
constructs were plated on LB plates containing 30 µg.ml
-1
 Kan and Cam 34 µg.ml
-1
 
concentrations of antibiotics to maintain selective pressure and incubated at 37°C for 12-16 h. 
After growth, a swipe of the transformed colonies was sub-cultured in 50 ml LB broth containing 
the appropriate antibiotics. Sub-cultures were grown for 12-16 h at 30°C, revolving at 150 rpm 
on a PSU20 multishaker (BOECO, Germany). After growth, 1 ml aliquots of the cell cultures 
were added to 0.5 ml pre-sterilized 50% glycerol and mixed thoroughly followed by stored at  
-80°C for further downstream experiments. Glycerol stocks of cells carrying empty constructs 
pET22b(+) and pET28b(+) were also prepared in the same manner.  
 
3.2.1.2. Pre-cultures for auto-inductions 
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The glycerol stock prepared in section 3.2.1.1 was revived prior to inoculation of the auto-
induction media. For pET28b(+) constructs, 1 ml of the glycerol stock was aseptically inoculated 
into 50 ml LB broth containing the appropriate antibiotics (30 µg.ml
-1 
kanamycin and 34 µg.ml
-1
 
chloramphenicol) in a 250 ml Erlenmeyer flask. For pET22b(+) plasmid containing hGCK, 1 ml 
of its glycerol stock was inoculated into 50 ml of LB broth with the appropriate antibiotics (100 
µg.ml
-1
 ampicillin and 34 µg.ml
-1
 chloramphenicol) in a 250 ml Erlenmeyer flask. Pre-cultures 
were incubated at 30°C for 12-16 h, aerobically, revolving at 150 rpm on a PSU20 multishaker 
(BOECO, Germany). Pre-cultures for the auto induction negative controls empty pET28b(+) and 
pET22b(+) were also prepared similarly.  
 
3.2.1.3. Inoculation for auto induction  
After the 16 h incubation (section 3.2.1.2), 10 ml of the TbHK pre-culture was aseptically 
inoculated into 1 liter of ZYP/5052 auto induction media composed of pre-sterilized 928 ml of 
ZY media (10 mg.l
-1
 tryptone, 5 mg.l
-1
 yeast extract), 50 ml of 20x NPS [0.5 M ammonium 
sulfate (NH4)2SO4), 1 M mono-potassium phosphate (KH2PO4), 1 M sodium phosphate dibasic 
(Na2 HPO4)], 20 ml of 50x 5,052 (250 g.l
-1
 glycerol, 25 g.l
-1
 glucose, 100 g.l
-1
 α-lactose), 2 ml of 
filter sterilized 1 M magnesiumsulfate (MgSO4). The media was supplemented with 30 μg.ml
-1 
kanamycin and 34 μg.ml-1 chloramphenicol to maintain selective pressure. A hundred milliliters 
of the auto induction mixture was aliquoted into 10x 500 ml Erlenmeyer flask aseptically (with 
intermittent flaming).  
For the human glucokinase, 10 ml of the pre-culture was inoculated into 1 liter of ZYP/5052 auto 
induction media with added 100 μg.ml-1 ampicillin and 34 μg.ml-1 chloramphenicol to maintain 
selective pressure. Similarly 100 ml aliquots were prepared. For the negative control of TbHK 
protein empty pET28b(+) plasmid, 1 ml of the pre-culture was also aseptically inoculated into 
100 ml of ZYP/5052 auto induction media. For the negative control of the human glucokinase 
protein, 1 ml of the negative control pre-culture empty pET22b(+) plasmid was also aseptically 
inoculated into 100 ml of ZYP/5052 auto induction media with appropriate antibiotics. 
Erlenmeyer flasks containing the auto induction mixture and the negative controls were then 
incubated aerobically at 20°C for 36 h, revolving at 150 rpm (Labotec, RSA). 
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3.2.1.4. Auto-induction studies 
The levels of protein expression were assessed over time by collecting 500 μl of the cultures at 
specific times. Samples were collected at 0, 6, 12, 18, 24, 30 and 36 h intervals. Collected 
samples were immediately centrifuged down at 12 000 xg for 10 minutes, the supernatant was 
discarded and the pellet stored at -20°C for further experiments. The frozen cell pellets of the 
auto induction study samples were thawed, re-suspended in 1 ml 50 mM Tris HCl buffer, pH 8.0 
and sonicated thrice at 100 mA for 30 sec (Sonics and materials Inc. USA). Samples were stored 
at 4°C pending further analysis. The protein concentration of the collected fractions will be 
determined (section 3.2.4) and subjected to SDS-PAGE analysis as described in section 3.2.3.1. 
 
3.2.2. Protein purification  
3.2.2.1. Biomass harvesting, washing  
After the 36 h of incubation (section 3.2.1.3) at 20°C, biomass was harvested and washed thrice, 
(6 000 xg; 4°C; 15 minutes), using an Avanti J.E centrifuge (Beckman Coulter, CA, United states 
of America). Pelleted cells were re-suspended in 50 mM Tris. HCl, pH 8.0, between each 
centrifugation step. After the final wash, the pellet was re-suspended in 50 mM Tris.HCl buffer 
in a 1: 20 weight: buffer volume ratio. The cell suspension was lyzed by the addition of 1 mg.ml
-
1
 lysozyme (Sigma) and 1 tablet of complete EDTA free protease inhibitor cocktail (Roche) was 
performed to inhibit the degradation of the expressed protein by the bacterial proteases. Cell 
disruption was aided by freezing the lyzed mixture at -80°C for a minimum of 2 h and then 
allowed to thaw at 4°C. 
 
3.2.2.2 Centrifugation 
The thawed samples were centrifuged (2 900 xg, for 30 minutes at 4°C) using Avanti J.E 
(Coulter Beckman, USA) to remove cellular debris and the supernatant collected for used in 
downstream purification steps. The soluble (cytoplasm) fraction was separated from the 
insoluble fraction (membrane) by ultra-centrifugation. Ultra-centrifugation was conducted using 
an Optima L-90K (Coulter Beckman, USA) ultracentrifuge at 100 000 xg for 90 minutes at 4°C 
in SW 28 rotor (Coulter Beckman, USA). The resulting supernatant was pooled, measured and 
stored at 4°C
 
for further experiments.    
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3.2.2.3. Immobilized metal affinity chromatography (IMAC) 
The recombinant proteins were purified through IMAC using a 5 ml His-trap FF column (GE 
Lifesciences, UK). The column was equilibrated according to the manufacturer’s instructions. 
Briefly, the column was cleaned with 50 ml distilled water, followed by the removal of the nickel 
sulphate using a stripping buffer (20 mM phosphate buffer, pH 8.0; 0.5 M sodium chloride; 50 
mM EDTA, pH 7.4). His-trap column was then charged using a 0.1 M nickel sulphate solution 
followed by washing with 50 ml distilled water. The column was placed into 1x binding buffer 
(20 mM imidazole, 20 mM Tris-HCl pH 7.4, 0.5 M sodium chloride). The protein mixture was 
loaded onto the HisTrap FF and unbound proteins eluted (5ml.min
-1
) using 20 mM sodium 
phosphate buffers, pH 7.4 containing 20 mM imidazole and 0.5M NaCl. The bound proteins 
were then eluted in the same buffer using a linear gradient (100 ml) of imidazole up to 0.5 M into 
5 ml fractions using the AKTA FPLC system (GE Healthcare, UK). Fractions of interest were 
carefully selected according to the peaks on the UV absorbance. The collected fractions were 
subjected to SDS-PAGE analysis as described in section 3.2.3.1 and were also assayed for 
hexokinase activity (section 3.2.5.1).  
 
3.2.2.4. Size exclusion chromatography  
Selected His-trap samples were pooled, measured and concentrated down to 2 ml using a 6 ml 
Vivaspin spin column (GE Healthcare) according to manufacturer’s instructions. The 
concentrated protein sample was mixed with a drop of glycerol and mixed by inverting and 
loaded onto a Sephacryl S100HR column (1.6 x 100 cm, Sigma) equilibrated with 50 mM Tris-
HCl, pH 7.4, containing 50 mM NaCl. Proteins were eluted using the same buffer at a flow speed 
of 1ml.min
-1
. Fractions were subjected to SDS-PAGE analysis as described in section 3.2.3.1 and 
hexokinase assay for enzymatic activity (section 3.2.5.1).   
 
3.2.2.5. Dialysis 
Dialysis was conducted using 10 kDa molecular weight cut off, snake skin dialysis tubing 
(Thermal Scientific, USA). The dialysis protocol was performed according to the manufacturer’s 
instructions. Sample was carefully added into the dialysis tubing and secured at both ends. The 
dialysis sample was suspended in 2 liters of 50 mM, pH 8.0 Tris-HCl dialysis buffer. To attain 
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equilibrium, the dialysis setup was kept for 4 h at 4°C while slowly stirring. Two additional 
buffer changes were performed, with an overnight and 12 h intervals, after which the dialyzed 
protein sample was carefully removed from the dialysis tubing, measured and stored at 4°C for 
further experiments. The dialyzed protein was subjected to SDS-PAGE analysis as described in 
section 3.2.3.1. The dialyzed sample was also assayed for hexokinase activity as described in 
section 3.2.5.1. 
 
3.2.2.6. Protein purification studies 
After each step of purification, 2x 500 µl samples were collected and stored at -20°C until 
needed. The sample aliquots were thawed on ice for a minimum of 5 minutes, one vial of each 
was used to determine protein concentration (section 3.2.4) followed by SDS-PAGE analysis 
(section 3.2.3.1). The second sample vial was assayed for hexokinase activity (section 3.2.5.1). 
This was performed in order to assess the effectiveness of the purification strategies in removing 
contaminating proteins and to assess if the purification had not negatively affected the proteins’ 
enzymatic activities. Hexokinase assay protocol is described in section 3.2.5.1 and activity 
calculations are described in section 3.2.5.2. The obtained data from the protein determinations 
and enzyme assay calculations were used to construct purification tables for both the expressed 
TbHK and hGCK.  
 
3.2.3. Polyacrylamide Gel Electrophoresis (PAGE) 
3.2.3.1. Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
Resolving and stacking gels for the SDS-PAGE gels were prepared as described in section 
3.2.3.1 using ingredients and amounts outlined in table 3.1 and table 3.2.  
 
Table 3.1: SDS-PAGE (0.75 mm, 12.5%) separation gel ingredients and amounts (for 1 gel) 
Ingredients 
     
Resolving gel (ml) 
30% / 0.8% Acryl / Bis 
    
1.518 
 3 M Tris pH 8.8 
     
0.485 
 H2O 
      
1.641 
 10% SDS 
      
0.091 
 10% APS 
      
0.0125 
 TEMED 
      
0.0025 
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The separation gel was left to completely polymerize in the gel cassette sandwich for about 2-3 
h. The top of the separation gel was overlaid with water saturated tert-amyl-alcohol to ensure a 
levelled top and avoid evaporation of the added stacking gel mixture. 
 
Table 3.2: SDS-PAGE (4%) stacking gel ingredients and amounts (for 1 gel) 
 
Ingredients 
     
Resolving gel (ml) 
30% / 0.8% Acryl / Bis 
    
0.2 
 3 M Tris pH 8.8 
     
105 
 H2O 
      
1.185 
 10% SDS 
      
0.015 
 10% APS 
      
0.015 
 TEMED 
      
0.0015 
  
 
To avoid trapping air bubbles in the gel, the casting stand was gently tapped, which dislodged 
any trapped air bubbles. After the polymerization of the separation gel, the overlaid water 
saturated tert-amyl-alcohol was thoroughly washed out with distilled water. The separation gel 
was prepared using ingredients in the amounts presented in table 3.1. A 4% prepared stacking gel 
mixture with ingredients provided in table 3.2 was then overlaid separation onto the separating 
gel in the cassette sandwich and an appropriate comb was carefully placed in between the 
cassette sandwich that was clamped on the casting frame and was left to solidify for about 2 h. 
 
The homogeneity of the proteins present in each fraction / sample was determined by 
electrophoresis under denaturing conditions or sodium dodecyl sulphate polyacrylamide gel 
electrophoresis. SDS-PAGE was performed using the Mini-Protean Tetra electrophoresis unit, 
from Bio-Rad, USA. The protocol used was that described by Laemmli (1970) using a 12.5% 
resolving gel and 4% stacking gel as set out in tables 3.1 and 3.2. Equal concentrations of 
samples to be analysed were mixed 1:1 with loading dye [50 µl TD and 200 µl TS (appendix E) 
followed by boiling for 10 min. Proteins were separated within the gels using a current of 100 V 
for 2 h. Page Ruler™ Pre-stained (10-170 kDa) Protein ladder (Thermal Scientific) was used as 
molecular weight markers in SDS-PAGE. 
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To visualize the protein bands, SDS-PAGE gels were stained and de-stained with Fairbank’s 
Coomasie Blue protein staining and de-staining protocol as described by Fairbanks, (1971). 
Polyacrylamide gel was placed in a covered microwavable container, about 100 ml of Fairbanks 
A solution (0.05% Coomassie Blue R-250, 25% isopropanol, 10% acetic acid) was poured onto 
the gel. The gel with the solution was heated in a conventional microwave oven on full power for 
about 2 minutes (until solution reached boiling point). The gel with the solution was left to cool 
down at room temperature for about 5 minutes while gently shaking on ultra rocker rocking 
platform (BioRad, USA) after which the solution was discarded and gel rinsed with distilled 
water. About 100 ml of Fairbanks B solution (0.005% Coomassie Blue R-250, 10% isopropanol, 
10% acetic acid), Fairbanks C solution (0.002% Coomassie Blue R-250, 10% acetic acid) and 
Fairbanks D solution (10% acetic acid) were sequentially added, boiled and discarded. The gel 
was rinsed with distilled water in between each Fairbanks solution change. The Fairbanks D 
solution changed 3 times. 
 
3.2.3.2. Native-PAGE  
Native-PAGE gels were prepared without the denaturing agent, thus analytes electrophoresed in 
these gels maintained their native structure and size of the folded protein assembly that governs 
the kinetics of the proteins in the gel. Therefore; proteins being separated by native gel 
electrophoresis do not only differ in their molecular mass and their cross sectional area, but also 
in their shape of the general structure. Native-PAGE gels allow for both conventional staining 
protocols and the use of specific enzyme linked stains. Resolving and stacking gels for the 
Native-PAGE gels were prepared as described in section 3.2.3.2 using ingredients and amounts 
outlined in table 3.3 and table 3.4.     
 
Samples analyzed by Native-PAGE electrophoresis were prepared by mixing sample and Native-
PAGE protein sample running buffer in a 1:1 ratio of the sample: buffer mixture. 
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Table 3.3: Ingredients with their corresponding amounts for the preparation of Native PAGE 
resolving gel. 
 
Ingredient Resolving gel (ml) 
30% / 0.8% Acryl / Bis  1.518    
3 M Tris pH 8.8  0.485     
H2O  1.641  
10% APS  0.0125        
TEMED  0.0025      
 
 
 
Table 3.4: Ingredients with their corresponding amounts for the preparation of Native PAGE 
stacking gel.        
   
Ingredient Stacking gel (ml) 
30% / 0.8% Acryl / Bis  0.2     
0.5 M Tris pH 6.8  0.105     
H2O  1.185  
10% APS  0.015        
TEMED  0.0015      
 
 
The samples were loaded into the gel wells accordingly. The electrophoresis run was performed 
using Mini-Protean Tetra System (Bio Rad, USA) where the gel cassette was carefully placed 
into the electrode assembly and was placed into the electrophoresis tank filled with 1x Native-
PAGE running buffer containing 3.028 g Tris, 14.4 g glycine in 1 000 ml (between the gel 
cassettes and outside the frame). The electrophoresis tank was then connected to Power Pac 300 
basic power supply (Bio Rad, USA), and run at 100 volts (V) for 1-2 h. The gels were visualised 
as described in section 3.2.3.1. 
 
3.2.4. Protein concentration determination 
Protein concentrations were determined by the use of the Bicinchoninic acid (BCA) method as 
first described by Smith et al. (1985). The commercially available kit from Thermo Scientific 
was used according to the manufacturer’s instructions. Standard curves of protein concentration 
versus absorbance (figures 3.2A and B) were constructed using the absorbance values obtained 
for protein standards prepared with BSA, using a Spectroquant Pharo 300 spectrophotometer 
(Merck, Germany) at 562 nm. Fifty micro litres of the standards and the unknown samples were 
first pipetted into a 1.5 ml Eppendorf tube and 1 ml of the working reagent was added and gently 
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vortexed. Assay tubes were incubated at 37°C (figure 3.1 A) and 60°C (figure 3.1 B) for 30 
minutes. Standard curves were plotted using Graph Pad prism, version 5.03 (figures 3.1 A and 
B). Protein concentrations between 250 and 1000 μg.ml-1 could be detected using the incubation 
at 37°C (figure 3.1A), while protein concentrations between 0 and 250 μg.ml-1 could be detected 
using the 60°C incubation (figure 3.1B). 
 
Figure 3.1: Standard curves for BCA protein assay using BSA protein standard incubated at (A) 
37°C and (B) 60°C. Absorbance readings were taken at 562 nm. 
 
 
3.2.5. Assays 
3.2.5.1. Hexokinase assay  
The hexokinase assay reaction is presented in equation 1.2 (section 1.6.1). Glucose, in the 
presence of ATP, is converted to glucose-6-phosphate and ADP by hexokinase. The glucose-6-
phosphate is oxidized by glucose-6-phosphate dehydrogenase in the presence of NAD
+
 to form 
6-phosphogluconolactone, H
+ 
and NADH. The hexokinase assay, adapted from Worthington 
enzyme manual (2012), detects the increase in NADH which is determined 
spectrophotometrically by measuring the increase in absorbance at 340 nm at 30°C through a 
coupled reaction with glucose-6-phosphate dehydrogenase. 
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Table 3.5: Hexokinase assay ingredients and quantities. 
Ingredients 
     
Volume (ml) 
50 mM Tris-HCL, pH 8.0 containing 13.3 mM 
MgCl2 
  
210 
 0.67 M Glucose 
     
50 
 16.5 mM ATP 
     
10 
 6.8 mM NAD 
     
10 
 300 U/ml Glucose-6-phosphate dehydrogenase 
  
10 
 Enzyme extract 
     
10 
   
To determine hexokinase activity, the hexokinase assays were performed in 96 well microtiter 
plates containing the ingredients and amounts as presented in table 3.5 and made-up to a final 
reaction volume of 300 µl with assay buffer (50 mM Tris-HCl, pH 8.0 containing 13.3 mM 
MgCl2). All assay ingredients except the enzyme extract were added into wells on a 96 well 
microtiter plate. Gen 5.0, version 1.10, software was used to compile/program the hexokinase 
assay protocol: 5 minutes incubation at 30°C to equilibrate the reaction mixture, addition of the 
enzyme solution followed by mixing for 5 sec by shaking. Upon addition of the enzyme solution, 
the mixture was incubated for an additional 5 min and the absorbance read at 20 sec intervals 
using a Synergy-MX microtiter plate reader (Biotek, USA). 
 
3.2.5.2. Enzyme activity calculations 
Enzyme activity was using equation 3.1.  
 
Equation 3.1: 
                               
 
Where ΔAbs is the change in absorbance; Vt is the total reaction volume (300 µl); ε = extinction 
coefficient of NAD/H (6.22 ml
-1
. µmol
-1
.); t is time in minutes; Ve is the volume of enzyme 
extract which was added into the reaction mixture (10 µl). The calculated results were expressed 
in µmol.ml
-1
.min
-1
 or U. ml
-1
. One unit of activity reduces 1 µmol of substrate (glucose) per 
minute at 30°C and pH 8.0. A negative control was run alongside the enzyme assay and was set 
up the same as in table 3.5 with the exception that the 10 µl enzyme solution was replaced with 
assay buffer. To confirm that the assay was able to quantify hexokinase activity a commercial 
Activity = (Δabs.Vt) / (ε.t.Ve) 
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hexokinase from S. cerevisiae (Sigma) was used as a positive control. The reaction was set up as 
described in table 3.5.
 
 
3.2.6. Trichloroacetic acid (TCA) protein concentration 
A TCA protein concentration procedure was carried out on the samples that had very low 
concentrations before preparation for SDS-PAGE run. Samples were mixed with 30% w/v TCA 
in a 1:1 ratio. The mixture was incubated on ice for 15-30 minutes followed by centrifugation 
(12 000 xg; 4°C; 15 min) in mini spin micro-centrifuge (Eppendorf, Germany) to collect the 
precipitated proteins. The supernatant was discarded and the pellet was rinsed by re-suspending 
the pellet in 1 ml ice cold isopropanol. The suspension was centrifuged (10 000 xg; 4°C; 5 min) 
and the supernatant removed and the pellet dried using a Labconco speed-vac system (Vacutec, 
USA) at 65°C for 30 minutes. Samples were stored for SDS-PAGE analysis as described in 
section 3.2.3.1. 
 
3.2.7. Characterization studies 
3.2.7.1. Temperature stability studies 
The thermal stability studies were conducted using temperatures ranging from 20°C to 70°C 
(20°C , 25°C , 30°C , 37°C , 40°C , 55°C and 70°C) at an assay pH of 8.0 (50 mM Tris-HCl) and 
incubated in digital dry bath incubators (Bio Rad, USA). The hexokinase assay parameters and 
ingredients were as outlined in section 3.2.5.1, but scaled-up to a reaction volume of 2 ml. An 
aliquot from each assay mixture was collected at specific time intervals (0, 15, 30, 45, 60, 90 and 
120 minutes) and the activity determined as described in section 3.2.5.1. Experiments were 
conducted on 3 different days in triplicate. Negative controls were run simultaneously with the 
characterization study assays at individual temperature and time intervals. Enzyme activity was 
calculated as described in section 3.2.5.2 and expressed as percentage relative activity, where 
100% activity was calculated using the highest activity at a given time across the temperature 
range. 
 
3.2.7.2. pH stability studies 
pH stability characterization studies were performed by subjecting the recombinant enzymes to 
different buffer conditions over a set period of time. Hexokinase assays were run as described in 
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Section 3.2.5.1, in triplicates and on 3 different days. A three component equimolar buffer 
cocktail ranging from pH 5.5 to 9.0 (5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9.0) were prepared. The 
components were 50 mM sodium acetate, 50 mM Tris-HCl and 50 mM 2 (N-morpholino) 
ethanesulfonic acid (MES). Sodium acetate buffer had the lower pH range (up to 5.0) and was 
adjusted using acetic acid to the required pH. MES buffer covered the pH range of pH 5.5 to 6.5, 
and was adjusted by either HCl or NaOH. Tris-HCl buffers covered the pH range between 7 and 
9, and were adjusted with HCl or NaOH. 
 
The purified TbHK and hGCK proteins obtained as described in sections 3.2.2 were prepared by 
serially diluting to appropriate concentrations and analyzed for their highest enzymatic activity 
using the hexokinase assay, and proteins were then concentrated to twice the obtained 
concentration that exhibited highest enzyme activity. The protein concentrates were then diluted 
with the individual pH buffers in a 1:1 protein to buffer cocktail ratio. Mixtures were incubated 
in a digital dry bath (Bio Rad, USA) at the optimum temperature obtained during the temperature 
stability characterization studies (section 3.2.7.1). Hexokinase assay readings were taken at 0, 15, 
30, 45, 60, 90 and 120 minute intervals. Experiments were conducted on 3 different days and in 
triplicate. Negative controls were run simultaneously with the characterization study assays at 
individual pH and time intervals. Enzyme activity was calculated as described in section 3.2.5.2 
and expressed as percentage relative activity, where 100% activity was calculated using the 
highest activity at a given time across the pH range. 
 
3.2.7.3. Stability study under optimum conditions 
The ability of the expressed TbHK and hGCK to maintain basal enzymatic activity over a longer 
period of time was studied at the optimal conditions (section 3.2.7). The purified hGCK and 
TbHK proteins were diluted with Tris-HCl buffer pH 7.5 and 8, respectively (section 3.2.7.2) to 
concentrations that exhibited highest enzymatic activity, and incubated at 37°C and 40°C, 
respectively. Hexokinase assay readings were conducted at 0, 0.25, 0.5, 1, 1.5, 2, 3, 5, 24, 36 and 
52 h intervals. Hexokinase assay parameters and ingredients were as outlined in section (3.2.5.1). 
Assay blanks were incubated and run simultaneously with the protein samples. Enzyme activity 
calculations were conducted as stated in section 3.2.5.2. Assay data was obtained from three 
independent readings and the assays performed in triplicates.  
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3.2.8. Kinetic studies 
In order to obtain the kinetic properties for the two expressed and purified proteins (section 
3.2.2), the TbHK and hGCK were subjected to varying concentrations of glucose using the 
standard hexokinase assay (section 3.2.5.1 and table 3.5), while keeping all other hexokinase 
assay parameters and conditions constant (table 3.6). Kinetic assays were performed at optimal 
pH, temperature and time interval as obtained in section 3.2.7. Km and Vmax properties of the 
expressed enzymes were calculated using a variation of the Michaelis-Menten equation (equation 
3.2), namely, the Hanes-Woolf. 
 
Equation 3.2:                                          
 
The following substrate concentrations were used for TbHK; 4, 8, 16, 33, 67, 100, 133, 167, 233 
and 333 µM. For hGCK the following substrate concentrations were used; 0.1, 1, 2.5, 5, 10, 15, 
20, 25, 30, 40, 50 and 100 mM. 
 
Table 3.6. Hexokinase assay ingredients and amounts for kinetic studies. 
Ingredients 
     
Volume (ml) 
50 mM Tris-HCL, pH 8.0 containing 13.3 mM MgCl2 
  
210 
 Varying substrate concentration (Glucose) 
  
50 
 16.5 mM ATP 
     
10 
 6.8 mM NAD 
     
10 
 300 U/ml Glucose-6-phosphate dehydrogenase 
  
10 
  
 
Final kinetic parameters were determined from three independent readings and hexokinase 
assays were performed in triplicates. Enzyme activity calculations were conducted as stated in 
section 3.2.5.2. 
 
3.2.9. Zymography  
Zymography is the detection of enzyme and activity based on the substrate specificity using an 
electrophoretic technique. In situ, in vivo and in gel zymographic techniques are in practice. In 
gel zymography is centered on the SDS-PAGE run under non-denaturing conditions in which a 
specific enzyme substrate can be co-polymerized in the gel, after the run, enzymes can be 
V=Vmax (S)/ [Km + (S)] 
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refolded and SDS removed by washing the gel in 2.5% Triton. Zymographic development 
mixture is applied onto the gel to enhance visualization (Yu and Woessner Jr, 2001) Frankowski. 
In gel zymographic analysis of TbHK and hGCK was performed as described by Jelnes (1971). 
Samples were prepared and run on two Native-PAGE gels (section 3.2.3.2). One of the duplicate 
gels was stained with coomassie (Section 3.2.3.1) and the other used for the zymogram study. 
To enhance visualization, the native gel was soaked in a developing reagent containing; 50 ml 50 
mM Tris.HCl pH 8, 25 mM MgCl2, 100 mg glucose, 25 mg ATP, 0.5 ml MTT, 0.5 ml NADP
+
 
and 0.25 PMS. The developing solution was pre-mixed thoroughly and poured onto the native 
gel. The native gel was incubated in the developing solution for 1 hour at 37°C, protected from 
obvious light. The reaction was terminated by washing the gel with distilled water thrice. 
 
3.3. Results and discussions 
The most important aim of the current chapter was to over-express both TbHK and hGCK 
proteins in a bacterial expression system and to purify them to homogeneity. 
 
3.3.1. Recombinant protein over-expression by auto-induction 
Chemically competent E. coli BL21(DE3) cells with p-RARE 2 that were transformed with 
pET28b(+) and pET22b(+) plasmids, harbouring TbHK and hGCK genes (Chapter 2, section 
2.2.2) respectively, were over-expressed by auto-induction technique (section 3.1.1). 
 
3.3.2. Auto-induction study samples 
The auto-induction samples (500 µl) for both TbHK and hGCK, including the auto-induction 
negative controls, were collected and immediately centrifuged as described in section 3.2.1.4. 
Samples were prepared for SDS-PAGE analysis and run as described in section 3.2.3. An 
obvious increase in the intensity of the colour and size of the protein band at 25 kDa (figure 3.2 
A) indicates the increase in the expressed TbHK protein over time. As compared to the negative 
control SDS-PAGE image (figure 3.2B), which has no obvious band that increases in its intensity 
at 25 kDa. 
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Figure 3.2: SDS-PAGE analysis of the samples collected at different time intervals during 
induction studies. Each lane was loaded with 150 µg.ml
-1
 protein. (A) pET28b(+) TbHK and (B) 
Empty pET28b(+) . Lanes (M) marker, (2) 0, (3) 6, (4) 12, (5)18, (6) 24, (7) 30 and (8) 36 h of 
incubation at 20°C in auto-induction media.  
 
For hGCK, there is a prominent increase in the intensity of the colour and size of the protein 
band at 55 kDa (figure 3.3 A), indicating an increase in the expressed human glucokinase protein 
over the auto-induction incubation period.  
 
 
Figure 3.3: SDS-PAGE analysis of the samples collected at different time intervals during 
induction studies. Each lane was loaded with 100 µg.ml
-1
 protein. (A) pET22b(+) hGCK and (B) 
Empty pET22b(+). Lanes (M) marker, (2) 0, (3) 6, (4) 12, (5) 18, (6) 24, (7) 30 and (8) 36 h of 
incubation at 20°C in auto-induction media. 
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As compared to the negative control SDS-PAGE image (figure 3.3 B), there is no band that 
increases in its intensity at 55 kDa (Gidh-Jain et al., 1993; Tiedge et al., 1996; Ronimus and 
Morgan, 2001). 
3.3.3. Protein purification studies 
After the removal of the cell debris by centrifugation and separation of the soluble fractions from 
the membrane fraction by ultracentrifugation (section 3.2.2.2), the over-expressed proteins were 
purified. Section 3.2.2 describes the strategies employed to obtain the pure proteins and herewith 
are the outcomes of such strategies. 
 
3.3.3.1. IMAC 
Several affinity-tags have been reported to be in use in the purification of recombinant proteins. 
These tags share common features such as; (i) specific and easy removal of the protein tags to 
produce a native protein, (ii) one step purification, (iii) minimal effect on protein tertiary 
structure and (iv), possibility to be fused to different proteins (Terpe, 2002). The use of affinity 
tags have been reported to improve recombinant protein yields (Rajan et al., 1998), prevent 
proteolysis, increase protein solubility, reduce fusion protein antigenicity and facilitate the re-
folding of proteins (Hammarstrom et al., 2002; Chen et al., 2005). Initially, IMAC was 
employed in the separation of proteins and peptides containing naturally present and exposed 
histidine residues, which were responsible for the binding of the molecules to the immobilized 
metal ions (Porath et al., 1971). Later the principle was adopted (Hochuli et al., 1987) for the 
purification of recombinant proteins with fused histidine residues. This approach can result in a 
purified recombinant protein with more than 90% purity (Arnau et al., 2006). Immobilized metal 
affinity chromatography was employed as the first strategy in the purification of the recombinant 
proteins (section 3.2.2.3). The elution profiles obtained from this purification step are presented 
in figures 3.4 and 3.5. 
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Figure 3.4: Elution profile obtained when the metal affinity resin was loaded with TbHK, the 
solid line represents the protein samples and the dashed line represents the percentage elution 
buffer. Fraction collection started at the beginning of the gradient (20 ml). 
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Figure 3.5: Elution profile obtained when the metal affinity resin was loaded with hGCK, the 
solid line represents the protein samples and the dashed line represents the percentage elution 
buffer. Fraction collection started at the beginning of the gradient (30 ml). 
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Both figures 3.4 and 3.5 show that as the percentage elution buffer increases, the bound proteins 
start to elute. The protein peak is observed when the elution buffer reaches 5% and continues 
until 25% is reached. This percentage of elution buffer (Fig 3.4 and 3.5, right y-axis) represents 
the concentration of imidazole in the elution buffer. Therefore 5-25% of the elution buffer 
represents 25-125 mM imidazole. Therefore it can be concluded that the bound TbHK and 
hGCK, including all other bound proteins, elute from the column at an imidazole concentration 
ranging from 25 mM to125 mM. The intensity of the ultraviolet light absorbance peak gives a 
rough indication of the concentration because of the aromatic amino acids; tryptophan, tyrosine 
and phenylalanine absorbing ultraviolet light at a wavelength of 280 nm (Held, 2003). The UV 
absorbance peak of about 150 milli-absorbance units (mAU) of TbHK and hGCK observed in 
figures 3.4 and 3.5 indicate that both proteins express in low concentrations that could be 
ascertained by BCA assay (section 3.2.4). 
 
 
Figure 3.6: SDS-PAGE presenting the protein profiles of the selected fractions (corresponding to 
the elution volumes presented in figure 3.5 of the absorbance peak. (A) TbHK and (B) hGCK. 
Lanes (1) marker, (2) fraction 2, (3) fraction 3, (4) fraction 4, (5) fraction 5, (6) fraction 6, (7) 
fraction 7 and (8) fraction 8. Showing the proteins of interest at (A) 25 kDa for TbHK and (B) 55 
kDa for hGCK. 
 
Despite the selective affinity for His-tagged proteins of the IMAC resin, contaminating proteins 
and other non-protein contaminants may bind to the beads in the metal affinity column or on the 
tagged protein itself, these contaminants may be eluted together with the protein of interest. This 
phenomenon is observed on the SDS-PAGE analysis of fractions selected from the absorbance 
peak regions (figure 3.6) where there are other visible protein bands other than the 25 kDa TbHK 
protein band and the 55 kDa hGCK protein band protein of interest.  
71 
 
3.3.3.2. Size exclusion chromatography 
In order to remove the persistent contaminating proteins, imidazole and other contaminating 
molecules eluted in the IMAC fractions (for TbHK and hGCK), the pooled samples (section 
3.2.2.3) were subjected to size exclusion chromatography as described in 3.2.2.4. The elution 
profiles obtained from this purification step are presented in figure 3.7 and figure 3.8. 
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Figure 3.7: An elution profile obtained for Sephacryl S-100 HR resin when loaded with TbHK. 
The area between the two arrows represents the region that was pooled for downsteream 
purification. 
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Figure 3.8: An elution profile obtained from Sephacryl S-100 HR resin when loaded with hGCK. 
The area between the two arrows represents the region that was pooled for downsteream 
purification. 
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The TbHK elution profile (figure 3.7) showed 5 distinct peaks and the SDS analysis of the 
selected fractions (figure 3.9A) showed that the circled peak (figure 3.7) represents the 
recombinant protein (25 kDa) which was also confirmed by the presence of hexokinase activity 
(section 3.2.5.1). The hGCK elution profile (figure 3.8) also has five peaks with one prominent 
peak. SDS-PAGE analysis (figure 3.9B) of the peak fractions showed that the prominent peak 
(circled on figure 3.7) was the peak that contained the recombinant human glucokinase protein 
(25 kDa). Fractions from this peak also exhibited hexokinase enzymatic activity (section 
3.2.5.1). 
 
        
Figure 3.9: SDS-PAGE gels representing the protein profiles of the size exclusion 
chromatography. (A) TbHK (25 kDa) - Lane (1) Marker, lanes (2-10) fractions number 12-19. 
(B) hGCK (55 kDa) - Lane (1) Marker, lanes (2-14) fractions 11-23. 
 
The peaks, when overlaid by the hexokinase activity, peaks between the arrows on figure 3.7 and 
figure 3.8 corresponded to the 25 kDa protein bands on the SDS-PAGE gels (figure 3.9). These 
fractions were pooled for further purification procedures. Comparing the intensities of the elution 
peaks (figure 3.9 A lanes 7 to 8 and figure 3.9 B lanes 5 to 9), it is evident that TbHK eluted in 
small quantities, unlike hGCK which had slightly higher protein concentrations. This comparison 
is based on the observed thickness and colour intensity of the protein bands on the SDS-PAGE 
gel. SDS-PAGE analysis (figure 3.9A and B) of both the recombinant proteins indicated that size 
exclusion chromatography eliminated most of the contaminating proteins visible in figure 3.7 
(SDS PAGE of IMAC); however, there are low levels of contaminating proteins (figure 3.9) that 
co-eluted with the proteins of interest,therefore, further purification steps were necessary. 
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3.3.3.3. Dialysis 
Results obtained from the TbHK and hGCK size exclusion chromatography elution profiles 
(figures 3.7 and 3.8) and SDS-PAGE gels (figure 3.9A and B) were used to select the fractions to 
be pooled for dialysis. Pooled fractions corresponded to the activity peaks which overlapped with 
a protein peak. After two buffer changes, samples were retrieved from the dialysis tube and 
protein concentrations were determined using the BCA protein assay as described in section 
3.2.4. The protein concentrations and volume of samples obtained after each step of purification 
were used to construct the purification tables (tables 3.7 and 3.8). 
 
To assess the purification of the protein during the purification strategies, 2x 500 µl samples 
were collected at each strategy (section 3.2.2). One of the samples was subjected to SDS-PAGE 
analysis (section 3.2.3.1), and the second for protein and enzyme activity. The purification table 
obtained for the recombinant TbHK is given as table 3.7. Total protein obtained after purification 
from one liter of auto induction media was 1.2 mg and had a purification fold of 27. The final 
percent yield was 11% with a specific activity of 0.041µmol.min
-1
.mg
-1
. These values are 
comparable to values reported in literature (Morris et al., 2006, Chambers et al., 2008). 
 
Table 3.7: Purification table for TbHK 
 
Fraction Volume  
 
(ml) 
Total 
protein 
(µg.ml-1) 
Total 
protein 
(mg) 
Activity  
 
(µmol.min-
1.ml-1) 
Total 
activity 
(µmol.min-1) 
Specific 
activity 
(µmol.min-
1 .mg-1 ) 
Purification 
fold 
Yield  
 
(%) 
Crude 165 1766 291 0.00268 0.44212 0.00151 1 100 
IMAC 30 245 7.3 0.00161 0.04823 0.00661 4 11 
100HR 25 56 1.4 0.00161 0.04019 0.02871 19 9 
Dialysis 23 54 1.2 0.00214 0.00214 0.04109 27 11 
 
 
The purification table obtained for the recombinant human glucokinase is given as table 3.8. 
Total protein obtained after purification from one liter of auto induction media was 3 mg and had 
a purification fold of 24. A final yield of 6% was obtained with a specific activity of 0.225 
µmol.min
-1
.mg
-1
. Each step given in the purification tables (tables 3.9 and 3.10) was also 
subjected to SDS-PAGE analysis as described in section 3.2.3.1. Figure 3.10 represents the SDS-
PAGE results and indicates that the purification strategies were successful. 
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Table 3.8: Purification table for human glucokinase 
 
Fraction Volume  
 
(ml) 
Total 
protein 
(µg.ml-1) 
Total 
protein 
(mg) 
Activity  
 
(µmol.min
-1 .ml-1) 
Total 
activity 
(µmol.min-1 ) 
Specific 
activity 
(µmol.min-
1 .mg-1 ) 
Purification 
fold 
Yield  
 
(%) 
Crude 250 5095 1274 0.04823 12.0579 0.00947 1 100 
IMAC 25 1501 38 0.01447 0.36174 0.00964 1 3 
100HR 30 281 8 0.01447 0.43408 0.05149 6 4 
Dialysis 28 125 3 0.02412 0.67524 0.22508 24 6 
  
The IMAC step proved to be a powerful tool among purification strategies as this step was 
responsible for removing most of the undesired proteins and non-protein compounds. The final 
step in purification of the TbHK (dialysis) resulted in a protein sample with high purity contained 
only one visible band (figure 3.10A lane 6). 
 
 
Figure 3.10: SDS-PAGE analysis of (A) TbHK and (B) hGCK purification strategies. On both 
images (M) Marker, (2) lysate (3) soluble fraction, (4) IMAC, (5) SEC, (6) Dialysis; showing the 
25 kDa and 55 kDa purified TbHK and hGCK proteins, respectively. 
 
The SDS-PAGE image obtained for the human glucokinase (figure 3.10 B), shows constant co-
purification of contaminating proteins ranging from 60 to 70 kDa even in the final step of the 
purification strategy (dialysis, figure 3.10 B, lane 6). During the immobilized metal affinity 
chromatography, concomitant expressed E. coli proteins that exhibit high affinity to the metal 
chelating resin may be co-eluted with the proteins of interest. These contaminating proteins have 
been classified into three classes (table 3.9). Class I, which are proteins that require >80 mM 
imidazole buffer for their elution, Class II proteins require 55 mM to 80 mM imidazole for 
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elution and class III proteins that need between 30 mM and 55 mM imidazole for their elution. 
Class III includes heat shock proteins (HSP60) with molecular weight of 60 kDa. 
 
Table 3.9: Classes of native E. coli proteins which have the ability to co-purify with His-tagged 
proteins during IMAC (adapted from Balanos et al., 2006) 
 
Class E. coli protein Molecular mass (kDa) % Histidine residue 
Class I Cu-Zn-SODM 17.6 
 
4.0 
 
 
ArgE 
 
42.3 
 
4.4 
 
 
Hfq 
 
11.1 
 
4.9 
 
 
Fur 
 
16.7 
 
8.1 
 Class II YadF 
 
25.0 
 
5.5 
 
 
GlgA 
 
51.7 
 
3.4 
 
 
GlmS 
 
66.8 
 
3.9 
 
 
CAT 
 
22.5 
 
5.5 
 Class III Hsp60 
 
57.0 
 
0.2 
 
 
ODOI 
 
10.5 
 
3.6 
  
 
 
Despite its co-elution, the contaminating protein may not have an influence on the hexokinase 
activity of the target proteins (hexokinase assay) because of the differences in the modes of 
actions between TbHK, hGCK and HSP60 (Bork et al., 1992). However, this hypothesis presents 
a viable area of further studies in assessing the effects of the contaminating E. coli proteins on 
the properties of the recombinant proteins expressed in E. coli. 
 
3.3.4. Characterization studies 
The purified TbHK and hGCK (section 3.2.2) were characterized to determine their optimum 
thermal and pH stability and this section provides the outcomes of these studies. 
 
3.3.4.1. Temperature stability studies 
The temperature at which the expressed and purified TbHK and hGCK exhibited the highest 
activities over time was determined as described in section 3.2.5.1. For TbHK, the optimum 
incubation time was 90 min (figure 3.11) and the optimum temperature was 40°C (figure 3.11). 
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Figure 3.11: Graphical presentation of temperature stability study of TbHK. 
 
For hGCK, the optimum incubation time was 90 min (figure 3.12) and the optimum temperature 
was 37°C (figure 3.12). The enzyme velocities at the respective temperature and time interval 
(for TbHK and hGCK) were used to calculate percentage relative activities. The percent relative 
activity for the individual temperature ranges and time intervals for TbHK and hGCK were 
calculated relative to the activity obtained at the optimum incubation time and temperatures. See 
appendix F for individual results obtained for the percentage relative activity at different time 
intervals. 
 
The thermal stability outcomes for human glucokinase are very similar to values reported in 
literature. Recombinant pancreatic β-cell glucokinase fused to GST tag exhibited higher relative 
enzymatic activity at temperatures ranging from 30°C to 50°C after incubating the expressed 
enzyme for a period of 30 minutes (Galan et al., 2006). 
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Figure 3.12: Graphical presentation of temperature stability study of hGHK. 
 
In 1999, Davis et al. (1999) reported on the expression of a wild type glucokinase in E. coli 
(DH5α strain) that showed increasing relative activity at 37°C after 20 minutes incubation.  
 
3.3.4.2. pH stability studies 
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Figure 3.13: Graphical presentation of pH stability study of TbHK. 
 
The pH level at which the expressed TbHK and hGCK exhibited the highest enzymatic activity 
over time was determined as described in section 3.2.7. For TbHK, the protein exhibited high 
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enzyme activity over a fairly wide pH ranging from 7.5 to 8.5 with pH 8.0 at 90 minutes (T90) 
exhibiting the highest activity (figure 3.13). Dodson et al. (2011) reported an optimum pH of 7.5. 
Nwagwu and Opperdoes (1982) reported an optimum pH value of TbHK activity of 7.8, which is 
comparable to our study. 
 
For hGCK, the optimum incubation time was 60 min (figure 3.14) and the optimum pH was 7.5 
(figure 3.14). The results obtained were used to calculate percentage respective relative activity 
and are graphically presented in figure 3.14. The percent relative activities for the individual pH 
ranges and time intervals for TbHK and hGCK were calculated relative to the activity obtained at 
90 min, pH 8.0 and 60 min, pH 7.5 respectively. Results obtained for the percentage relative 
activity different time interval are presented in appendix F. 
 
The pH value obtained for the recombinant human glucokinase in this study is closely 
comparable to reports by Van dercammen and Van Schaftingen (1990) where they observed that 
hGCK exhibited an increase in enzymatic activity at pH values ranging from 6.55 to 8.15, 
measured at 5 mM glucose. Grossbard and Schimke (1966) investigated the optimum pH for the 
hexokinase isoenzymes (I, II, III) and reported that the highest enzyme activity was observed at 
pH values ranging from 7.8 to 8.8. 
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Figure 3.14: Graphical presentation of pH stability study of hGHK at T60. 
 
3.3.4.3. Stability study under optimum conditions                
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The final stability conditions were used to determine how stable the enzyme activity for both 
proteins. TbHK and hGCK were diluted in Tris. HCl, pH 8.0 and incubated at 40°C (TbHK) and 
37°C (hGCK). Standard hexokinase assays at specific time intervals over 52 hours were 
conducted as described in section 3.2.5.1. Hexokinase assay reading at time zero incubation was 
used as the reference result for the calculations of percent relative activity. TbHK was the more 
stable protein as it maintained a relatively high activity of about 75% and above for a period of 
up to 36 h with a decrease in relative activity to approximately 25% at 52 h (figure 3.15 A). 
Recombinant hGCK has a unique pattern of enzymatic activity. As shown in figure 3.15 B, it 
exhibits a steady increase in its relative activity from 30 minutes to about 90 minutes, where its 
activity spontaneously drops in activity to about 60%. However this relative enzyme velocity is 
maintained up to 36 h. No activity was observed at 52 h. 
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Figure 3.15: Graphical presentation of stability of (A) TbHK and (B) hGCK. 
 
3.3.5. Kinetic studies 
Enzymes with multiple binding sites may exhibit either a positive or a negative cooperativity to 
its substrate. In positive cooperativity, the formation of the complex increases the affinity of the 
binding of the second substrate molecule. In negative cooperativity, the binding of the first 
substrate to its active site reduces the affinity of the enzyme to the second substrate. Sigmoidal 
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behaviour of an enzyme indicates substrate cooperativity which is a deviation from the 
conventional Michaelis-Menten kinetics. Its substrate saturation curve exhibits a palm shape as 
compared to the hyperbolic curve observed in Michaelis-Menten (Kamata et al., 2004). The 
magnitude of the Hill coefficient is derived from the slope of the Hill plot that indicates the 
extent and direction of cooperativity. Thus, enzymes with consented enzyme kinetics (no 
cooperativity) will have an h value of 1; enzymes with negative cooperativity to its substrate will 
have an h value of less than 1; enzymes with positive cooperativity will have an h value of 
greater than 1. Therefore, enzymes that exhibit sigmoidal behaviour will have a Hill coefficient 
value of >1 (Roders and Gibson, 2004). 
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Figure 3.16: TbHK enzyme kinetic plots (A) Hanes-Woolf plot and (B) Michaelis–Menten plot. 
                     
The kinetic study experiments were carried out as presented in section 3.2.8 to determine the 
kinetic properties of TbHK and hCGK. Experimental data was analyzed using Hanes-Woolf 
(HW) and Michaelis-Menten (MM) plots. Figure 3.16 represents the obtained MM and HW 
plots. The Km and values read from the MM graph were 39.3 µM and 0.066 µmol.min
-1
.ml
-1
, 
respectively, which were comparable to the Km and values read from the HW plot of 39 µM and 
0.066 µmol.ml 
-1
.min
-1
, respectively. The Hanes-Woolf enzyme kinetic analysis is a more precise 
method for the calculation of the enzymatic parameters (Ritchie and Prvan, 2006). The obtained 
Km and Vmax for TbHK in the current study are strongly comparable to those reported in literature 
(Nwagwu and Opperdoes, 1982; Morris et al., 2006, Chembers et al., 2007; Chembers et al., 
2008). For example, Km values for TbHK are reported to be 43 µM (Caceres, 2002). 
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Experimental kinetic data obtained for hGCK was analyzed using the Michaelis-Menten 
equation (Equation 3.2) and the Hanes-Woolf plot (figure 3.17). The Km and Vmax values read 
from the HW graph were 4.5 mM and 0.032 µmol.min
-1
.ml
-1 
respectively, which is comparable 
to the Km and Vmax values read from the MM plot 4 µM and 0.032 µmol.min
-1
.ml
-1
 respectively.  
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Figure 3.17: hGCK enzyme kinetic plots (A) Hanes-Woolf plot and (B) Michaelis–Menten plot. 
 
The Hill coefficient value of 1.5 obtained for the recombinant human glucokinase in this project 
agrees with the sigmoidal behaviour of the enzyme which displays positive cooperativity (Gidh-
Jain et al., 1992; Matschinsky et al., 1993; Stoffel et al., 1993; Davis et al., 1999; Kamata et al., 
2004). Table 3.10 is a summary of the Vmax and Km values obtained using the different kinetic 
equations/plots and can be used to draw a comparison between the human and Tb proteins. When 
comparing Km values it is evident that the human protein has a lower affinity for the substrate 
than the trypanosome protein. This can be concluded based on the catalytic turnover rate and 
efficiency of proteins. TbHK has a higher turnover rate (Kcat) of its enzyme-substrate complex 
(2.05 min
-1
) as opposed to the turnover rate of human glucokinase (11.25 min
-1
); the human 
glucokinase exhibits a lower efficiency (2.5 min
-1
.µmol
-1
) as compared to TbHK efficiency 
(0.0526 min
 -1
.µmol
-1
). 
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Table 3.10: Kinetic properties of the recombinant human glucokinase with the hill coefficient 
and TbHK proteins 
 
Plot type TbHK 
   
 hGCK 
    
 
Km Vmax Kcat Kcat/Km  Km Vmax h Kcat Kcat/Km 
 
(µM) 
(µmol.min-
1.mg-1) 
(min-
1) 
(mol-
1.min-1)  (mM) 
(µmol.min-
1.mg-1) 
 
(min-
1) (mol-1.min-1) 
Michaelis- 39.3 0.066 2.05 0.0522  4 0.032 
 
11.25 2.813 
Menten 
    
 
     Hanes- 39 0.066 
 
0.0526  4.5 0.032 1.5 
 
2.5 
Woolf 
    
 
      
 
 
 
Glucokinase (Hexokinase IV) an isoform of hexokinase enzymes (I, II, III and IV) in humans is 
reported to have significantly different kinetic properties. Despite glucokinase being a 
monomeric enzyme it exhibits a sigmoidal dependency to glucose as compared to the 
conventional Michaelis-Menten glucose dependency exhibited by its isoforms (I, II, III). Despite 
the differences in their substrate dependency, the hexokinase isotypes share common features, 
including the presence of large and small domains (figure 3.18) that are connected by an α-helix 
interconnecting region (Kamata et al., 2004; Molnes et al., 2011).  
           
Figure 3.18: Human glucokinase structure complexed with a compound (yellow) showing the 
closed substrate bound state (taken from Kamata et al., 2004). 
There are two reported possible explanations for the substrate cooperativity of glucokinase. 
Firstly, as explained by Cornish-Bowden and Storer, (2004) the mnemonical mechanism is 
proposed where there is a selectively slow inter-conversion between two free forms of the 
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enzyme, secondly; Patterson (1986) attributed the deviation from the Michaelis-Menten kinetics 
to a random order of binding of the substrate. However, based on various kinetic studies and 
crystal structure analysis of glucokinase, the global conformation conversion and the kinetic 
cooperativity upon binding to substrate may be summarized in equation 3.4, where GCK 
represents the substrate free, inactive enzyme, GCK-Glc is the enzyme-substrate complexes of 
low activity (thus lower substrate affinity), GCK*-Glc is the highly active (thus higher substrate 
affinity) enzyme state (figure 3.19) (Cornish-Bowden and Storer, 1977; Storer and Cornish-
Bowden, 1986; Patterson, 1986; Kamata et al., 2004; Molnes et al., 2011). TbHK follows classic 
Michaelis-Menten kinetics (Nwagwu and Opperdoes, 1982; Seyfang and Duszenko, 1991). 
 
Equation 3.4:  
                                                               k1                             k2 
                                      GCK + Glc                GCK . Glc               GCK* . Glc 
                                                               k-1                                     k-2 
 
 
3.3.6. Zymography 
Zymographic studies were conducted as described in section 3.2.9, development of purplish 
discoloration was observed, although too faint to determine if activity was being displayed. For 
this reason, western blotting was performed and the interpretation of the obtained results is 
presented in appendix A. 
 
3.3.7. Conclusions 
The main objectives of the current chapter were to express, purify and characterize recombinant 
TbHK and hGCK. TbHK and hGCK proteins were readily over-expressed in an E. coli 
expression system as soluble proteins by using auto induction media. The expressed proteins 
maintained their enzymatic activity throughout the purification strategies (centrifugation, IMAC, 
SEC and dialysis). Although the finally purified proteins (TbHK and hGCK) co-purified with 
other non specific proteins (figure 3.10A and B), these proteins did not significantly affect the 
characterization studies. Protein characterization studies revealed that TbHK is stable at 
temperatures ranging from 37°C to 45°C with and an optimum of 40°C and a pH range of 7.0 to 
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8.5 with an optimum of 8.0. The recombinant human glucokinase exhibited stability at 
temperatures and pH ranging from 30°C to 40°C with an optimum of 37°C and 7.0 to 8.5 with an 
optimum of 7.5. At optimum conditions the recombinant TbHK maintained activity of up to 75% 
for up to 36 h. Similarly, recombinant human glucokinase maintained enzymatic activity of up to 
65% for up to 24 h at optimum conditions. 
 
Studies of the kinetic parameters of the enzymes revealed that TbHK had a Km of 39 µM, Vmax of 
0.066 µmol.min
-1
.ml
-1
 and kcat of 2.05 min
-1
 and a Kcat / Km of 0.0526 (min
-1
.µmol
-1
) as 
determined by Hanes-Woolf. Human glucokinase enzyme kinetic studies revealed a Km of 4.5 
mM, Vmax of 0.032 µmol.min
-1
.ml
-1
, Kcat of 11.25 min
-1
 and a Kcat / Km of 2.5 (min
-1
.µmol
-1
) 
using the Hanes-Woolf plot. The human hexokinase has a Hill coefficient of 1.5, confirming the 
sigmoidal behaviour and unique characteristic of the enzyme. However the expressed proteins 
have slightly lower maximal velocity (Vmax), turnover rate (Kcat) and less efficiency (Gidh-Jain et 
al., 1993; Km et al., 2007; Molnes et al., 2011). These may be attributed to the expression of the 
protein with the N-terminal (TbHK) and C-terminal His-tag (hGCK). When determining 
enzymatic kinetic parameters for the enzyme-nanoparticle interaction studies (Chapter 4), the Km 
and Vmax values determined from the Hanes-Woolf plots will be employed. The His-tag may 
have affected the folding and unfolding of the protein, As this is hypothetical , it presents a 
feasible research route to express the proteins either without the His-tag or to remove the tag and 
compare the their characteristics to the ones presented here and to research work found 
elsewhere in literature. The parameters determined from the optimization and characterization of 
the two enzymes was used in chapter 4 where TbHK and hGCK were interacted with chemically 
synthesized silver NPs. 
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Chapter 4 
Metallic silver NPs synthesis characterization and interactions with 
hexokinase 
4.1. Introduction  
Nanotechnology is an emerging and an important field of current research. This field focuses on 
the design, synthesis of nano-scale particles (1-100 nm), and their manipulation. Metallic NPs, 
including silver NPs, have shown importance in many areas of research due to their size and 
shape dependent optical, electrical and magnetic properties (The royal society, 2004). Silver NPs 
(AgNPs) have been synthesized using chemical (Pal et al., 2008; Patil et al., 2011) and 
biological methods (Galvez et al., 2008; Krutyakov et al., 2008; kasthuri et al., 2009; Das et al, 
2011Huang et al., 2013). 
 
4.1.1. Chemical methods 
The citrate and the sodium borohydride methods are two of the most commonly used chemical 
methods for synthesizing silver nanomaterials (Krutyakov et al., 2008). The citrate method was 
originally used for the synthesis of metallic gold NPs (the Turkevich method) of gold 
nanoparticle synthesis (Krutyakov et al., 2008). Guzman et al. (2009) used the principles of the 
citrate method to synthesize spherical silver NPs, where 1 mM – 6 mM of silver nitrate (AgNO3) 
was reduced to silver NPs by a combination of sodium citrate (1 mM - 2 mM) and hyrdazine 
hydrate (2 mM - 12 mM) as reducing agents. The NPs were stabilized by 8% (w/w) sodium 
dodecyl sulphate at room temperature. Elsewhere silver NPs have been synthesized using the 
citrate method (Fang et al., 2005; Šeikate et al., 2006). 
 
One of the most common methods for synthesizing silver NPs is the use of sodium borohydride 
as a reducing agent of silver nitrate. Sodium borohydride has also been used as both the reducing 
and stabilizing agent (Mavani and Shah, 2013). In this method 2 ml of 1 mM silver nitrate is 
added to 2 mM sodium borohydride cooled in an ice bath, at a rate of 1 drop per second while 
stirring (Dong et al., 2012; Mavani and Shah, 2013). Song et al. (2008), reported on the synthesis 
of silver NPs using the sodium borohydride method with the addition of sodium dodecyl sulphate 
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as a stabilizer. Silver NPs of controlled size and shape can be prepared by laser irradiation of an 
aqueous solution of silver salt and surfactants. Microwave assisted synthesis of silver NPs 
employing silver nitrate solution (Pal et al., 2008), carboxymethyl cellulose sodium (Chen et al., 
2008), silver nitrate-ethylene-glycol-H2-[PtCl6]-polyvinylpyloridone solution (Tsuji et al., 2008) 
have been reported. 
  
Silver NPs can be synthesized using polysaccharides as both a reducing agent and as a capping 
agent (Korberkandi and Iravan, 2012). Raveendran and Wallen (2003) reported on the synthesis 
of starch – silver NPs using the polysaccharide method where α-D-glucose was used as a 
reducing agent and starch as a capping agent. Huang and Yang (2004) experimented on the 
synthesis of silver NPs by the use of negatively charged heparin as a reducing agent, stabilizing 
agent and a nucleation controller. Tollens method is another simple one step process that has 
recently been used to make silver NPs where the size is controlled (Kaler et al., 2010). This 
method involves the reduction of diaminosilver [Ag(NH3)2] (The Tollens reagent) by an 
aldehyde. Silver ions are reduced by saccharides in the presence of ammonia, yielding silver NPs 
with sizes ranging from 50 to 200 nm. It has been reported that glucose, galactose, maltose and 
lactose can also be used as reducing agents in the synthesis of silver NPs (Korberkandi and 
Iravan, 2012).  
 
4.1.2. Biological synthesis 
Biological synthesis of silver NPs with desired morphology and sizes have been achieved by the 
use of natural reducing, capping and stabilizing agents. Biological method of synthesizing silver 
NPs have become a major focus of research since in this method there is very limited or no use 
of harsh, highly toxic and expensive chemical substances. Extracts from proteins, enzymes, 
amino acids, vitamins polysaccharides, plants, bacteria, fungi, yeast, viruses and actinomycetes 
have been employed as bio-reducing agents (Huang et al., 2007; Korbekandi and Iravan, 2012).  
 
Silver NPs synthesis using bacteria, a mechanism that utilizes the presence of nitrate reductase 
enzyme is widely accepted where nitrate reductase converts nitrate into nitrite. During the 
reduction it is proposed that an electron is transferred to the silver ion Ag
+
, reducing the silver 
ion to Ag
0
 (Prahbu and Poulose, 2012). This was observed in Bacillus licheniformis (figure 4.1) 
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which secretes NADPH and NADPH-dependent enzymes such as nitrate reductase that 
effectively convert Ag
+
 to Ag
0
 (Vaidyanathan et al., 2007). Anil Kumar et al. (2006) further 
reported the synthesis of silver NPs by using purified nitrate reductase from Bacillus subtilis, 
Corynebacterium and Lactobacillus have also been used to induce the formation of silver NPs 
(Mouxing et al., 2006; Saifuddin et al., 2009; Korbekandi and Iravani, 2012). Haefeli et al. 
(1984) reported the synthesis of silver NPs by Pseudomonus stutzeri. Culture supernatants of 
Escherichia cloacae, Klebsiella  pneumonia and E. coli (Shahverdi et al., 2007; Gurunathan et 
al., 2009), Bacillus licheniformis, Staphylococcus aureas (Nanda and Saravanan, 2009) are all 
able to cause rapid formation of silver NPs. 
 
Figure 4.1: Possible mechanism for silver NPs synthesis involving nitrate reductase that may 
convert Ag
+
 to Ag
0
 through electron transfer mechanism (adapted from Kalimuthu et al., 2008). 
 
Another method of synthesizing silver NPs is by using fungi. Ahmed et al. (2003) experimented 
with the extracellular synthesis of silver NPs ranging in size from 5 to 50 nm. In their findings 
they discussed the action of an NADH-dependent reductase that was thought to be responsible 
for the reduction of Ag
+
 and the subsequent formation of silver NPs. Ingle et al. (2008) managed 
to extracellulary prepare AgNPs with an average size of 19 nm by F. solani. Bhainsa and Souza 
in 2006 employed the fungus Aspergillus fumigatusin to synthesis silver NPs. Kathiresan et al. 
(2009) produced AgNPs using a marine fungus Penicillium fellutanum isolated from coastal 
88 
 
mangrove sediments. Other fungal strains used to synthesize silver NPs include; P. 
chrysosporium (Vigneshwaran et al., 2006); Phanerochaete boryanum (Lengke et al., 2007); 
Cladosporium cladosporiodes (Balaji et al., 2009) and Coriolus versicolor (Sanghi and Verma, 
2009). Plants and plant extracts have also been employed in the synthesis of AgNPs. Camelia 
sinensis and black tea leaf extracts have been used as reducing agents in the synthesis of AgNPs 
(Vilchis – Nester et al., 2008; Begum et al., 2009). Song and Kim, (2008) reported the rapid 
biological formation of silver NPs using Pinus desiflora, Diospyros kaki, Ginko biloba, 
Magnolia kobas and Platanus orientalis leaf broths that produced AgNPs of between 15 and 500 
nm. 
4.1.3. Potential uses for silver NPs 
AgNPs have attracted the attention of researchers due to their dynamic and extensive 
applicability over a broad range of disciplines that includes but not limited to; sensors, bio-
labelling, filters, antimicrobial deodorant fibres, low cost paper batteries, and antimicrobials. 
AgNPs have been used widely as antimicrobial agents hence their usage in health, textile 
coating, food storage and a number of environmental areas (Korbekandi and Iravani, 2012). Cho 
et al. (2005) as well as Duran et al. (2005) reported on the antimicrobial effects of AgNPs on E. 
coli, V. cholera, B. subtilis and P. aerogenosa. Due to their antimicrobial effects, silver NPs have 
been used in various applications including disinfecting medical devices, home appliances and in 
water treatment, and as additives to some medical devices i.e. polymethylmetacrylate bone 
cement, surgical masks and implantable devices. Roe et al. (2008) reported on the antimicrobial 
properties of silver NPs coated on plastic catheters against E. coli, S. aureas, Enterococcus, C 
albicans, P. aerogenosa and Staphylococcus. HIV-1 virus infected cells (Hut/CCR5) undergo a 
HIV-associated apoptosis due to the inhibition of the viral replication by silver NPs, further 
AgNPs antiviral effects were reported where they successfully prevented the binding of the virus 
to the host cell (Sun et al., 2005). The prevention of cell free and cell associated transmission of 
HIV-1 and the pressure that AgNPs exerts in the early viral replication steps prevent CD4-
dependent viral binding, fusion and ultimate infectivity (Lara et al., 2010). Lu et al. (2011) 
reported on the possibility of silver NPs inhibiting in vitro assembly of hepatitis B virus. Xiang 
et al. (2011) reported on the inhibitory effects of silver NPs against H1N1 influenza-A virus. 
Silver NPs also have notable effects on various viruses including; Respiratory syncytial virus, 
Monkeypox virus, Tacaribe virus (TCRV), Herpes simplex virus type-1 (HSV-1) (Galdiero et al 
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2011) Singh et al. (2008) reported that AgNPs have also been used in the diagnosis and 
treatment approaches in cancer and Alzheimer’s patients. 
 
There is increase in AgNP consumer products, which has increased research in order to 
understand the correlation between the unique properties of AgNPs and their risk to human 
health and to the environment. There is inadequate information on the serious effects of silver 
NPs to humans that have so far been reported. As articulated by Lubick, (2008), it is not known 
whether the cytotoxicity is a result of the effects from NPs, or by Ag
+
 released by the AgNPs, or 
possibly both. Negative effects of silver NPs include argyria, a skin condition that results from a 
prolonged ingestion of silver NPs (Korbekandi and Iravani, 2012). Haase et al. (2011) 
demonstrated the cytotoxic effects of silver NPs on human macrophages and liver cells’ 
oxidative stress dependent cytotoxicity was reported by Kim et al. (2009). Furthermore, Park et 
al. (2011) reported the size dependent cell toxicity and inflammatory response in human cells. 
 
The main aims of the current chapter are; 
 
1. Chemical synthesize silver NPs 
2. Characterization of the synthesized silver NPs  
3. Assessment of the effects of silver NPs on the activity of TbHK and hGCK 
 
4.2. Materials and methods 
4.2.1. Silver NPs synthesis 
In order to synthesize silver NPs, 100 mM sodium nitrate solution was prepared (16.988 mg 
silver nitrate dissolved in 1 ml of distilled water), and 200 μl of this solution was then added to 
10 ml of 1% ethanolic polyvinylpyrrolidone (PVP) (100 mg PVP dissolved in 10 ml of 95% 
ethanol) in a total volume of 25 ml. The solution was microwaved for 5 sec at full power (Defy, 
700W MD 0348 model microwave).The solution was left at room temperature and the colour 
change, from clear to pale yellow, which denoted the formation of the silver NPs. The sample 
was stored in a glass bottle in the dark for further experimental procedures. In this AgNPs 
synthesis, ethanol and heat acted as reducing agents while polyvinylpyrrolidone was used as 
stabilizing agent (Pal et al., 2009). 
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4.2.2. Silver nanoparticle characterization 
The final concentration of the prepared AgNPs solution (section 4.2.1) was estimated to be 64 
mM. The NPs were characterized in terms of size, morphology and distribution using 
transmission electron microscopy and UV-visible spectroscopy. 
 
4.2.2.1. Transmission Electron Microscopy  
The transmission electron microscopy (TEM) samples were prepared 24 h in advance of viewing 
in order for the sample to completely dry. A drop of the AgNPs solution was placed on 
Formvar/carbon film on 200 mesh copper grids (Agar Scientific) and sample was allowed to 
settle for 20-30 sec. The excess sample was removed by touching the edges of the copper TEM 
grid with a filter paper. The TEM grid was left overnight to completely dry. Micrographs were 
obtained using Zeiss Libra 120 Transmission Electron Microscope operating at 120 keV.  
 
4.2.2.2. Ultra-violet visible spectroscopy 
Ultra-violet visible spectroscopy also referred to as absorption or reflectance spectroscopy within 
the Ultraviolet-visible region was used to characterize the optical properties of the synthesized 
AgNPs. The synthesized silver nanoparticle samples (section 4.2.1) analyzed using a wave scan 
at a wavelength range from 300 -700 nm using a Spectroquant Pharo 300 (Merck, Darmstadt, 
Germany) UV-Visible spectrophotometer to obtain the surface plasmon resonance (SPR) of the 
silver NPs.  
 
4.2.2.3. Silver NPs stability 
The synthesized NPs (section 4.2.1) were assessed for their stability at different storage 
conditions and the effects of light on storage. Two 10 ml samples were aliquoted into screw 
capped bottles and wrapped with tin foil (Morales-Sanchez et al., 2011). One nanoparticle 
sample bottle was kept at room temperature and the other was kept at 4°C over a period of one 
month. Samples collected at the beginning and end of the incubation period after which the 
samples were analyzed using TEM (section 4.2.2.1) and ultra-violet visible spectroscopy (section 
4.2.2.2). 
 
4.2.3. Interaction of G6PDH with AgNPs 
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To assess the effect of AgNPs on the hexokinase assay (section 4.2.4) used to determine activity 
of the TbHK and hGCK, different concentrations of AgNPs were incubated with the assay 
components (table 3.5 Chapter 3). AgNP concentrations evaluated ranged from 0.1 to 100 μM. 
As described in section 3.2.5.1 the hexokinase assay is a coupled assay and the coupling enzyme 
(G6PDH) was assayed independently to evaluate the effect of the AgNPs using the Worthington 
G6PDH assay. The G6PDH assay components are given in table 4.1. The G6PDH assay was 
adapted from the Worthington glucose-6-phosphate dehydrogenase assay, with changes made in 
order to replicate the reaction mixture conditions used in the standard hexokinase assay. A 
normal G6PDH assay (without added NPs) was performed in parallel to the interaction assay and 
this was used as a reference to calculate the percent relative activity as described in section 
3.2.5.2. 
 
Table 4.1: G6PDH and silver NPs interaction assay components. 
 
Ingredients 
 
G6PDH (µl) G6PDH / AgNPs (µl) AgNPs (µl) 
Tris-HCl reaction buffer, pH 8.0 270 260 
 
260 
16.8 mM NAD 
 
10 10 
 
10 
100 mM G6P 
 
10 10 
 
10 
300 U G6PDH 
 
10 10 
 
0 
AgNPs (0.1 to100µm) 
 
0 10 
 
10 
 
 
 
In the standard coupled hexokinase assay, G6PDH was a pre-added ingredient in the reaction 
mixture and reaction is initiated by the addition of hexokinase (section 3.2.5.1). In order to 
replicate this in the current assay; all assay ingredients were pre-added, including the different 
AgNP concentrations and the reaction was initiated by the addition of the G6PDH. Enzyme 
activity calculations were conducted as the standard coupled hexokinase assay (section 3.2.5.2), 
since in both assays the production of NADH is monitored at 340 nm.  
 
4.2.4. Silver NPs interaction with TbHK and hGCK (NP range finding) 
In order to obtain the appropriate nanoparticle concentration for the enzyme-silver nanoparticle 
kinetic studies; various nanoparticle concentrations were prepared and interacted with the 
expressed enzymes using the standard hexokinase assay (section 3.2.5.1). The initial silver 
nanoparticle concentrations ranged from 0.1 to 100 μM. Ethanol/PVP (1%) solution was used as 
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negative control, and was diluted by the same procedure as the nanoparticle solution. Assay 
additive concentrations and assay parameters are given in table 4.2 which is an adaptation of the 
conditions described in section 3.2.5.1. A standard coupled hexokinase assay for TbHK and 
hGCK was performed simultaneously with the interaction assays and their outcomes were used 
as the 100% relative activity values.  
 
Table 4.2: Silver NPs range finding interaction hexokinase assay components (adapted from 
table 3.5). 
 
Ingredients 
 
Protein (µl) Protein  EtOH.PVP Assay Control 
    
AgNPs (µl) Control (µl) (µl) 
Tris-HCl reaction buffer, pH 8.0 210 200 200 220 
0.67 M Glucose 
 
50 50 50 50 
16.5 ATP 
  
10 10 10 10 
6.8 mM NAD 
 
10 10 10 10 
300 U G6PDH 
 
10 10 10 10 
TbrHK/hGCK 
 
10 10 10 0 
AgNP ranges 
 
0 10 0 0 
EtOH.PVP 
 
0 0 10 0 
 
 
 
4.2.5. Enzymes (TbHK and hGCK) and AgNPs interaction studies kinetics 
In order to evaluate the type of effect the silver NPs have on TbHK and hGCK, a full set up of 
kinetic experiments were performed that were similar to the kinetic experiments described in 
section 3.2.8. A nanoparticle concentration of 0.1 µM was selected for the interaction studies 
(sections 4.3.6.1) for both the TbHK and hGCK NPs interaction kinetic studies. The substrate 
concentration used for the TbHK/AgNP kinetics were 4 µM, 8 µM, 16 µM, 33 µM, 67 µM, 100 
µM, 133 µM, 167 µM, 233 µM, 333 µM and for the hGCK interaction kinetic studies the 
substrate concentrations used were 0.1 mM, 1 mM, 2.5 mM, 5 mM, 10 mM, 15 mM, 20 mM, 25 
mM, 30 mM, 40 mM, 50 mM and 100 mM. The standard hexokinase assay (section 3.2.5.1) was 
employed with appropriate modifications, after optimum incubation at 40°C for TbHK and 37°C 
for hGCK (section 3.2.7), respectively. Kinetic data was recorded at 60 minutes (T60) for TbHK 
and at 90 minutes (T90) for hGCK. The experimental data for the enzyme and silver NPs 
interaction kinetics obtained for TbHK and hGCK were analyzed using Michaelis-Menten and 
Hanes-Woolf plots. The enzyme and silver NPs interaction hexokinase assays were performed 
concurrently with the assay negative control and a normal kinetic run. 
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4.3. Results and Discussion 
4.3.1. Silver nanoparticle synthesis 
Silver NPs were prepared using a microwave assisted method (Pal et al., 2009) as described in 
section 4.2.1. Immediately after adding AgNO3 into the ethanolic PVP solution, no obvious 
discoloration was observed (figure 4.2A). Heating the AgNO3 / ethanolic-PVP solution for 5 
seconds in the microwave led to a colour change from colourless to pale yellow (figure 4.2B), 
indicating the formation of silver NPs (Solomon et al., 2007; Pal et al., 2009; Vaidyanathan et 
al., 2010; Patil et al., 2011).  
 
Overnight storage of the microwaved solution at room temperature in the dark resulted in the 
development of an intense orange/yellow colour (figure 4.2C). This observation can be 
contributed to the seeding phenomenon, which is explained as the maturation (growth) of the 
initial nanoparticle seeds formed upon microwaving (Šileikaite et al., 2009). 
                    
Figure 4.2: Microwave assisted silver NPs synthesis. (A) Solution prior to microwaving, (B) 
Solution immediately after microwaving, showing slight colour formation (C) 24 hours after 
microwaving, showing intense colour formation. 
 
4.3.2. Transmission Electron Microscopy  
Silver NPs synthesized as described in section 4.2.1 were visualized using TEM as described in 
section 4.2.2 to determine nanoparticle sizes, shape and distribution. Three hundred NPs were 
counted and the sizes were determined using Image J software (version 1.42). Figure 4.3A is 
representative of the nanoparticle morphology immediately after synthesis, while figure 4.3B 
represents the nanoparticle counts and size distribution plot. The size of the NPs immediately 
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after synthesis ranged from 2-18 nm and was consistently spherical in morphology. The average 
size was 6 nm. These observations are similar to those reported in the literature (Pal et al., 2009; 
Singh et al., 2009; 2009; Hsu and Wu, 2011). At 24 h post synthesis nanoparticle morphology 
was still spherical but there was a slight shift in the size distribution.  
 
 
Figure 4.3: TEM micrographs of silver NPs and their size distribution. (A and B) AgNPs 
morphology and sized distribution immediately after synthesis. (C and D) AgNPs morphology 
and size distribution 24 h after synthesis. 
Figure 4.3B showed a narrow size distribution with particles mostly between 5 and 8 nm. While 
figure 4.3D shows a slight increase in nanoparticle size but still with an average size of 6 nm. 
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With the observation made, it is recommended to use freshly prepared NPs for experiments for 
any slight change in their sizes may bring changes in their size dependent properties.   
 
4.3.3. Ultra-Violet visible spectroscopy 
A characteristic UV light absorbance wavelength of silver NPs synthesized is shown in figure 
4.4 is consistent with reported spectrums (Gusman et al., 2009; Nanda and Siravanan, 2006; 
Kalimuthu et al., 2008; Gurunathan et al., 2009; Viadyanathan et al., 2010; Patil et al., 201l; Hsu 
and Wu, 2011). 
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Figure 4.4: Silver NPs spectrophotometric analysis. (A) Silver NPs exhibiting a strong peak at 
421 nm (solid line) at time 0 h and a negative control (dashed line) showing no apparent peak. 
(B) Silver NPs with a peak at 423 nm 24 hour after synthesis (solid line) and a negative control 
(dashed line) showing no peak. 
 
4.3.4. Nanoparticle stability  
Retaining nanoparticle stability is of vital importance in the study of NPs since they are prone to 
aggregation under varying conditions (Huang et al., 2010). Silver NPs synthesized as described 
in section 4.2.1 were stored under varying conditions. After one month of storage at room 
temperature and in the dark the NPs still had a spherical morphology (figure 4.5A) and a similar 
size distribution pattern (figure 4.5B) to the 24 h synthesized nanoparticle solution (figure 4.3D) 
with average nanoparticle size of 9-10 nm. When the nanoparticle solution was store at 4°C, the 
AgNPs tended to form aggregates (figure 4.5C) and had a slight increase in size, from 6 nm to 18 
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nm. This may imply that nanoparticle stability is temperature dependent, and for this reason, NPs 
stored at room temperature and obscured from direct light were used for the enzyme interaction 
studies (section 4.3.6). This is in line with reports in literature (Morales-Sanchez et al., 2011). 
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Figure 4.5: Silver nanoparticle stability under different conditions for 8 weeks. (A and B) TEM 
micrograph and size distribution graph of the sample stored at room temperature in the dark, (C 
and D) TEM micrograph and the size distribution graph of silver nanoparticles stored a 4°C in 
the dark. 
 
4.3.5. Interaction of G6PDH with AgNPs 
The effect of silver NPs on the enzymatic activity of the coupling enzyme (G6PDH) in the 
standard hexokinase assay (section 3.2.5.1) was investigated as described in section 4.2.3. 
G6PDH activity was determined in the presence of various concentrations of silver NPs. Figure 
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4.6 represent the results obtained and indicates that the lower concentration range had the least 
effect on the assay. AgNP concentrations of 0.1 and 0.25 μM only inhibit G6PDH activity by 35 
and 41%, respectively, and concentrations of 0.5, 1, 5, 20, 50, 100 μM inhibit TbHK by 63 %, 
65%, 80%, 75%, 70% and 82%, respectively. The latter concentrations inhibit the enzyme 
activity in higher magnitudes and therefore were not ideal concentrations for the interaction 
studies. Therefore the final concentration of 0.1 μM silver NPs was chosen for the enzyme-silver 
nanoparticle interaction kinetics. 
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Figure 4.6: A bar graph of different AgNP concentrations vs percent relative activity of G6PDH. 
(C) represents a control assay containing 1% ethanol.PVP and (N) represents a standard HK 
assay (100% activity). 
 
4.3.6. Silver nanoparticle interaction studies with TbHK and hGCK 
TbHK and hGCK were subjected to varying silver nanoparticle concentrations both to determine 
the concentration of nanoparticle that would present desired outcomes of minimal inhibition and 
allow the determination of the enzymes’ kinetic behaviour under the influence of silver NPs.  
 
4.3.6.1. Silver nanoparticle range finding 
TbHK and hGCK were subjected to varying concentrations of silver NPs (0.1-100 µM) as 
described in section 4.2.4. Figure 4.7A illustrates that Ethanol.PVP has no apparent effect on the 
TbHK enzymatic activity. Silver nanoparticle concentrations of 0.1 µM and 0.25 µM inhibited 
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the enzyme activity by approximately 10% and 30%, respectively. A 40% inhibition to the TbHK 
activity was observed with silver nanoparticle concentrations of 0.5 µM and 1 µM. AgNP 
concentrations of 5 µM , 20 µM and 100 µM exhibited more than 50% inhibition of the enzyme 
activity, making them not ideal for the interaction kinetics as they inhibited the enzyme activity 
by too a higher margin. Therefore a concentration of 0.1 µM was selected and used in the 
enzyme-nanoparticle interaction kinetics. 
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Figure 4.7: Silver nanoparticle range finding interaction assays for (A) TbHK and (B) hGCK 
 
Figure 4.7B illustrates that silver nanoparticle concentrations of 0.1 µM, 0.25 µM and 0.5 µM 
exponentially increased the enzymatic activity of the human glucokinase (up to 4 fold) as 
compared to the hexokinase assay without silver NPs. Silver nanoparticle concentrations of 1 
µM and 5 µM activated the enzyme by approximately 20% and concentrations of 20 µM, 50 µM 
and 100 µM of silver NPs inhibited the enzyme by approximately 20%. The interaction negative 
control (Ethanol.PVP) had negligible effect on the assay as it showed the same percent relative 
activity as the reference assay. When a molecule is bound to an enzyme, it has a negative or a 
positive effect on the activity of the enzyme. Some molecules increase the enzyme activity 
(enzyme activators) and others inhibit the activity of the enzyme (enzyme inhibitor).In the 
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current work, the synthesized enzyme TbHK and hGCK (chapter 3) and their changes in activity 
will be assessed after being interacted with silver NPs (section 4.2.5). 
 
Enzyme inhibition can be divided into 2 main types, reversible and irreversible inhibition. The 
reversible enzyme inhibition is further typified into 4, these includes: (i)Competitive inhibition: 
in this type of inhibition, the inhibitor competes with the substrate in binding to the active site of 
the enzyme, thereby negatively affecting the affinity of the enzyme for its apparent substrate. 
However, further increase in substrate concentration alleviates the inhibitory effect. Therefore in 
competitive inhibition there is an increase in the apparent Km and with a constant Vmax; (ii) Un-
competitive inhibition: an uncompetitive inhibitor binds to the enzyme only after the enzyme has 
forms an enzyme-substrate complex.  
 
The binding of the inhibitor to the enzyme decreases the enzyme’s ability to remain bound to the 
substrate. This result in the decrease of both Km and Vmax values, an effect brought about by the 
elimination of the enzyme-substrate complexes, the increased binding efficacy as the enzyme 
develops a new reaction equilibrium state in counteracting the imposing effect (Le Chateliars 
principle) and as a result of removing the activated complexes respectively; (iii) Non-competitive 
inhibition: in this type of inhibition, the inhibitor can bind to both complexed and free enzyme. 
The binding of the inhibitor to the enzyme reduces the enzymatic activity but it does not affect 
the substrate binding affinity; therefore the Vmax decreases while the Km may remain constant; 
(iv) Mixed inhibition: in this type, the inhibitor can bind the enzyme at the same time as the 
substrate binds to the enzyme. The binding of the inhibitor may cause the enzyme to have less 
affinity to its substrate. This inhibition may be reduced but not overcome by an increase in 
substrate concentration. The induced inhibition is generally a result of the inhibitor binding to an 
allosteric site that triggers the enzyme’s conformational change with a concomitant reduction in 
the affinity of the enzyme active site to its substrate. Therefore, mixed inhibition results in an 
increased Km and reduced Vmax (Stryer, 1995; and Voet, 2004). With irreversible inhibition the 
enzyme usually gets modified when the inhibitor binds to the enzyme. Irreversible inhibitors 
usually interact with serine, threonine, tyrosine and cysteine amino acid side chains (hydril and 
sulfhydril groups) and form covalent bonds.  
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4.3.6.2. Effect of silver NPs on TbHK and hGCK 
The effects exerted by silver NPs on the TbHK and hGCK enzymes activity were investigated as 
described in section 4.2.5. A complete set of enzyme kinetics (chapter 3) and enzyme-NPs 
(chapter 4) interaction kinetics were carefully performed using 0.1 µM silver NPs as 
inhibitor/activator. The kinetic data was analyzed by Michaelis-Menten and Hanes-Woolf 
plotting. The comparison of the kinetic TbHK and hGCK studies to those of TbHK and hGCK 
under the influence of 0.1 µM silver NPs is presented in figures 4.8 and figure 4.9. 
 
0 50 100 150 200 250 300 350
0.00
0.02
0.04
0.06
A
[S] (M)
A
c
ti
v
it
y
 (
m
in
.m
l-
1
)
0 50 100 150 200 250 300 350
0
2000
4000
6000
8000
10000
12000
B
[S] (M)
A
c
ti
vi
ty
 (

m
o
l.
m
in
.m
l-
1
)
 
Figure 4.8: Hanes-Woolf and Michaelis-Menten of TbHK kinetics (solid lines) and TbHK 
kinetics under the influence of silver NPs (dashed lines). 
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Figure 4.9: Hanes-Woolf and Michaelis-Menten of the normal hGCK kinetics (solid lines) 
hGCK kinetics under the influence of silver NPs (dashed lines).  
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As illustrated in table 4.3, TbHK and silver NPs interaction kinetic parameters using Hanes-
Woolf plotting indicates an increase in the Km value, from 39 µM to 54 µM with an apparent 
reduction in Vmax from 0.066 µmol.min
-1
.ml
-1 
to 0.033 µmol.min
-1
.ml
-1 
and Kcat / Km value from 
0.0526 min
-1
.µmol
-1
 to 0.0380 min
-1
.µmol
-1
 This represents a 38% reduction in the enzymes 
affinity to its substrate, 50% reduction in its activity and a 28% reduction in the enzyme 
efficiency. Although Hanes-Woolf plotting was the analysis choice in the interaction kinetic 
studies, Michaelis Menten analysis of the kinetic data revealed a similar pattern of the kinetic 
parameters, where an increase in the Km value from 39 µM to 68 µM was determined, 
representing a 74% reduction in the enzyme’s affinity to its substrate. There was an observed 
decrease in the Vmax value from 0.066 µmol.min
-1
.ml
-1 
to 0.035 µmol.min
-1
.ml
-1
, representing a 
47% decrease the enzyme’s activity, a 42% reduction in the enzyme efficiency from 0.0522 min-
1
 to 0.0303 min
-1
. There is a close similarity in the change of the activity when the interaction 
data is analyzed by both Michaelis-Menten and Hanes-Woolf, but the change in Km provides 
different outcomes of 74% and 50%, respectively. However Hanes-Woolf results were accepted 
for this project for its accuracy. The inhibition pattern obtained for TbHK (increased Km and 
reduced Vmax) falls under the mixed type of inhibition where there is a resultant decrease in the 
affinity of the enzyme to its substrate with a concomitant reduction in the overall enzyme 
activity. A phenomenon that is caused by the enzyme inhibitor and the substrate binding to the 
enzyme simultaneously, thereby reducing the affinity of the enzyme to its substrate and thus 
reducing its activity. 
 
Table 4.3: A comparison of TbHK to silver nanoparticle and TbHK interaction kinetics 
parameters. 
 
Plot type   TbHK kinetics  AgNPs/TbrHK interaction kinetics 
 Km 
(µm)   
Vmax   
(µmol.ml-1.min-1)  
Kcat 
(min-1) 
Kcat/Km  
(mol-1.min-1) 
Km 
(µm)    
Vmax    
(µmol.ml-1.min-1) 
Kcat 
(min-1) 
Kcat/Km 
(mol-1.min-1) 
Michaelis-
Menten 
39.3 0.066 2.05 0.0522 68 0.035 2.05 0.0302 
Hanes-
Woolf 
39. 0.066  0.0526 54 0.033  0.0380 
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Table 4.4: A comparison of hGCK to silver nanoparticle and hGCK interaction kinetics 
parameters. 
 
Plot type  hGCK kinetics  
 
AgNPs/hGCK interaction kinetics 
 
Km Vmax h Kcat Kcat/Km Km Vmax h Kcat Kcat/Km 
 
(µm) (µmol.min-1.ml-1) 
 
(min-1) (min.µmol-1) (mM) (µmol.min-1.ml-1) 
 
(min-1) (min-1.µmol-1) 
Michaelis- 4.0 0.032  11.25 2.813 3 0.028  11.25 3.75 
Menten 
  
 
    
 
  
Hanes- 4.5 0.032 
 
1.5 
 
2.5 3 0.029 
 
1.8 
 
3.75 
Woolf 
  
 
    
 
    
As illustrated in table 4.4, when the human glucokinase is interacted with silver NPs, a unique 
pattern is revealed when the kinetic data is analyzed by Hanes-Woolf plotting. There is a 
significant decrease in the Km value from 4.5 mM to 3 mM representing a 33% increase in the 
affinity of the enzyme to its substrate (glucose). There is a notable slight decrease in the Vmax 
value from 0.032 µmol.min
-1
.ml
-1 
to 0.029 µmol.min
-1
.ml
-1 
representing 9% decrease in the 
maximal enzyme activity (Vmax), and an apparent increase in the enzyme efficiency from 2.5 
min
-1
 to 3.75 min
-1
, representing a 50% increase. Michaelis-Menten analysis of the interaction 
kinetic data reveals a similar change in the Km value, from 4.0 to 3 mM, a 13% reduction in 
maximal enzyme activity (Vmax) and 34% increase in the enzyme efficiency (Kcat/Km).  
 
This inhibition pattern falls under the un-competitive inhibition. This type of inhibition is as a 
result of the inhibitor binding to the enzyme after the enzyme has already formed a complex with 
its substrate, resulting in the release of the initially formed enzyme-substrate complex and the 
enzyme binds to a new substrate, thereby reducing the enzyme activity but increasing the 
substrate affinity. 
 
In general, designed hexokinase or glucokinase inhibitors should possess features that include; 
(i) compounds should be derivatives of glucosamine that facilitates a high similarity to the 
enzyme substrate (glucose), (ii) C-2 position should be the substituted atom, (iii) the presence of 
an aryl group is required to promote the binding of the compound to the enzyme through an 
amidic bond, (iv) the length of the aryl substituent should be varied to maximize contact with the 
enzyme, (v) substituent molecule on the aromatic ring should be alternated according to their 
103 
 
ability to release or withhold electrons, (vi) the ortho and meta positions of the aromatic ring 
should be varied so that the space within the active site may be explored by ring rotation (Wilson 
et al., 2002). Silver NPs have no similarities to the designed glucosamine inhibitors that inhibit 
TbHK (Wilson et al., 2002) and the reported mechanism of inhibition of the glucosamine 
compounds cannot possibly apply in to the mixed inhibition model of TbHK obtained in this 
research project. Joyce et al. (2013) reported on the most implausible mechanism of the TbHK 
by Ebselen, selenium containing variant of isobenzothiazolinone (Shallow et al., 2010). Ebselen 
forms a seleno-sulfide bond with cysteine residues and its resultant oxidation, rather than 
modification, thereby significantly decreases the enzymatic activity of TbHK. 
Silver NPs have been reported to interact with the thiol groups of the amino acid cysteine (Shen 
et al., 2007; Galdeiro et al., 2011). The tertiary structure of TbHK has free cysteine residues 
proximal to the active site at positions C103, C212, C242, C327, C369, C386, C401, C402 and 
C445. Oxidation of cysteine residues C327 and C386 effectively decreases the activity of TbHK 
(Joyce et al., 2013). Therefore, it is possible to speculate that the mixed inhibitory effects that 
silver NPs have on TbHK observed in this research may be a result of the AgNP interacting with 
one or more of the cysteine residues found on distant positions to the active site. The NPs may 
have either oxidized or modified the cysteine residues that resulted in the decrease in enzyme 
activity and the reduction in the substrate affinity.  
The interaction of silver NPs with human glucokinase may have been facilitated by the presence 
of free cysteine residues; hGCK has five cysteine residues on positions C213, C220, C230, 
C233, C252 that assume a ring surrounding the enzyme’s active site, and cysteine residues at 
positions C364, C371, C382 proximal to the active site. The oxidation of cysteine residue C364 
and C371 by a pyrimidine derivative glucokinase inhibitor alloxan result in the reduction of 
glucokinase activity (Tiedge et al., 2000).  
 
With the above information, it is possible to suggest that silver NPs interact with the proximal 
cysteine residues, regarding the uncompetitive effects of the NPs. Thus having a resultant release 
of the pre formed enzyme-substrate complex and a decrease in enzyme activity. As the enzyme 
adjusts to a new state it forms a new enzyme-substrate complex with higher affinity. The 
uncompetitive inhibition pattern observed was also reported by Storer and Cornish-Bowden 
(1977) with the use of MgATP
 
as the inhibitor and glucose as a variable substrate of rat liver 
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glucokinase (Monasterio and Cardenas, 2003). The hill coefficient for the hGCK and AgNPs 
interaction sigmoidal kinetic analysis reveals an increase from 1.5 to 1.8 representing a 2% 
increase in the enzyme cooperativity to glucose.  
 
4.4. Conclusions 
The principle objectives of this chapter were to synthesize, characterize and assess the effects of 
silver NPs on the activity of TbHK and hGCK respectively. 
 
Silver NPs were successfully synthesized using a microwave assisted method with ethanol and 
PVP as reducing and stabilizing agent, respectively. TEM and wavescan spectroscopy revealed 
that the silver NPs had a characteristic spherical shape, an average size of 6 nm with an 
absorption peak at 422 nm. The obtained NPs maintained their size and distribution over a period 
of 8 weeks when store in the dark and at room temperature. 
 
TbHK and hGCK exhibited unique kinetic properties in the presence of 0.1 µM silver NPs. 
Hanes-Woolf analysis of the TbHK-nanoparticle interaction kinetics revealed a mixed type 
inhibition with 38% reduction in the enzyme’s affinity to its substrate (increase in Km), 50% 
reduction in the maximal activity of the enzyme (decrease Vmax) and a 28% reduction in its 
efficiency (decrease in Kcat/Km). The human glucokinase interaction kinetics indicated an un-
competitive inhibition pattern with a characteristic 33% increase in the enzyme’s affinity to 
glucose, 9% decrease in the maximal enzyme activity and a 50% increase in the overall enzyme 
efficiency. These distinctive inhibition patterns exhibited by TbHK and hGCK with 0.1 µM 
concentration silver NPs can be a result of the interaction between silver NPs and the thiol 
groups on cysteine amino acid residues that are situated at positions C103, C212, C242, C327, 
C386, C401, C403 and C445 for TbHK and on position C364, C371 and C382 for human 
glucokinase. Oxidation of these proximal cysteine amino acids have been validated to initiate a 
conformational shift that may trigger a variety of enzyme activity and kinetic behaviour. The 
precise TbHK and hGCK amino acid-nanoparticle interactions and their mechanisms presents a 
viable option for further research work in order to fully understand these aspects. 
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                              Chapter 5 
General discussions, conclusions and recommended future studies 
5.1. Discussions and Conclusions 
HAT a much neglected disease, is a parasite borne infection with Tb as its causative agent. 
Increasing reports of drug resistant trypanosomes calls for new anti-trypanosome approaches 
(Rupol and Burke, 1977; Pepin et al., 1994; Brun et al., 2001). In its human host, Tb relies 
completely on glycolysis for its energy production. The glycolytic pathway, especially 
hexokinase, the first enzyme in the pathway has been validated as a viable target for anti-
trypanosome agents (Morris, 2002; Chembers, 2005; Joyce et al., 2013). In pursuit of more novel 
approaches to new anti-trypanosome agents, the current study focussed on the interaction of 
TbHK and hGK with silver NPs. The changes in enzyme activities were evaluated.  
 
The TbHK (1 417 bp) and hGCK (1 398 bp) were PCR amplified. TbHK and hGCK can readily 
be over expressed in E. coli (Studier, 2005) cells using auto-induction protocols. Both proteins 
were expressed containing a 6 histidine-tag to facility purification. Studies using the purified, 
recombinant proteins showed that TbHK exhibited thermal stability between 30-55°C and pH 
stability between 7.5 and 8.5, while the hGCK is thermally stable between 30 and 40°C and 
stable between pH 7.0 and 8.0. Kinetic studies revealed that TbHK and hGCK have Km values of 
39 µM and 4.5 mM, indicating that the TbHK protein had a higher affinity for glucose as 
substrate. TbHK has a Vmax of 0.066 µmol.min
-1
.ml
-1
, while the Vmax for the human glucokinase 
is 0.032 µmol.min
-1
.ml
-1
. The catalytic  (Kcat/Km) of the TbHK protein was 0.0522 min
-1
.µmol
-
1
and the hGCK was 2.5 min
-1
.µmol
-1
. hGCK exhibited a hill coefficient of 1.5.  
 
Silver NPs were synthesized using the microwave assisted method (Pal et al., 2009). The 
obtained NPs have a characteristic spherical shape with an average size of 6 nm and exhibited a 
plasmon resonance band at 423 nm. The nanoparticle solution was stable for one month when 
stored at room temperature in the dark. 
Upon incubation of the recombinant proteins with AgNPs, apparent differences in the inhibition 
patterns were observed for TbHK and hGCK. TbHK interaction kinetic analysis showed a mixed 
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type of inhibition when incubated in the presence of 0.1 µM silver NPs. A 38% reduction in the 
enzyme’s affinity to its substrate was noted and a 50% reduction in the maximal activity of the 
enzyme was also observed. This is turn led to a 28% reduction in enzyme efficiency. The hGCK 
interaction kinetics indicated an uncompetitive inhibition pattern with a characteristic 33% 
increase in the enzyme’s affinity to glucose, a 9% decrease in the maximal enzyme activity and a 
50% increase in the overall enzyme efficiency. From the experimental data, it was observed that 
0.1 µM silver NPs selectively inhibit TbHK hexokinase over hGCK. This observation proves the 
hypotheses that silver NPs selectively inhibit TbHK over hGCK. 
 
The inhibition of TbHK by silver NPs presents an interesting possibility for its use in the 
development of anti-trypanosomal agents. This could be applied in two folds; firstly the NPs 
may be conjugated to the known anti-trypanosomal chemotherapeutic compounds. This approach 
may enhance targeted delivery to the brain, which is still a major challenge in the treatment of 
trypanosomiasis (Olbrich et al., 2004). Secondly, the unconjugated NPs could be used to 
selectively inhibit the parasite hexokinase, which is crucial for parasite survival. 
 
In trying to enhance the access of drugs to the central nervous system, various drug carriers and 
hyperosmolar solutions, such as liposomes (Bigon et al., 1979), lithium chloride and sucrose 
have been investigated (Odika et al., 1995). Another approach is the use functionalized NPs for 
the delivery of drugs to the CNS. Troster et al. (1990) reported on the accumulation of 
poly(methylmethacrylate) (PMMA) NPs in rat brain, demonstrating their ability to cross the 
blood-brain barrier. Elsewhere, anti cancer drugs dalagin and loperamide have been delivered to 
the brain after been functionalized to NPs (Kreuter et al., 1994, Kreuter, 2001).  
 
The second stage of HAT presents with the same problem, namely the failure to get the anti-
trypanosomal agents across the blood-brain barrier. Olbrich et al. (2004) reported on diminazine 
diaceturate, an anti-trypanosomal agent which was delivered to the CNS of mice by formulating 
a lipid-drug conjugate (LDC)-nanoparticle complex. Daunorubicin conjugated to 
polycyanocrylate NPs have been shown to enter the trypanosoma parasite, and premaquine and 
pentamidine combined with NPs have proved useful in the experimental visceral leishmaniasis 
(Croft, 1999). Unconjugated NPs have also been reported to possess an anti parasitic property 
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(Lherm et al., 1987; Golingtly, 1988; Croft, 1999). With this knowledge from literature and data 
obtained from this study, the inhibition of TbHK by unconjugated silver NPs with an average 
size of 6 nm may add to the effect of the anti-trypanosomal agent that could be functionalized to 
the nanoparticle, doubling the efficiency in killing the parasite with limited or no negative effect 
to the human hosts. 
 
Results from this study can be extrapolated to include a possible treatment for the reduction of 
fasting hyperglycemia observed in maturity onset diabetes of the youth (MODY) (Byrne et al., 
1993), as the hGCK efficiency was enhanced. Glucokinase have been validated to be a vital 
target in the treatment of diabetes, as it has high correlation to glucose levels control because of 
glucose sensor function in the pancreas and its involvement in decreasing high glucose levels and 
synthesis of glycogen in the liver (Matschinsky 2009; Matschinsky et al., 2010; Matschinsky and 
Porte Jr, 2010; Angadi et al., 2013). Studies have been conducted where solid lipid NPs (Liu et 
al., 2007), [poly(-εcaprolactone)] (Damģe, 2006) and dextran NPs (Chalasani et al., 2007) have 
been pre-loaded with insulin and used as delivery systems in the treatment of diabetes. Silver 
NPs have also been employed to enhance the healing of a delayed diabetic wound (Mishra et al., 
2008). The versatility of silver NPs and data obtained by this research project could be utilized 
either on their own as it has been found to increase enzyme efficiency or by functionalized to 
various anti-diabetic agents including insulin, thereby yielding its potential in two folds. 
 
The highly selective inhibitory effects of AgNPs observed between TbHK and hGCK may be 
attributed to the high affinity of the NPs to thiol groups in the surface cysteine amino acid 
residues. These residues are located away from the active sites of both proteins. The binding of 
AgNPs to these specific amino acids may induce changes in the protein’s structure with resultant 
distinct changes in the properties of the proteins. 
 
5.2. Recommended future studies 
The outcomes obtained from this research project have presented platforms for various 
interesting possible future studies. The selective inhibitory effects of AgNPs on the studied 
proteins can be used in the designing of new and dynamic nanoparticle based anti-trypanosomal 
drugs. Since tagged recombinant proteins may have some of its properties affected (Terpe, 
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2002), it would be very interesting to carry out similar studies on the effects of silver NPs on 
wild type TbHK and hGCK. The wild type protein can be closely mimicked by expressing the 
protein without an affinity tag or to cleave the tag post expression and purification. The Tb arm 
of the project could be expanded by investigating the inhibitory properties of silver NPs on 
hexokinase of the trypanosomes in vitro. This could be performed in trypomastigotes cultures, 
and this investigation could determine if the inhibition is dose dependent, and elucidate the 
internalization mechanism of the NPs into the trypanosomes and the organelle. 
 
 In silico studies could be performed on the TbHK and hGCK to investigate if the subunits 
assume different orientations after binding to the NPs and also to determine which of the 
cysteine residues are responsible for the binding of the NPs and the change in properties. 
Furthermore, the cysteine residues may be mutated to other amino acids like alanine that have no 
affinity to silver NPs and investigate the response of the mutated proteins to the 
inhibitory/activating effects of silver nanoparticle. 
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Appendices 
 
A. Chemiluminescence-based Western analysis 
A.1. Method 
The proteins (TbHK and hGCK) separated by SDS-PAGE (chapter 3, section 3.2.3.1) were 
transferred onto nitrocellulose membrane, pre-soaked in distilled water and transfer buffer [13 
mM Tris-HCl, 100 mM glycine and 20% (v/v) methanol] for 10 minutes each, using a semi-dry 
Transblot (LASEC, USA) at a constant amplitude of 400 mA for 50 minutes (Towbin et al, 
1979). The transferred proteins were confirmed by Ponceau staining [0.5% (w/v) Ponceau S in 
1% (v/v) glacial acetic acid]. Nitrocellulose membrane with transferred proteins was blocked 
with 1% Blotto [non-fat dry milk (Sant Cruz Biotechnology) in Tris-buffered saline-Tween 
(TBST; 50 mM Tris, pH 7.5, 150 mM NaCl, 1% {v/v} Tween20)] for 30 minutes and incubated 
with His-probe [Rabbit polyclonal; Santa Cruz Biotechnology (sc-8040)] at 4°C overnight with 
agitation, diluted 1:1000 in 1% Blotto. The membrane was rinsed four times in TBST for 15 
minutes replacing the TBST each rinse. The membrane was incubated with species-specific anti-
Rabbit IgG conjugated to horseradish peroxidase [HRP] (AbCAM, ab6802) at 1:5000 dilution in 
1% Blotto for 45 minutes at room temperature with agitation. After the incubation with the 
secondary antibody, the membrane was rinsed with TBST four times 15 minutes each rinse. 
Protein bands were detected using the Clarity Western ECL Substrate kit (Biorad; UK) with 
visualization of chemi-illuminescence on x-ray film (AGFA, USA). 
 
A.2. Results and discussions 
Western blot analysis of the recombinant proteins (TbHK and hGCK) is presented in figure A1. 
                                                      
Figure A1: Western blot image showing the presence of His-tagged human glucokinase loaded in 
lane (H1). TbHK was loaded in lane H2. 
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The western blot results (figure A1) show that His-tagged human glucokinase can be detected by 
the use of the anti-His antibody. However, His-tagged TbHK could not be detected by anti-His 
antibodies used in the current procedure. This could be attributed to sub-potential protein transfer 
that could come about due to the low quality membranes, improper western transfer procedure 
and incorrect SDS-PAGE gel preparation and/or run (Gomez A.V. 2009).  
 
B. Virtual PCR products for TbHK and hGCK  
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Figure B1: TbHK virtual PCR product, showing the NdeI and XhoI primers 
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Figure B2: hGCK virtual PCR product, showing the NdeI and XhoI primers 
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C. Rubidium Chloride method for preparing competent E. coli cells. 
C.1. Reagents and solutions 
C.1.1. Psi broth / liter 
5g Yeast extract 
20g Tryptone 
5g magnesium sulphate 
pH 7.6 adjusted with potassium hydroxide. 
 
C.1.2. TfbI Buffer 
30mM Potassium acetate 
100mM rubidium chloride 
10mM Calcium chloride 
50mM manganese chloride 
15% glycerol v/v 
pH 5.8 adjusted with acetic acid 
C.1.3. TfbII Buffer 
10mM 3-(N-morpholino)propanesulfonic acid (MOPS)  
75mM Calcium chloride 
10mM rubidium chloride 
15% glycerol v/v 
pH 6.5 adjusted with diluted sodium hydroxide 
 
C.2. Procedure: 
 Inoculate 1ml from overnight culture into 100ml Psi broth (scale up or down as required) 
 Incubate at 37oC with aeration to A550 =0.48 
 Incubate on Ice for 15 minutes 
 Pellet cells in appropriate centrifuge tube 3-500 xg for five minutes (about 5000 rpms ) 
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 Discard supernatant and add 0.4 volume (i.e. of original volume, here it is 40 ml) TfbI, 
re-suspend and incubate on ice for 15 minutes 
 Discard supernatant and re-suspend in 0.04 volume of TfbII 
 Incubate on ice for 15 minutes and either use immediately of quick freeze at -70oC for 
storage. Store in 0.1ml aliquots 
 Quick freeze in ethanol-dry ice or liquid nitrogen prior to storage in a -70oC to -80oC 
freezer 
 Thaw on ice just before using in a transformation experiment. 
 
D. TCA protein concentration protocol   
 Mix the sample with the 30% Trichloroacetic acid and the sample in 1:1 ratio 
 Incubate on ice for 15-30 minutes 
 Spin in microcentifuge at 40C for 15 minutes 
 Rinse pellet with ice cold Isopropanol  
 Centrifuge at 10,000g for 5 minutes at 40C 
 Remove the supernant and dry the pellet using speed-vac system at 65 for 300C minutes 
 If the sample is to be run on SDS, re-suspend the dried pellet in required amount of SDS 
loading buffer. 
 
E. PAGE protocols 
E.1. SDS-PAGE Running Buffer (10x) 
30.3 g Tris-base 
144.0 g glycine 
10.0 g SDS 
completely dissolve in about 800 ml dH2O and then more dH2O up to 1 liter. 
 
E.2. Staining solutions and procedure 
E.2.1. Coomassie staining 
E.2.1.1. Fairbanks A 
0.5g Coomassie Blue R-250 
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250ml Isopropanol 
100ml Acetic acid 
650ml distilled water 
 
E.2.1.2. Fairbanks B 
0.05g Coomassie Blue R-250 
100ml Isopropanol 
100ml Acetic acid 
800ml distilled water 
 
E.2.1.3. Fairbanks C 
0.02g Coomassie Blue R-250 
100ml Acetic acid 
900ml distilled water 
 
E.2.1.4. Fairbanks D 
100ml Acetic acid 
900ml distilled water 
 
E.3. Silver staining  
E.3.1. Reagents and solutions 
E.3.1.1. 1.5mM Sodium dithionite (m.r. 174.10) 100 ml 
 26.115mg weigh and dissolve in 100 ml of distilled water  
 
E.3.1.2. 5% silver nitrate 
 0.02g dissolved in 100 ml of distilled water. 
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 Cover the stock bottle with foil paper of prepare into a brown bottle to avoid exposure to 
direct sun light. 
 
E.3.1.3. Sodium thiosulfate (2 μM) 
 Prepare 2mM Sodium thiosulfate (Mr. 158.11) and dilute to 2 μM  
 Weigh 31.622 mg, dissolve in 10 ml of distilled water 
 Dilution of 2 mM Sodium thiosulfate to 2 μM; 
 10 μl into 90 μl of distilled water 
 
E.3.1.4. Silver staining developer 
6% Sodium carbonate in 2 μM Sodium thiosulfate. 
Weigh 6g of sodium carbonate and dissolve it in 100 ml of 2μM Sodium thiosulfate 
 
E.3.1.5. Silver staining stop reagent (5% Acetic acid) 
2.5 ml of acetic acid into 97.5 ml of distilled water 
 
E.3.2. Protocol for silver-staining 
As described by Rabilloud et al. (1988)  
 
E.3.2.1. Materials 
 Complete destain solution (40% EtOH and 10% acetic acid) 
 1.5mM Sodiumdithionite (25mg/10ml) 
 5% silver nitrate 
 Developer 
 6% Sodium carbonate (Na 2CO3); 2ul anhydrous sodium thiosulfate (Na 2S 2O3)  
 Stop reagent: 5% Acetic acid 
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E.3.2.2. Method 
 After migration the gel is fixed with 10% Acetic acid- 30% ethanol overnight or stained 
with Coomassie brilliant blue and destained. Use the complete destain solution to destain 
gel for silver staining 
 Wash gel 2x for 15 min with distilled water 
 Leave in sodiumdithionite for 1 minute 
 Wash the gel 2x for 29 seconds with distilled water 
 Leave in silver nitrate for 20-30 minutes 
 Wash gel for 5 minutes in distilled water  
 Leave in developer for 5 minutes 
 Discard developer and put gel into 50 ml developer with 200ul Formaldehyde (Mix 
before adding to gel) 
 Stop the reaction by adding acetic acid solution directly to the developer mixture 
 Wash the gel with distilled water to remove background. 
 Dry the gel or store in 20% ethanol at 4oC 
 
F. TbHK and hGCK temperature and pH stability studies. 
F.1. Temperature stability studies for TbHK   
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Figure F1: Graphical presentation of temperature stability study of TbHK at (A) T0, (B) T15, (C) 
T30, (D) T45, (E) T60, (F) T90 and (G) T120. 
 
F.2. Temperature stability studies for hGCK 
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Figure F2: Graphical presentations of temperature stability study of hGHK at (A) T0, (B) T15, 
(C) T30, (D) T45, (E) T60, (F) T90, (G) T120. 
 
F.3. pH stability studies for TbHK 
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Figure F3: Graphical presentation of temperature stability study of TbHK at (A) T0, (B) T15, (C) 
T30, (D) T45, (E) T60, (F) T90 and (G) T120. 
 
F.4. pH stability studies for hGCK 
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Figure F4: Graphical presentation of temperature stability study of hGHK at (A) T0, (B) T15, 
(C) T30, (D) T45, (E) T60, (F) T90 and (G) T120. 
 
G. Zymogram  
G.1. Reagents 
G.1.1. 50 mM Tris.HCl pH 8.0 (mr 121.1) / 250 ml 
1.5138 g Tris base- weighed and dissolved in 200 ml distilled water; pH adjusted appropriately 
by HCl and topped up to 250 ml. 
G.1.2. 25 mM MgCl2 (mr 203.3) in 50 mM Tris.HCl buffer, pH 8.0./ 0.25L 
1.271g MgCl2 weigh and dissolve in 0.2L 50 mM Tris.HCl, pH 8.0 buffer, top up to 0.25L. 
G.1.3. 100 mg glucose/ 50 ml: 
Weigh 100 mg into 50 ml of 50 mM Tris.HCl, 25 mM Mg Cl2. 
G.1.4. 25mg ATP (50 ml)  
Dissolve 25 mg ATP in 50 mM Tris.HCl containing 25 mM MgCl. 
G.1.5. Phenazine methosulfate (PMS) - 5 mg.ml
-1
 
Add 10 mg PMS into 2 ml of distilled water. 
G.1.6. 5 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) - 5 mg.ml
-1
 
Add 10 mg into 2 ml of distilled water. 
G.1.7. NADP - 5 mg.ml
-1
 
Add 10 mg into 2 ml of distilled water. 
